Cover Page
Cover Page | 12 Months Ended |
Dec. 31, 2019shares | |
Cover [Abstract] | |
Document Type | 20-F |
Amendment Flag | false |
Document Period End Date | Dec. 31, 2019 |
Document Fiscal Year Focus | 2019 |
Document Fiscal Period Focus | FY |
Entity Registrant Name | DBV Technologies S.A. |
Entity Central Index Key | 0001613780 |
Current Fiscal Year End Date | --12-31 |
Entity Current Reporting Status | Yes |
Entity Filer Category | Accelerated Filer |
Entity Voluntary Filers | No |
Entity Interactive Data Current | Yes |
Entity Well-known Seasoned Issuer | Yes |
Entity Common Stock, Shares Outstanding | 47,028,510 |
Document Annual Report | true |
Document Transition Report | false |
Document Shell Company Report | false |
Entity Shell Company | false |
Entity Emerging Growth Company | false |
Entity Address, Country | FR |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | [1] | Dec. 31, 2017 | [1] |
Non-Current assets | |||||
Intangible assets | € 43 | € 29 | € 123 | ||
Right-of-use assets related to leases | 20,589 | ||||
Property, plant, and equipment | 22,270 | 20,219 | 17,808 | ||
Other non-current assets | 16,488 | 6,033 | 3,012 | ||
Total non-current assets | 59,390 | 26,281 | 20,942 | ||
Current assets | |||||
Inventories | 2,038 | 1,566 | |||
Customer accounts receivable and related receivables | 1,265 | ||||
Other current assets | 8,021 | 21,131 | 17,721 | ||
Cash and cash equivalents | 172,027 | 122,770 | 137,880 | ||
Total current assets | 182,086 | 145,468 | 156,865 | ||
TOTAL ASSETS | 241,476 | 171,749 | 177,807 | ||
Shareholders' equity | |||||
Share capital | 4,703 | 3,016 | 2,499 | ||
Premiums related to the share capital | 725,460 | 539,292 | 406,709 | ||
Reserves | (405,014) | (254,946) | (131,592) | ||
Net (loss) | (153,587) | (166,076) | (147,693) | ||
Total shareholders' equity | 171,563 | 121,286 | 129,923 | ||
Non-Current liabilities | |||||
Long-term financial debt | 721 | 1,278 | 1,825 | ||
Long-term lease debt | 19,579 | ||||
Non-current provisions | 1,474 | 1,536 | 1,260 | ||
Other non-current liabilities | 71 | 4,105 | 8,869 | ||
Total non-current liabilities | 21,845 | 6,919 | 11,954 | ||
Current liabilities | |||||
Bank overdrafts | 0 | 0 | |||
Short-term financial debt | 577 | 1,201 | 2,325 | ||
Short-term lease debt | 3,282 | 0 | |||
Current provisions | 644 | 1,270 | 913 | ||
Supplier accounts payable | 21,368 | 28,567 | 16,941 | ||
Other current liabilities | 22,197 | 12,506 | 15,751 | ||
Total current liabilities | 48,068 | 43,543 | 35,930 | ||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | € 241,476 | € 171,749 | € 177,807 | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Consolidated Statements of (Los
Consolidated Statements of (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | [1] | Dec. 31, 2017 | [1] | |
Operating income | |||||
Revenues | € 0 | € 0 | € 0 | ||
Other income | 13,139 | 14,537 | 11,909 | ||
Total income | 13,139 | 14,537 | 11,909 | ||
Operating expenses | |||||
Cost of goods sold | 0 | 0 | 0 | ||
Research & Development | (101,497) | (107,171) | (105,232) | ||
Sales & Marketing | (18,941) | (32,169) | (15,824) | ||
General & Administrative | (44,401) | (41,399) | (35,837) | ||
Total expenses | (164,839) | (180,739) | (156,892) | ||
Operating (loss) | (151,700) | (166,202) | (144,983) | ||
Financial revenues | 67 | 493 | 616 | ||
Financial expenses | (1,409) | (351) | (3,325) | ||
Financial profit (loss) | (1,341) | 141 | (2,709) | ||
Income tax | (545) | (15) | (1) | ||
Net (loss) | € (153,587) | € (166,076) | € (147,693) | ||
Basic/diluted earnings per share | € (4.15) | € (5.74) | € (5.97) | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | [1] | Dec. 31, 2017 | [1] | |
Statement of comprehensive income [abstract] | |||||
Net (loss) | € (153,587) | € (166,076) | € (147,693) | ||
Actuarial gains and losses on employee benefits, net of corporate tax | 529 | 19 | (177) | ||
Profit (loss) directly recognized in shareholders' equity | 529 | 19 | (177) | ||
Other comprehensive income | (63) | (683) | 3,280 | ||
Total comprehensive (loss) | € (153,121) | € (166,740) | € (144,591) | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | |||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||||
Statement of cash flows [abstract] | ||||||
Net (loss) for the period | € (153,587) | € (166,076) | [1] | € (147,693) | [1] | |
Cash flows used in operating activities: | ||||||
Amortization and provision | 5,700 | 2,830 | [1] | 2,926 | [1] | |
Retirement pension obligations | 467 | 295 | [1] | 230 | [1] | |
Expenses related to share-based payments | 14,923 | 25,904 | [1] | 30,781 | [1] | |
Other elements | 912 | 752 | [1] | 130 | [1] | |
Operating cash flows before change in working capital | (131,585) | (136,294) | [1] | (113,627) | [1] | |
Inventories | (471) | (1,566) | [1] | [1] | ||
Customer accounts receivable | 30 | 1,229 | [1] | 3 | [1] | |
Other current assets | 2,841 | (2,591) | [1] | (3,458) | [1] | |
Supplier accounts payable | (6,836) | 9,095 | [1] | 3,333 | [1] | |
Other current and non-current liabilities | 7,502 | (6,493) | [1] | (566) | [1] | |
Change in working capital requirement | 3,066 | (326) | [1] | (687) | [1] | |
Net cash flow used in operating activities | (128,519) | (136,620) | [1] | (114,314) | [1] | |
Cash flows used in investing activities: | ||||||
Acquisitions of property, plant, and equipment | (4,973) | (4,710) | [1] | (7,246) | [1] | |
Acquisitions of intangible assets | (27) | (41) | [1] | (299) | [1] | |
Acquisitions of non-current financial assets | (58) | (3,890) | [1] | (289) | [1] | |
Net cash flows used in investing activities | (5,058) | (8,641) | [1] | (7,834) | [1] | |
Cash flows provided by financing activities: | ||||||
Increase in conditional advances | [1] | [1] | ||||
(Decrease) in conditional advances | (1,181) | (1,800) | [1] | (578) | [1] | |
Treasury shares | 154 | (479) | [1] | (25) | [1] | |
Capital increases, net of transaction costs | 187,856 | 133,099 | [1] | 861 | [1] | |
Repayment of lease liabilities | (2,972) | [1] | [1] | |||
Interest paid on lease liabilities | (1,013) | [1] | [1] | |||
Other cash flows related to financing activities | (52) | (144) | [1] | 28 | [1] | |
Net cash flows provided by financing activities | 182,791 | 130,676 | [1] | 286 | [1] | |
(Decrease) / Increase in cash | 49,214 | (14,586) | [1] | (121,863) | [1] | |
Net Cash and cash equivalents at the beginning of the period | [1] | 122,770 | 137,880 | 256,473 | ||
Impact of exchange rate fluctuations | 43 | (525) | [1] | 3,269 | [1] | |
Net cash and cash equivalents at the close of the period | € 172,027 | € 122,770 | [1] | € 137,880 | [1] | |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholder's Equity - EUR (€) € in Thousands | Total | Share capital [Member] | Share premium [Member] | Reserve [Member] | Profit (loss) [Member] | ||
Beginning balance at Dec. 31, 2016 | € 242,849 | € 2,465 | € 405,882 | € (50,968) | € (114,531) | ||
Beginning balance at Dec. 31, 2016 | 24,648,828 | ||||||
Net (loss) | (147,693) | [1] | (147,693) | ||||
Foreign exchange translation | 3,280 | 3,280 | |||||
Profit (loss) directly recognized in shareholders' equity | (177) | [1] | (177) | ||||
Total comprehensive income (loss) | (144,591) | [1] | 3,103 | (147,693) | |||
Allocation of prior income (loss) | (114,531) | 114,531 | |||||
Increase in capital | 571 | € 34 | 536 | ||||
Increase in capital, shares | 341,994 | ||||||
Treasury shares | 23 | 23 | |||||
Issue of share warrants | 290 | 290 | |||||
Share-based payments | 30,781 | 30,781 | |||||
Ending balance at Dec. 31, 2017 | [1] | 129,923 | € 2,499 | 406,709 | (131,592) | (147,693) | |
Ending balance at Dec. 31, 2017 | [1] | 24,990,822 | |||||
Net (loss) | [1] | (166,076) | |||||
Foreign exchange translation | (683) | (683) | |||||
Profit (loss) directly recognized in shareholders' equity | 19 | [1] | 19 | ||||
Total comprehensive income (loss) | (166,740) | [1] | (665) | (166,076) | |||
Allocation of prior income (loss) | (147,693) | 147,693 | |||||
Increase in capital | 132,936 | € 517 | 132,419 | ||||
Increase in capital, shares | 5,166,955 | ||||||
Treasury shares | (900) | (900) | |||||
Issue of share warrants | 164 | 164 | |||||
Share-based payments | 25,904 | 25,904 | |||||
Ending balance at Dec. 31, 2018 | [1] | 121,286 | € 3,016 | 539,292 | (254,946) | (166,076) | |
Ending balance at Dec. 31, 2018 | [1] | 30,157,777 | |||||
Net (loss) | (153,587) | (153,587) | |||||
Foreign exchange translation | (63) | (63) | |||||
Profit (loss) directly recognized in shareholders' equity | 529 | 529 | |||||
Total comprehensive income (loss) | (153,121) | 466 | (153,587) | ||||
Allocation of prior income (loss) | (166,076) | 166,076 | |||||
Increase in capital | 187,856 | € 1,687 | 186,169 | ||||
Increase in capital, shares | 16,870,733 | ||||||
Treasury shares | 619 | 619 | |||||
Share-based payments | 14,923 | 14,923 | |||||
Ending balance at Dec. 31, 2019 | € 171,563 | € 4,703 | € 725,460 | € (405,013) | € (153,587) | ||
Ending balance at Dec. 31, 2019 | 47,028,510 | 47,028,510 | |||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
The Company
The Company | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
The Company | Note 1: The Company Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin ™ TM ™ Viaskin ™ Peanut The Company’s lead product candidate, Viaskin ™ ™ ™ ™ In August 2017, the Company initiated Part A of the EPITOPE (EPIT ™ ™ two-part, ™ ™ © Viaskin ™ Milk The Company is developing its second product candidate, Viaskin ™ ™ µg (intent-to-treat, ™ m Viaskin ™ Egg In February 2015, the Company announced the development of a third product candidate, Viaskin ™ ™ Other Viaskin ™ application In addition to the Company’s the Company is its ™ proof-of-concept ™ Main events in 2019 1. CLINICAL PROGRAMS Viaskin ™ On October 4, 2019, the Company announced that the FDA accepted for review the BLA for its investigational Viaskin ™ On February 21, 2020, the Company announced that the FDA announced that an Allergenic Products Advisory Committee meeting would be held on May 15, 2020 to discuss the BLA. On March 16, 2020, the Company announced that the FDA had informed the Company that during the FDA’s ongoing review of the BLA, it had identified questions regarding efficacy, including the impact of patch-site adhesion. Therefore, the Advisory Committee meeting to discuss the BLA will no longer take place as previously scheduled on May 15, 2020. The Company is in communication with the FDA regarding the potential submission, as part of the ongoing BLA review, of additional information on patch-site adhesion from the Company’s clinical program as well as on its long-term efficacy results from the three-year open-label extension trial, PEOPLE. At this time, the Company has received no additional information regarding the timeline of the BLA review and believes the target action date of August 5, 2020 remains unchanged. However, the submission of additional information to the FDA may constitute a major amendment to the BLA and could extend the target action date. 2. FINANCING On April 8, 2019, the Company announced the closing one-half On October 15, 2019, the Company announced the closing on October 11, 2019 of an underwritten global offering of an aggregate of 9,484,066 ordinary shares reserved to specified categories of investors in (i) an offering of 7,914,622 ordinary shares in the form of 15,829,244 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe, at an offering price of $6.59 per ADS (on the basis of an exchange rate of $1.0945 = €1.00), and (ii) a private placement of 1,569,444 ordinary shares in Europe (including France), at a public offering price of €12.04 per ordinary share. The Company also announced the closing on October 15, 2019 of 1,368,667 additional ordinary shares in the form of 2,737,334 ADSs, at an offering price of $6.59 per ADS, after full exercise of the underwriters’ option to purchase additional ordinary shares in the form of ADSs (the “Option”). The total gross proceeds from the global offering, after exercise of the Option, were approximately $143.0 million (approximately €130.7 million), before deducting commissions and estimated offering expenses. 3. CHANGE IN THE GROUP’S EXECUTIVE COMMITTEE MEMBERSHIP AND BOARD MEMBERS On January 3, 2019, the Company announced the following changes to its leadership team as the Company strengthens its organizational competencies in the development of the Viaskin ™ • DBV’s Chief Scientific Officer (CSO), Dr. Hugh Sampson, assumed the role of interim Chief Medical Officer (CMO) effective on January 3, 2019. Dr. Sampson succeeded Dr. Lucia Septien-Velez. As CSO and during his time as interim CMO, Dr. Sampson leads both the scientific and medical teams at the Company and reports to Daniel Tassé, Chief Executive Officer of DBV Technologies. • Julie O’Neill was engaged to direct all product development, manufacturing, supply chain, quality assurance, and end-to-end process optimization at the Company. She directly advises Daniel Tassé. Julie, who was appointed to DBV’s Board of Directors in 2017, continues to serve as a director, while overseeing the submission of the Viaskin™ Peanut BLA in children 4 to 11 years of age. Julie O’Neill’s role as a consultant was completed with the submission of the BLA to the FDA in August 2019. • Alan Kerr, Senior Vice President, Head of Global Regulatory Affairs of DBV Technologies, reports to the Company’s CEO, Daniel Tassé effective from January 3, 2019. On March 5, 2019, the Company also provided an update on leadership and operational changes: • Charles Ruban, former Chief Operating Officer, who oversaw regulatory, product development and commercial operations, resigned from the Company, effective March 15, 2019. • Laurent Martin, former Chief Development Officer, resigned from his regulatory and product development role, effective March 15, 2019. Mr. Martin’s primary responsibilities were first taken by Julie O’Neill, who stepped in as an advisor to the CEO on DBV’s manufacturing and operations, overseeing product development, manufacturing, supply chain, quality assurance, and end-to-end Pharmacien Responsable On March 4, 2019, the Board of Directors appointed existing board member, Michel de Rosen, as Non-Executive co-founder, Non-Executive d On May 14, 2019, the Company announced that its Deputy Chief Executive Officer and Principal Financial Officer, David Schilansky, had decided to leave the Company by the end of August 2019. While a new Chief Financial Officer search was underway, DBV did not fill the Deputy CEO role following David Schilansky’s departure. Sébastien Robitaille served as the Company’s interim Chief Financial Officer and Principal Financial Officer, from August 31, 2019 until the appointment of Ramzi Benamar as Chief Financial Officer on January 2, 2020. On May 24, 2019, the Company also announced that Viviane Monges, who has 30 years of global pharmaceutical leadership experience in financial operations, had On July 22, 2019, Pharis Mohideen, M.D. joined the Company as its CMO. Dr. Mohideen serves as a member of the Executive Committee and reports to Daniel Tassé. Effective as of Dr. Mohideen’s start date, Dr. Hugh Sampson, who assumed the role of interim CMO in early 2019, continued to serve as CSO. On September 2, 2019, Caroline Daniere joined the Company as Chief Human Resources Officer. As of the date of this report, the Board of Directors of the Company is composed o f 4. OTHER KEY EVENTS A class action complaint was filed on January 15, 2019, in the United States District Court for the District of New Jersey, entitled Travis Ito-Stone 2:19-cv-00525. , Officer and its former Chief Business 10b-5 The plaintiff seeks damages on behalf of a purported class of purchasers of the Company’s securities between February 14, 2018 and December 19, 2018. The Company believes that the allegations contained in the complaint are without merit and intend to defend the case vigorously. However, whether or not the plaintiff’s claims are successful, this type of litigation is often expensive and diverts management’s attention and resources, which could adversely affect the operation of the Company’s business. If the Company is ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect its operations. The Company may be the target of similar litigation in the future. Any future litigation could result in substantial costs and divert management’s attention and resources, which could cause serious harm to the Company’s business, operating results and financial condition. The company maintains liability insurance; however, if any costs or expenses associated with this or any other litigation exceed its insurance coverage, the Company may be forced to bear some or all of these costs and expenses directly, which could be substantial. |
General Information and Stateme
General Information and Statement of Compliance | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
General Information and Statement of Compliance | Note 2: General Information and Statement of Compliance Preliminary remarks DBV Technologies Inc. was incorporated in Delaware on April 7, 2014 (the “US subsidiary”). The share capital of this US subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Australia Pty Ltd. was incorporated in New South Wales, Australia on July 3, 2018 (the “Australian subsidiary”). The share capital of this Australian subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Canada Ltd. was incorporated in Ottawa, Ontario on August 13, 2018 (the “Canadian subsidiary”). The share capital of this Canadian subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Pharma was incorporated in Paris on December 21, 2018 (the “French subsidiary”). The share capital of this French subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). All these subsidiaries are fully consolidated according to the global integration method as of December 31, 2019. General principles The accompanying consolidated financial statements and related notes (the “Financial Statements”) present the operations of DBV Technologies S.A. and its subsidiaries (the “Group”) as of December 31, 2019. The Company is a corporate venture under French law ( société anonyme , France, at December 31, 2019. The Company’s Financial Statements as of December 31, 2019 have been prepared under the responsibility of DBV Technologies’ management. The Financial Statements were approved by the Board of Directors of DBV Technologies on March 20 All amounts are expressed in thousands of euros, unless stated otherwise. For consolidation purposes, DBV Technologies S.A. and its subsidiaries have prepared individual financial statements for the periods ended December 31, 2017, December 31, 2018 and December 31, 2019. Statement of Compliance The Company’s Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”) and whose application is mandatory for the year ended December 31, 2019. Comparative figures are presented for December 31, 2017 and 2018. Due to the listing of the Company’s ordinary shares on the Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the financial statements of the Group are also prepared in accordance with IFRS, as adopted by the European Union (“EU”). As of December 31, 2019, there are no differences in the IFRS published and mandated by the IASB and EU. As a result, the Financial Statements comply with IFRS as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (“IFRS”), International Accounting Standards (the “IAS”), as well as the interpretations issued by the Standing Interpretations Committee (the “SIC”), and the International Financial Reporting Interpretations Committee (“IFRIC”). The main accounting methods used to prepare the Financial Statements are described below. The following standards , amendments to standards and interpretations, which are mandatorily effective for annual periods beginning on or after January 1, 2019 were adopted by the Company: • IFRS 16 – Leases; • Amendments to IFRS 9 - Prepayment features with negative compensation; • Amendments to IAS 28 - Long-term Interests in Associates and Joint Ventures; • Amendments to IAS 19 - Plan Amendment, Curtailment or Settlement; • IFRIC 23 - Uncertainty over Income Tax Treatments; • Annual Improvements to IFRS Standards 2015–2017 Cycle The impacts of the first-time application of IFRS 16 are described in detail in Note 3.2. The other amendments have not had any impact on the consolidated financial statements as of December 31, 2019. The Company did not elect for early application of the following new standards, amendments and interpretations which were adopted by the IASB but not mandatory as of January 1, 2019: • IFRS 17 – Insurance contracts ; • Amendments to IFRS 3 - Definition of a Business; • Amendments to IAS 1 and IAS 8 - Definition of Material ; • Amendments to References to the Conceptual Framework in IFRS Standards . Management is in the process of evaluating the impact of the other standards and amendments and is therefore, not currently able to estimate reliably the impact of their adoption on the Company’s results on financial position or cash flows. The accounting policies and measurement principles adopted for the Financial Statements as of and for the year ended December 31, 2019 are the same as those used as of and for the years ended December 31, 2017 and 2018, except for the first application of IFRS 16 as described in detail in Note 3. The 2019 consolidated Financial Statements were approved by the Board of Directors of DBV Technologies on March 20 |
Accounting Principles
Accounting Principles | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Accounting Principles | Note 3: Accounting Principles Methods of consolidation The Financial Statements incorporate the standalone financial statements of DBV Technologies S.A and its subsidiaries which are controlled by the Company. Control is achieved when the Company: • has power over the subsidiary; • is exposed, or has rights, to variable returns from its involvement with the subsidiary; and • has the ability to use its power to affect its returns. The Company reassesses whether or not it controls a subsidiary if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of subsidiaries begins when the Company obtains control over the subsidiary and ceases when the Company loses control over the subsidiary. Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non- non-controlling non-controlling When necessary, adjustments are made to the financial statements of subsidiaries to align their accounting policies with the Group’s accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are neutralized in consolidation. Translation of financial statements in foreign currencies In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into euros using exchange rates prevailing at the end of each reporting period. Income and expense items are translated at the average exchange rates at the dates of the transactions. Exchange differences arising, if any, are recognized in other comprehensive income and accumulated in equity. Going concern The Company has primarily funded these losses through equity financings, and, to a lesser extent, by obtaining public assistance in support of innovation and reimbursements of research tax credit. To date, the Company has not generated any product revenue and the Company continue s its The Company expects operating losses to continue for the foreseeable future. Current cash-on-hand and cash equivalents, including the €136.4 million net proceeds from the offering in first quarter of The Company expects that it will need to raise additional capital in the future as it commercializes Viaskin Peanut, if approved, and continues to discover and develop other product candidates using its Viaskin Platform The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings. However, no assurance can be given at this time as to whether the Company will be able to achieve these financing objectives. The financial statements have been prepared on a going concern basis assuming that the Company will be successful in its financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. Refer to the liquidity risk disclosed in Note 24 3.1 Intangible Assets In application of the provisions in IAS 38 Intangible Assets Research and Development Expenses Research expenses are recorded in the Financial Statements as expenses. In accordance with IAS 38, development expenses are recorded in the Financial Statements as intangible assets only if all the following criteria are met: (a) technical feasibility necessary for the completion of the development project; (b) intention on the part of the Company to complete the project and to utilize it; (c) capacity to utilize the intangible asset; (d) proof of the probability of future economic benefits associated with the asset; (e) availability of the technical, financial, and other resources for completing the project; and (f) reliable evaluation of the development expenses. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 are only fulfilled once the Market Access Authorization has been obtained from the competent authorities. The application of this principle has resulted in all development costs being expensed as incurred. Software The costs related to the acquisition of licenses to software are posted to assets on the basis of the costs incurred to acquire and to implement the software in question. They are amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. 3.2 Lease contracts IFRS 16 became applicable on January 1, 2019, requiring the Company to update its accounting policies on leases. IFRS 16 aligns the balance sheet accounting treatment of operating leases on that of finance leases with the recognition of a liability for future lease payments, and of an asset for the associated rights-of-use. contract-by-contract The first-time application of IFRS 16 also lead to a change in presentation: • On the opening balance sheet: the recognition of an asset corresponding to the rights-of-use • On the income statement: the lease expense previously recognized as a component of operating income is, under IFRS 16, recognized partly as depreciation expense within operating income, and partly within Financial expenses; • On the statement of cash flows: the lease payments previously presented within net cash provided used in operating activities is, under IFRS 16, presented within net cash used in financing activities to the extent that those payments are allocated to repayment of the lease liability. For its transition method, the Group has elected to apply the simplified approach as of January 1, 2019. Prior-period comparative data will therefore not be restated at the transition date. The Group has decided to apply the exemptions to lease with a term of less than 12 months and to leases of low-value Measurement of the right- of use asset At the commencement date, the right-of-use • The amount of the initial measurement of the lease liability, adjusted by the amount of any prepaid or accrued lease payments recognized in the statement of financial position immediately before the date of initial application; • Where relevant, any initial direct costs incurred by the lessee for the conclusion of the contract. These are incremental costs which would not have been incurred if the contract had not been concluded; • Estimated costs for restoration and dismantling of the leased asset according to the terms of the contract. The majority of leases entered into by the Company are operating leases in which the Company is a lessee. The Group’s operating leases mainly relate to real estate assets and to a lesser extent to industrial equipment and company cars. Following the initial recognition, the right-of-use In accordance with IAS 36 “Impairment of Assets”, right-of-use Measurement of the lease liability At the commencement date, the lease liability is recognized for an amount equal to the present value of the lease payments over the lease term. Amounts involved in the measurement of the lease liability are the contractual rents. The lease liability is subsequently measured based on a process similar to the amortized cost method using the discount rate: • The liability is increased by the accrued interests resulting from the discounting of the lease liability, at the beginning of the lease period; • Less payments made. The discount rate applied to each contract takes into account the remaining terms of the contracts from the date of first application, i.e. January 1, 2019, and the currency of each contract. The discount rates applied at the transition date are based on the Company’s marginal borrowing rate, to which is added a spread of its own which takes into account the nature and the total duration of the contract. The discount rates and remaining term of the contracts determined by management are based on historical information and other factors considered reasonable in the circumstances. The interest cost for the period as well as variable payments, not taken into account in the initial measurement of the lease liability and incurred over the relevant period are recognized as costs. In addition, the lease liability may be remeasured in the following situations: • Change in the lease term; • Modification related to the assessment of the reasonably certain nature (or not) of the exercise of an option; • Adjustment to the rates and indices according to which the rents are calculated when rent adjustments occur. The following tables present the impacts of the first application of IFRS on the opening balance sheet: Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 ASSETS Intangible assets 29 — 29 Right-of-use — 23,792 23,792 Property, plant, and equipment 20,219 — 20,219 Other non-current 6,033 — 6,033 Total non-current 26,281 23,792 50,074 Total current assets 145,468 — 145,468 TOTAL ASSETS 171,749 23,792 195,542 Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 LIABILITIES Shareholders’ equity Total shareholders’ equity 121,286 — 121,286 Non-current Long-term financial debt 1,278 — 1,278 Long-term lease debt — 22,682 22,682 Non-current 1,536 — 1,536 Other non-current 4,105 (1,546 ) 2,559 Total non-current 6,919 21,136 28,055 Current liabilities Short-term financial debt 1,201 — 1,201 Short-term lease debt — 2,973 2,973 Current provisions 1,270 — 1,270 Supplier accounts payable 28,567 — 28,567 Other current liabilities 12,506 (317 ) 12,189 Total current liabilities 43,543 2,656 46,200 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 171,749 23,792 195,542 The following table present the reconciliation of lease liabilities on the date of transition with off-balance sheet (in thousands of euros) Commitments given under operating leases as of December 31, 2018 30,429 Effects of rental expenses not recognized into IFRS 16 (4,061 ) Other effects, including currency effects and rent-free periods 4,035 Lease debt before discounting 30,402 Effect of discounting (4,748 ) Lease debt after discounting 25,655 Existing finance leases as of December 31, 2018 — Lease debt as of January 1, 2019 after first-time application of IFRS 16 25,655 Commitments given at December 31, 2018 included €30,267 thousand under real estate leases and €163 thousand under industrial equipment and vehicles leases. 3.3 Property, Plant, and Equipment Property, plant, and equipment are recorded at their acquisition cost or, if applicable, at their production cost. Property, plant, and equipment are depreciated on the basis of the straight-line method over the estimated use period of the property. The fixtures of property rented are depreciated over the term of their own lifetime or of the term of the rental agreement, whichever is shorter. The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years 3.4 Financial Assets IFRS 9 defines the rules applicable to the classification and recognition of financial instruments, the impairment of financial assets (using a model of expected losses to replace the model of losses incurred) as well as hedge accounting. The Company did not hold any hedging instrument as of December 31, 2018 and as of December 31, 2019. As of December 31, 2019, financial assets can be classified into three categories: Financial assets at amortized cost Financial assets at amortized cost are mainly cash and cash equivalent, loans and receivables, measured at amortized cost using the effective interest rate method, adjusted for expected credit losses and at initial recognition at their fair value (acquisition cost and transaction costs). Interest recognized at the effective interest rate is recognized under “Other financial income and expenses” in the statement of profit and loss. Financial assets at fair value through profit or loss: Financial assets at fair value through profit or loss is comprised of: • instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are managed other than with a view to collecting cash flows and/or selling the asset; • instruments that management has designated as ‘fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items Financial income or Financial expenses. Financial assets at fair value through other comprehensive income mainly comprise: Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January 1, 2019 and as of December 31, 2019. Impairment of financial assets measured at amortized cost The Company considers that a financial asset is impaired according to the expected loss method in order to take into account any defaults during the asset holding period. The amount of the expected loss is recognized in the balance sheet. Impairment losses are recognized in profit or loss. 3.5 Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment The property, plant, and equipment and intangible assets that have an established lifetime are subjected to an impairment test when the recoverability of their book value is called into question by the existence of indications of impairment. An impairment is posted to the accounts up to the amount of the excess of the book value over the recoverable value of the asset. The recoverable value of an asset corresponds to its fair value minus the costs of sale or its use value, whichever is higher. 3.6 Inventories and Work in Progress Inventories are measured at production costs calculated using the first-in, first-out Depreciation may be recorded on finished goods and work in progress (i) if their production value is greater than their net realizable value, we estimate that the estimated costs for finalization and the estimated costs for the sale, or (ii) if certain products are no longer used by the company, otherwise they are perishable. At December 31, 2018 and at December 31, 2019, inventories were exclusively composed of work in progress relating to the production of the first batches that may be used for the commercialization and secondly to requalified batches that are not intended to be commercialized, which were fully depreciated. 3.7 Share Capital Common shares are classified under Shareholders’ Equity. The costs of share capital transactions that are directly attributable to the issue of new shares or options are recorded in the Financial Statements in Shareholders’ Equity as a deduction from the revenue from the issue, net of tax. 3.8 Payments in Shares Since its incorporation, the Company has established several plans for compensation paid in equity instruments in the form of employee warrants ( bons de souscription de parts de créateur d’entreprise “ bons de souscription d’actions non-employee Pursuant to IFRS 2 Share-based payment The Company has applied IFRS 2 to all equity instruments granted since 2002 to corporate officers, members of the Scientific Committee and employees of the Company, as well as to certain persons bound by a service or investment contract. consultant to the Company. The options are not subject to any market conditions. The characteristics of the options are presented in Note 18. 3.9 Recognition and measurement of Financial Liabilities Non-derivative Other non-derivative Borrowings and debt Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within Financial expenses in the income statement over the term of the debt using the effective interest method. 3.10 Subsidies and Conditional Advances The Company receives assistance in the form of subsidies, which are grants that are not repayable by the Company. Subsidies The subsidies are recognized when there is reasonable assurance that: • the Company will comply with the conditions attached to the subsidies, and • the subsidies will be received. Subsidies that are upfront non-refundable A public subsidy that is to be received (e.g. from OSEO, the French Agency for Innovation) either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without associated expenses or losses, is recognized as other income ratably over the duration of the funded project. Conditional advances The Company also receives from time to time assistance in the form of conditional advances, which are advances repayable in whole or in part based upon acknowledgment by the funder of a technical or commercial success of the related project by the funding entity. The details concerning the conditional advances are provided in Note 12. The amount resulting from the deemed benefit of the interest-free nature of the award is considered a subsidy for accounting purposes. This deemed benefit is determined by applying a discount rate equal to the rate of fungible treasury bonds over the time period that corresponds to the time period of the repayment of the advances. In the event of a change in payment schedule of the stipulated repayments of the conditional advances, the Company makes a new calculation of the net book value of the debt resulting from the discounting of the expected new future cash flows. The adjustment that results therefrom is recognized in the income statement for the fiscal year during which the modification is recognized. 3.11 Provisions Provisions for Risks and Expenses The provisions for risks and lawsuits correspond to the commitments resulting from lawsuits and various risks whose due dates and amounts are uncertain. A provision is posted to the accounts when the Company has a legal or implicit obligation to a third party resulting from a past event, concerning which it is likely or certain that it will cause an outflow of resources to that third party, without consideration that is anticipated to be at least equivalent to the latter, and that the future outflows of liquid assets can be estimated reliably. The amount recorded in the accounts as a provision is the best estimation of the expenses necessary to extinguish the obligation. Pension Retirement Obligations The employees of the Company receive the retirement benefits stipulated by law in France: • obtaining a compensation paid by the Company to employees upon their retirement (defined-benefit plan); • payment of retirement pensions by the Social Security agencies, which are financed by the contributions made by companies and employees (defined-contribution plans). For the defined-benefit plans, the costs of the retirement benefits are estimated by using the projected credit unit method. According to this method, the cost of the retirement pensions is recognized in the Consolidated Statement of (Loss) so that it is distributed uniformly over the term of the services of the employees. The retirement benefit commitments are valued at the current value of the future payments estimated using, for the discounting, the market rate based on the long-term obligations of the first-category companies with a term that corresponds to that estimated for the payment of the services provided. The difference between the amount of the provision at the beginning of a fiscal year and at the close of that year is recognized through profit or loss for the portion representing the costs of services rendered and through other comprehensive income for the portion representing the actual gains and losses. The Company’s payments for the defined-contribution plans are recognized as expenses on the income statement of the period with which they are associated. 3.12 Revenue The Company accounts for revenue when the amount can be reliably assessed, future economic benefits are likely to benefit the Company, and specific criteria are met for the Company’s business, which is in accordance with IFRS 15. 3.13 Other Income Subsidies Since it was formed, because of its innovative character, the Company has received a certain number of sources of assistance or subsidies from the central government or from local public authorities such as OSEO or the Banque Publique d’Investissement (BPI), intended to finance its operations or the recruitment of specific personnel. When the obtention of the subsidy is reasonably certain, these subsidies are recognized as “Other income” during the calendar year over which the corresponding expenses or expenditures were recorded. Research Tax Credit The Research Tax Credit ( Crédit d’Impôt Recherche, The Company has received the Research Tax Credit annually since it was formed. The Company received the reimbursement of the 2018 Research Tax Credit for an amount of €10.8 million during the year 2019. Beginning in the fiscal year ending December 31, 2019, the Company will no longer benefit from the immediate reimbursement of the Research Tax Credit due to the loss of the Small and Medium-sized the event cannot The repayable portion of the Research Tax Credit in more than one year is recorded in other non-current Collaboration agreement with Nestlé Health Science On May 31, 2016, the Company announced its entry into an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use non-refundable Regarding the first application of IFRS 15 on January 1, 2018, an analysis has been completed on performance conditions, revenue recognition method for milestones payment and on the sale price allocation for the collaboration contract signed with Nestlé in 2016. It has been determined that the license and developments to be made by the Company are a unique performance obligation. As a result, the Company has concluded that under IFRS 15, revenue related to the contract will be recognized progressively, up to the costs incurred by the Company. No margin is recognized at this stage of the development. Deferred revenue is recognized and reversed over the period in which there is a contractual obligation. This this agreement is not considered an onerous contract for the year-ended December 31, 3.14 Taxes Income Tax Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of the assets and liabilities that appear in the financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward. The tax rates that have been ratified by a legal text as of the closing date are utilized to determine the deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is likely that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforward in the Consolidated Statements of Financial Position. 3.15 Segment Information The Company operates in a single operating segment: the conducting of research and development of epicutaneous immunotherapy products in order to market them in the future. The assets, liabilities, and operating losses recognized are primarily located in France. 3.16 Other Items in the Comprehensive (or Loss) The revenue and expense items for the period that are not posted in the Consolidated Statements of (Loss) as stipulated by the applicable standards are presented, as necessary, under the rubric “Other items in the comprehensive (or loss).” 3.17 Use of Estimates The preparation of the Company’s Financial Statements requires the management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. Estimates and assumptions are based on historical experience and other factors that management believes to be reasonable under the circumstances. Estimates and assumptions are measured on an ongoing basis. Actual results may differ from these estimates. These estimates and judgments mainly involve: • an estimate of time and costs required to complete the collaboration agreement with Nestlé Health Science; • a valuation of the fair value of the employee warrants (BSPCEs) granted to employees and/or executives and share warrants (BSAs) granted to non-employee • an estimate of the expected dates of achievement of the performance conditions for the duration of the spillover from the granting of stock options and free shares; • an estimate of the Research Tax Credit based on internal and external expenses incurred by the Company during the year. Only eligible research expenses are included in the calculation of the research tax credit; • an estimate of provisions. 3.18 Presentation of Financial Assets and Financial Liabilities Measured at Fair Value In accordance with the amendments to IFRS 13, Fair value measurement and IFRS 7, financial instruments are presented in three categories based on a hierarchical method used to determine their fair value: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. 3.19 Subsequent events The Consolidated Statements of Financial Position and the Consolidated Statements of (Loss) of the Company are adjusted to reflect the subsequent events that alter the amounts related to the situations that exist as of the closing date. The adjustments are made until the date the financial statements are approved and authorized for issuance by the Board of Directors. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Intangible Assets | Note 4: Intangible Assets The intangible assets are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Patents, licenses, trademarks 414 201 201 Software 450 703 730 Total, gross 864 905 931 Accumulated depreciation of patents, licenses, and trademarks (340 ) (200 ) (201 ) Accumulated depreciation of software packages (401 ) (675 ) (688 ) Accumulated amortization and depreciation (741 ) (875 ) (889 ) Total, net 123 29 43 There has been no recognition of impairment losses in application of IAS 36 Impairment of Assets for the calendar years presented. |
Lease Contracts
Lease Contracts | 12 Months Ended |
Dec. 31, 2019 | |
Lease liabilities [abstract] | |
Lease Contracts | Note 5: Lease contracts Analysis of right-of-use Real Other Total At January 1, 2019 — — — First application of IFRS 16 23,462 330 23,792 Addition of assets — 130 130 D expense (3,257 ) (125 ) (3,382 ) Translation adjustments and other 48 — 48 At December 31, 2019 20,253 336 20,589 Analysis of maturities of lease liabilities as of December 31, 2019. 12/31/2019 Less than One Y 3,281 One to Five Years 13,282 More than Five Years 6,296 Total 22,860 As of December 31, 2019, interest expense related to lease liabilities amount ed to There has been no recognition of impairment losses in application of IAS 36 Impairment of Assets. |
Property, Plant, and Equipment
Property, Plant, and Equipment | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Property, Plant, and Equipment | Note 6: Property, Plant, and Equipment 1/1/2017 Increase Decrease 12/31/2017 (Amounts in thousands of Euros) Laboratory equipment 3,097 2,806 (83 ) 5,820 Building fixtures 4,610 534 (46 ) 5,098 Office equipment 607 275 (116 ) 766 Computer equipment 986 116 (30 ) 1,073 Property, plant, and equipment in progress 6,385 3,384 (55 ) 9,714 Total, gross 15,685 7,114 (329 ) 22,470 Accumulated depreciation of laboratory equipment 1,505 802 (63 ) 2,244 Accumulated depreciation of the building fixtures 1,109 484 (14 ) 1,580 Accumulated depreciation of office equipment 212 213 (105 ) 320 Accumulated depreciation of computer equipment 377 172 (30 ) 520 Total accumulated amortization and depreciation 3,202 1,671 (211 ) 4,663 Total, net 12,482 5,443 (118 ) 17,807 1/1/2018 Increase Decrease 12/31/2018 (Amounts in thousands of Euros) Laboratory equipment 5,820 6,305 (12 ) 12,113 Building fixtures 5,098 133 — 5,231 Office equipment 766 25 — 790 Computer equipment 1,073 434 — 1,507 Property, plant, and equipment in progress 9,714 7,623 (9,750 ) 7,587 Total, gross 22,470 14,520 (9,762 ) 27,228 Accumulated depreciation of laboratory equipment 2,244 1,567 — 3,811 Accumulated depreciation of the building fixtures 1,580 352 (12 ) 1,919 Accumulated depreciation of office equipment 320 129 — 449 Accumulated depreciation of computer equipment 520 310 — 830 Total accumulated amortization and depreciation 4,663 2,358 (12 ) 7,009 Total, net 17,807 12,162 (9,750 ) 20,219 1/1/2019 Increase Decrease 12/31/2019 (Amounts in thousands of Euros) Laboratory equipment 12,113 383 (64 ) 12,432 Building fixtures 5,231 582 — 5,813 Office equipment 790 18 — 808 Computer equipment 1,507 187 — 1,694 Property, plant, and equipment in progress 7,587 3,842 (24 ) 11,405 Total, gross 27,228 5,012 (88 ) 32,152 Accumulated depreciation of laboratory equipment 3,811 1,786 (64 ) 5,533 Accumulated depreciation of the building fixtures 1,919 671 — 2,590 Accumulated depreciation of office equipment 449 129 — 578 Accumulated depreciation of computer equipment 830 351 — 1,181 Total accumulated amortization and depreciation 7,009 2,937 (64 ) 9,882 Total, net 20,219 2,075 (24 ) 22,270 Over the three years presented, the acquisitions correspond primarily to building fixtures and to laboratory and production equipment and material. As of December 31, 2018, the investments are mainly explained by the setup of the Company’s industrial machines (mainly Gen 4.0 et Cut Pack). In 2019, the increase in “property plan and equipment in progress” is related to the purchase of materials for the design and development of future industrial machines (Gen 3.2, 3.3 and 4Bis), whose setup is expected during 2020. |
Non-Current Financial Assets
Non-Current Financial Assets | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Non-Current Financial Assets | Note 7: Non-Current December 31, 2017 2018 2019 (Amounts in thousands of Euros) Research tax credit — — 9,764 Pledged securities and other non-current 1,102 4,226 4,314 Deposits 577 1,374 1,359 Liquidity contract 1,333 432 1,051 Total non-current 3,012 6,033 16,488 The non-current s Under the liquidity contract, 9,000 treasury shares were allocated as a reduction of Shareholders’ Equity as at December 31, 2019 with the cash balance being maintained in financial assets. Research tax credit The Company benefits from the provisions in Articles 244 quater B and 49 septies F of the French Tax Code related to the Research Tax Credit. In compliance with the principles described in Note 3.13 to the financial statements for the year ended December 31, 2018, the Research Tax Credit is posted to the accounts as “Other Income” during the year with which the eligible research expenditures are associated. Beginning in the fiscal year ending December 31, 2019, the Company will no longer benefit from the immediate reimbursement of the Research Tax Credit due to the loss of its three the event cannot The repayable portion of the Research Tax Credit in more than one year is recorded in other non-current The variance in Research Tax Credit during the three years presented is presented as follow: Amount in thousands Opening balance sheet receivable as of January 1, 2017 7,228 + Operating revenue 9,217 - Payment received (7,341 ) - Adjustement 113 Closing balance sheet receivable as of December 31, 2017 9,217 Amount in thousands Opening balance sheet receivable as of January 1, 2018 9,217 + Operating revenue 10,829 - Payment received (9,479 ) - Adjustement 262 Closing balance sheet receivable as of December 31, 2018 10,829 Amount in thousands Opening balance sheet receivable as of January 1, 2019 10,829 + Operating revenue 9,764 - Payment received (10,835 ) - Adjustement 6 Closing balance sheet receivable as of December 31, 2019 9,764 The Company accounted as other revenue a research tax credit of €9.8 million as of December 31, 2019 and of €10.8 million as of December 31, 2018. |
Inventories and Work in Progres
Inventories and Work in Progress | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Inventories and Work in Progress | Note 8: Inventories and Work in Progress December 31, 2017 2018 2019 (Amounts in thousands of Euros) Inventories of raw materials — — 64 Work in progress — 2,338 3,150 Depreciation of inventories (charged to income statement) — (772 ) (1,177 ) Total net value of the inventories — 1,566 2,038 As of December 31, 2018, inventories were , which relate to the production of the first batches potentially intended for the commercialization, if approved. As of December 31, 2019, the inventories are composed of raw materials and work in progress for a net value of €2,038 thousand. An allowance for inventory write-down was recorded at December 31, 2018 and at December 31, 2019 for non-commercial ™ |
Customer Accounts Receivable an
Customer Accounts Receivable and Other Current Assets | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Customer Accounts Receivable and Other Current Assets | Note 9: Customer Accounts Receivable and Other Current Assets 9.1 Customer Accounts Receivable and Related Receivables December 31, 2017 2018 2019 (Amounts in thousands of Euros) Accounts receivable 1,265 — — Valuation allowance (charged to income statement) — — — Total net value of accounts receivable 1,265 — — All the customer accounts receivable have As of December 31, 2017, the accounts receivable corresponds primarily to the amounts due under the collaboration agreement with Nestlé Health Science. 9.2 Other current assets The other current assets are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Research tax credit 9,217 10,829 — Other tax claims 5,258 4,292 3,995 Other receivables 1,192 1,745 825 Prepaid expenses 2,054 4,265 3,201 Total 17,721 21,131 8,021 The reimbursement of 2018 Research Tax Credit presented in other current assets as of December 31, 2018, occurred in November 2019. Following a tax inspection led by the French tax authorities for On June 25, 2018, the Company received the final reassessment for €58 thousand. The accrual initially recognized for €0.9 million has been reversed in the December 31, 2018 financial statements. A tax audit covering all the tax declarations for the period from January 1, 2015 to December 31, 2016, extended to December 31, 2017 for VAT, was conducted in the third quarter of 2018. The conclusions of this tax audit were received in November 2018 without major financial consequences for the Group. The other tax debt claims are primarily related to the deductible VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of rental and insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Cash and Cash Equivalents | Note 10: Cash and Cash Equivalents The cash and cash equivalents item is broken down as follows (in thousands of Euros): 2017 2018 2019 (Amounts in thousands of Euros) Cash 32,054 77,236 51,524 Cash equivalent term deposits 105,826 45,534 120,503 Total cash and cash equivalent as reported in statement of financial position 137,880 122,770 172,027 Bank overdrafts — — — Total net cash and cash equivalents as reported in the statement of cash flow 137,880 122,770 172,027 Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements. |
Capital
Capital | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Capital | Note 11: Capital 11.1 Share Capital Issued The share capital, as of December 31, 2019, is set at the sum of €4,702,851.00. It is divided into 47,028,510 fully authorized, subscribed and paid-up This number does not include share warrants (“BSA”), employee warrants (“BSPCE”), stock-options (“SO”) and free non-employees All the shares give their owners the right to a proportional share of the income and the net assets of the Company. The table below presents the historical changes in the share capital of the Company as of December 31, 2017, 2018 and 2019: Date Nature of the transactions Share Share Number of Nominal Balance as of January 1, 2017 2,464 . 405,882 . 24,648,828 0.10 € 2/3/2017 Capital increase by issuance of common shares 2.0 100.7 20,010 0.10 € 2/9/2017 Issue of share subscription warrants 237.4 5/16/2017 Capital increase by issuance of common shares 4.0 170.7 40,365 0.10 € 7/12/2017 Capital increase by issuance of common shares 0.2 8.3 1,650 0.10 € 8/4/2017 Capital increase by issuance of common shares 0.1 64.6 1,200 0.10 € 8/15/2017 Issue of share subscription warrants 53.1 9/14/2017 Capital increase by issuance of common shares 3.6 208.2 35,925 0.10 € 9/29/2017 Capital increase by issuance of common shares 0.1 4.0 500 0.10 € 9/30/2017 Capital increase by incorporation of reserve 23.1 -23.1 230,843 0.10 € 10/2/2017 Capital increase by issuance of common shares 0.1 4.0 500 0.10 € 12/15/2017 Capital increase by incorporation of reserve 1.1 -1.1 11,001 0.10 € Balance as of December 31, 2017 2,499 . 406,709 . 24,990,822 0.10 € Balance as of January 1, 2018 2,499 . 406,709 . 24,990,822 0.10 € 1/8/2018 Capital increase by issuance of common shares 0.7 52.3 7,000 0.10 € 1/9/2018 Capital increase by issuance of common shares 0.5 25.2 5,010 0.10 € 1/16/2018 Capital increase by issuance of common shares 2.0 100.4 19,950 0.10 € 1/18/2018 Capital increase by issuance of common shares 12.9 963.6 129,000 0.10 € 1/30/2018 Capital increase by issuance of common shares 1.3 97.1 13,000 0.10 € 1/31/2018 Capital increase by issuance of common shares 2.0 149.4 20,000 0.10 € 2/16/2018 Capital increase by incorporation of reserve 23.8 -23.8 238,337 0.10 € 3/13/2018 Capital increase by incorporation of reserve 23.8 -23.8 238,319 0.10 € 3/23/2018 Capital increase by issuance of common shares 352.8 122,095.5 3,527,752 0.10 € 3/26/2018 Capital increase by issuance of common shares 52.9 18,314.3 529,162 0.10 € 4/5/2018 Capital increase by issuance of common shares 1.2 91.9 12,302 0.10 € 4/6/2018 Capital increase by incorporation of reserve 5.8 -5.8 57,500 0.10 € 4/6/2018 Capital increase by issuance of common shares 1.4 105.6 14,138 0.10 € 4/9/2018 Capital increase by issuance of common shares 0.4 26.6 3,560 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 21.2 2,500 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 20.0 2,500 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 46.7 2,500 0.10 € 6/21/2018 Capital increase by incorporation of reserve 19.3 -19.3 193,000 0.10 € 7/2/2018 Issue of share subscription warrants 163.7 7/5/2018 Capital increase by issuance of common shares 3.3 164.1 32,625 0.10 € 7/11/2018 Capital increase by issuance of common shares 6.4 478.1 64,000 0.10 € 8/16/2018 Capital increase by incorporation of reserve 1.0 -1.0 10,000 0.10 € 9/1/2018 Capital increase by incorporation of reserve 0.5 -0.5 5,000 0.10 € 9/21/2018 Capital increase by issuance of common shares 0.5 37.3 5,000 0.10 € 10/27/2018 Capital increase by incorporation of reserve 1.5 -1.5 15,000 0.10 € 12/9/2018 Capital increase by incorporation of reserve 2.0 -2.0 19,800 0.10 € 12/31/2018 Fees charged to share premium -10,292.6 Balance as of December 31, 2018 3,015 . 539,292 . 30,157,777 0.10 € Balance as of January 1, 2019 3,015 . 539,292 . 30,157,777 0.10 € 4/8/2019 Capital increase by issuance of common shares 600.0 71,520.0 6,000,000 0.10 € 9/30/2019 Fees charged to share premium -5,733.4 10/4/2019 Capital increase by incorporation of reserve 1.8 -1.8 18,000 0.10 € 10/11/2019 Capital increase by issuance of common shares 948.4 113,255.8 9,484,066 0.10 € 10/15/2019 Capital increase by issuance of common shares 136.9 16,344.7 1,368,667 0.10 € 12/31/2019 Fees charged to share premium -9,216.7 Balance as of December 31, 2019 4,702 . 725,460 . 47,028,510 0.10 € On April 8, 2019, the Company announced the closing one-half On October 15, 2019, the Company announced the closing on October 11, 2019 of an underwritten global offering of an aggregate of 9,484,066 ordinary shares reserved to specified categories of investors in (i) an offering of 7,914,622 ordinary shares in the form of 15,829,244 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe, at an offering price of $6.59 per ADS (on the basis of an exchange rate of $1.0945 = €1.00), and (ii) a private placement of 1,569,444 ordinary shares in Europe (including France), at a public offering price of €12.04 per ordinary share. The Company also announced the closing on October 15, 2019 of 1,368,667 additional ordinary shares in the form of 2,737,334 ADSs, at an offering price of $6.59 per ADS, after full exercise of the underwriters’ option to purchase additional ordinary shares in the form of ADSs (the “Option”). The total gross proceeds from the global offering, after exercise of the Option, were approximately $143.0 million (approximately €130.7 million), before deducting commissions and estimated offering expenses. 11.2 Share Warrants and Employee Warrants The Company has issued share warrants (BSAs), employee warrants (BSPCEs), f r Grant date Type Number of Number of Number of Number of Number of Maximum of Number of Subscription 6/24/2011 BCE 7,166 — — — 7,166 107,490 107,490 5.13 6/24/2011 BSA2010 500 — — — 500 7,500 7,500 5.13 9/25/2012 BSA 5,000 — — — 5,000 5,000 5,000 8.59 7/25/2013 BSA 7,000 — — — 7,000 7,000 7,000 8.10 9/18/2013 SO 203,000 — — — 203,000 203,000 203,000 7.57 6/3/2014 SO 40,000 — — 40,000 — — — 19.01 3/24/2015 BSA 10,000 — — — 10,000 10,000 10,000 43.00 6/23/2015 SO 120,000 — — — 120,000 120,000 120,000 48.90 11/19/2015 BSA 15,000 — — — 15,000 15,000 15,000 66.06 11/19/2015 SO 170,000 — — 170,000 — — — 66.06 12/15/2015 BSA 73,500 — — — 73,500 73,500 73,500 64.14 1/4/2016 SO 75,000 — — — 75,000 75,000 56,250 65.68 4/21/2016 SO 22,000 — — — 22,000 22,000 16,500 62.82 6/21/2016 SO 87,500 — — 50,000 37,500 37,500 32,813 53.96 6/21/2016 BSA 20,000 — — — 20,000 20,000 20,000 52.97 8/1/2016 SO 10,000 — — — 10,000 10,000 7,500 62.24 9/15/2016 SO 9,300 — — — 9,300 9,300 6,975 62.80 10/17/2016 SO 9,300 — — — 9,300 9,300 6,975 64.39 11/15/2016 SO 8,300 — — — 8,300 8,300 6,225 68.33 12/9/2016 BSA 34,008 — — — 34,008 34,008 34,008 69.75 12/9/2016 SO 51,995 — — 9,050 42,945 42,945 32,209 69.75 12/15/2016 SO 1,100 — — — 1,100 1,100 825 69.35 1/16/2017 SO 19,100 — — 19,100 — — — 66.11 3/14/2017 AGA 17,000 — 6,000 5,000 6,000 6,000 — 3/15/2017 SO 7,200 — — 7,200 — — — 66.25 4/18/2017 SO 7,200 — — — 7,200 7,200 4,500 60.77 4/20/2017 AGA 24,000 — 12,000 4,000 8,000 8,000 — 6/15/2017 BSA 9,000 — — — 9,000 9,000 9,000 59.05 6/15/2017 SO 91,000 — — 30,000 61,000 61,000 38,125 60.54 6/15/2017 SO 111,600 — — 55,000 56,600 56,600 41,000 59.05 7/17/2017 SO 7,200 — — — 7,200 7,200 3,600 71.61 9/15/2017 SO 45,400 — — — 45,400 45,400 22,700 74.22 12/5/2017 SO 540,075 — — 204,050 336,025 336,025 183,013 39.00 12/15/2017 SO 8,300 — — — 8,300 8,300 4,150 38.18 1/15/2018 SO 8,300 — — — 8,300 8,300 3,113 43.60 4/16/2018 SO 16,500 — — — 16,500 16,500 6,188 38.64 7/2/2018 BSA 44,000 — — — 44,000 44,000 44,000 37.24 5/15/2018 SO 16,500 — — — 16,500 16,500 6,188 40.84 6/15/2018 SO 23,600 — — — 23,600 23,600 8,850 38.92 6/22/2018 AGA 465,028 — — 64,100 400,928 400,928 — 6/22/2018 SO 50,000 — — — 50,000 50,000 — 37.22 7/16/2018 SO 28,800 — — — 28,800 28,800 — 33.81 8/15/2018 SO 33,500 — — 7,200 26,300 26,300 — 32.90 9/6/2018 AGA 450 — — — 450 450 — 9/6/2018 SO 65,000 — — — 65,000 65,000 — 36.96 9/17/2018 SO 80,900 — — 36,425 44,475 44,475 — 40.94 10/15/2018 SO 76,700 — — 5,400 71,300 71,300 — 37.28 11/1/2018 AGA 46,500 — — 2,500 44,000 44,000 — 11/15/2018 SO 26,000 — — 7,200 18,800 18,800 — 32.57 11/29/2018 SO 350,000 — — — 350,000 350,000 — 30.02 12/12/2018 AGA 19,250 — — 4,250 15,000 15,000 — 12/12/2018 SO 34,000 — — — 34,000 34,000 — 27.96 12/17/2018 SO 7,200 — — — 7,200 7,200 — 26.76 1/15/2019 SO — 9,500 — 7,200 2,300 2,300 — 15.61 3/20/2019 SO — 547,100 — 52,300 494,800 494,800 — 14.58 5/10/2019 AGA — 100,000 — 20,000 80,000 80,000 — 5/15/2019 SO — 7,200 — — 7,200 7,200 — 16.82 5/24/2019 SO — 150,000 — — 150,000 150,000 — 16.99 6/17/2019 SO — 7,200 — — 7,200 7,200 — 16.38 7/1/2019 SO — 403,400 — 49,400 354,000 354,000 — 15.43 7/22/2019 SO — 75,000 — — 75,000 75,000 — 17.90 7/31/2019 AGA — 23,750 — — 23,750 23,750 — 9/16/2019 SO — 34,000 — — 34,000 34,000 — 18.00 10/11/2019 AGA — 40,000 — — 40,000 40,000 — 10/16/2019 SO — 3,500 — — 3,500 3,500 — 15.30 12/16/2019 SO — 53,100 — — 53,100 53,100 — 15.80 12/20/2019 AGA — 23,600 — — 23,600 23,600 — Total 3 258 972 1,477,350 18,000 849,375 3,868,947 3,976,271 1,143,194 The totals presented above do not include the warrants cancelled prior to December 31, 2009. As part of the initial public offering on Euronext, the nominal value of the shares underwent a fifteen-for-one The impact of the share-based payments on the net income (or loss) is presented in Note 18. |
Financial and Other Non-Current
Financial and Other Non-Current Liabilities | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Financial and Other Non-Current Liabilities | Note 12: Financial and Other Non-Current 12.1 Conditional Advances The conditional advances from public institutions are subject to contracts with OSEO. As of December 31, 2018, the Company had two advance contracts with OSEO Innovation. These advances are 100% repayable at their nominal value in the event of technical and/or commercial success and do not bear interest. The Company also benefited from a third grant from BpiFrance Financement in November 2014. The portion of the conditional advances for terms longer than one year is classified as non-current The table below presents the details of the debts recorded on the statement of financial position by the type of conditional advance: 3rd OSEO 4th OSEO BPI contract contract advance Total Balance sheet debt at start of period 01/01/2017 192 1,684 2,751 4,627 Receipts — — — — Repayments (128 ) — (450 ) (578 ) Other transactions 1 16 84 101 Balance sheet debt as at 12/31/2017 64 1,700 2,386 4,150 Of which - Non-current 1,825 Of which - Current portion 2,325 Stated interest rate No 2,05 % No Discount rate 0.4%- 1.9% 1.5%- 1.8% 3.2 % Maturity (in years) 0-3 7-9 2-7 3rd OSEO 4th OSEO BPI contract contract advance Total Balance sheet debt at start of period 01/01/2018 64 1,700 2,386 4,150 Receipts — — — — Repayments (64 ) (1,136 ) (60 ) (1,80 ) Other transactions — 60 69 129 Balance sheet debt as at 12/31/2018 — 624 1,854 2,479 Of which - Non-current 1,278 Of which - Current portion 1,201 Stated interest rate No 2,05 % No Discount rate 0.4%- 1.9% 1.5%- 1.8% 3.2 % Maturity (in years) 0-3 7-9 2-7 4th OSEO BPI contract Balance sheet debt at start of period 01/01/2019 624 1,854 2,479 Receipts — — — Repayments (624 ) (600 ) (1,224 ) Other transactions — 44 44 Balance sheet debt as at 12/31/2019 — 1,298 1,298 Of which - Non-current 721 Of which - Current portion 577 Stated interest rate 2.05% No Discount rate 1.5%- 1.8% 3.2 % Maturity (in years) 7-9 2-7 The changes appearing in “Other transactions” are comprised of the effect of discounting conditional advances. Third OSEO Advance In 2011, the Company was notified by OSEO Innovation of a new grant in the form of a conditional advance of up to €640,000 to finance the development of its program to treat the allergy to proteins in cow’s milk. The amount of the assistance was paid as follows: • €256,000 after the contract was signed (payment was received in 2011); • €256,000 from June 30, 2012 upon a call for funds (payment was received in 2013); • the balance of €128,000 after confirmation of the end of the program notified on December 31, 2013 (payment was received in 2014). In the event of technical or commercial success of the program, the repayment schedule will be the following: • Four quarterly repayments of €64,000 each starting no later than September 30, 2014; • Twelve quarterly repayments of €32,000 each starting no A fixed sum of €256,000 has been repaid in four quarterly installments of €64,000 beginning on September 30, 2014. The agreement with OSEO terminated on June 30, 2018. Fourth OSEO Advance In 2013, OSEO has provided assistance in the form of conditional advances for €3,206,162 to the Company as part of a collaborative research and clinical development in mite allergy in young children. ImmunaVia, the program, will be funded according to the following schedule, subject to the progress of the program: • €903,500 paid in April 2013; • €903,500 in October 2014 (funds which were to be paid in October 2014 were finally received on January 22, 2015 for an amount of €864,989); • €918,000 in October 2015 (not received); • €481,162 in April 2018 (not received). The funds that the Company actually received amounts to €1,768,489. Such conditional advance bears interest at an annual rate of 2.05%. In case of technical or commercial success of the project, the repayment schedule plans reimbursement with progressive amounts between June 30, 2021 and June 30, 2024. Following the defection of a sponsor, the Immuna V e This agreement with OSEO terminated in 2019. BpiFrance Financement Interest Free Loan In 2014, BpiFrance Financement granted an interest-free Innovation loan of €3,000,000 to DBV Technologies to help financing the pharmaceutical development of Viaskin ™ . This amount was received in a single disbursement on November 27, 2014. The planned repayment is scheduled in 20 quarterly repayments of €150,000 each, starting on June 30, 2017. 12. 2 non-current Due dates of the financial liabilities recognized as of December 31, 2017: Gross Less than One One to Five More than (Amounts in thousands of Euros) Conditional advances 4,150 2,325 1,825 — Lease debt — — — — Other liabilities 24,620 15,751 8,421 448 Supplier accounts payable and related payables 16,941 16,941 — — Total financial, current and non-current 45,711 35,017 10,246 448 Due dates of the financial liabilities recognized as of December 31, 2018: Gross Less than One One to Five More than (Amounts in thousands of Euros) Conditional advances 2,479 1,201 1,278 — Lease debt — — — — Other liabilities 16,611 12,506 3,991 114 Supplier accounts payable and related payables 28,567 28,567 — — Total financial, current and non-current 47,656 42,273 5,269 114 Due dates of the financial liabilities recognized as of December 31, 2019: Gross Less than One to More than (Amounts in thousands of Euros) Conditional advances 1,298 577 721 — Lease debt 22,860 3,282 13,282 6,296 Other liabilities 22,268 22,197 71 — Supplier accounts payable and related payables 21,368 21,368 — — Total financial, current and non-current 67,794 47,423 14,074 6,296 As detailed in Note 14.2, other current liabilities mainly include social security and deferred revenues from the collaboration agreement with Nestlé Health Science , |
Non-Current Provisions
Non-Current Provisions | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Non-Current Provisions | Note 13: Non-Current December 31, 2017 2018 2019 Pension retirement obligations 1,260 1,536 1,474 Total 1,260 1,536 1,474 Commitments for Compensation Payable to Employees Upon Their Retirement Amounts in As of January 1, 2017 (853 ) Costs of services rendered (operating expense) (219 ) Interest expense (financial expense) (11 ) Benefit paid — Actuarial gains (177 ) As of December 31, 2017 (1,260 ) Costs of services rendered (operating expense) (412 ) Interest expense (financial expense) (24 ) Benefit paid 141 Actuarial gains 19 As of December 31, 2018 (1,536 ) Costs of services rendered (operating expense) (443 ) Interest expense (financial expense) (24 ) Benefit paid — Actuarial gains 529 As of December 31, 2019 (1,474 ) As part of the estimation of the retirement commitments, the following assumptions were used for all categories of employees: 2017 2018 2019 % social security contributions 50,0 % 50,0 % 50,0 % Salary increases 2,0 % 2,0 % 2,0 % Discount rate 1,30 % 1,57 % 0,77 % Assumptions for the years ended December 31, 2017, 2018 and 2019 • Retirement age: 65 years old; • Terms of retirement: voluntary retirement; • Life table: TGH05-TGF05; • Collective agreement: Convention Collective Nationale de l’Industrie Pharmaceutique (National Collective Agreement in the Pharmaceutical Industry); • Turn-over of the personnel declining with age. The discount rates come from the corporate Iboxx Corporates AA 10+. |
Supplier Accounts Receivable an
Supplier Accounts Receivable and Other Current Liabilities | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Supplier Accounts Receivable and Other Current Liabilities | Note 14: Supplier Accounts Receivable and Other Current Liabilities 14.1 Supplier Accounts Payable and Related Payables No discounting was performed on the supplier accounts payable and related payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal year presented. 14.2 Other Current Liabilities 2017 2018 2019 (Amounts in thousands of Euros) Social security 12,094 6,343 18,100 Tax liabilities 428 448 384 Other debts 440 1,354 510 Deferred revenues 2,789 4,360 3,204 Total 15,751 12,506 22,197 The other liabilities include the short-term debts to employees, as well as social welfare and tax agencies. Deferred revenues include subsidies, conditional advances and current part of deferred revenues from the collaboration agreement with Nestlé Health Science. The current part of deferred revenues from the collaboration agreement with Nestlé Health Science amounted to €3.2 million as of December 31, 2019. |
Financial Instruments Recognize
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | Note 15: Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) 2017 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 3,012 1,333 1,679 — 3,012 Customer accounts receivables and related receivables 1,265 — 1,265 — 1,265 Other current financial assets 378 — 378 — 378 Cash and cash equivalents 137,880 137,880 — — 137,880 Total financial assets 142,534 139,213 3,321 — 142,534 Financial liabilities Long-term conditional advances 1,825 — — 1,825 1,825 Long term financial rent debt — — — — — Other long-term liabilities 8,869 — — 8,869 8,869 Short-term conditional advances 2,325 — — 2,325 2,325 Short - — — — — — Other short-term liabilities 15,751 — — 15,751 15,751 Account payable and other liabilities 16,941 — — 16,941 16,941 Total financial liabilities 45,711 — — 45,711 45,711 2018 Book value in the Fair value through Financial assets at Non- derivative Fair value (2) Financial assets Long-term financial assets 6,033 432 5,600 — 6,033 Customer accounts receivables and related receivables — — — — — Other current financial assets 912 — 912 — 912 Cash and cash equivalents 122,770 — 122,770 — 122,770 Total financial assets 129,715 432 129,283 — 129,715 Financial liabilities — — — — — Long-term conditional advances 1,278 — — 1,278 1,278 Long term financial rent debt — — — — — Other long-term liabilities 4,105 — — 4,105 4,105 Short-term conditional advances 1,201 — — 1,201 1,201 Short - — — — — — Other short-term liabilities 12,506 — — 12,506 12,506 Account payable and other liabilities 28,567 — — 28,567 28,567 Total financial liabilities 47,656 — — 47,656 47,656 2019 Book value in Fair value Financial assets Non- Fair value (2) Financial assets Pledged securities and other non-current 4,314 — 4,314 — 4,314 Deposits 1,359 — 1,359 — 1,359 Liquidity contract 1,051 1,051 — — 1,051 Other current financial assets 679 — 679 — 679 Cash and cash equivalents 172,027 — 172,027 — 172,027 Total financial assets 179,430 1,051 178,379 — 179,430 Financial liabilities Conditional advances 1,298 — — 1,298 1,298 Lease debt 22,860 — — 22,860 22,860 Other liabilities 22,268 — — 22,268 22,268 Supplier accounts payable 21,368 — — 21,368 21,368 Total financial liabilities 67,794 — — 67,794 67,794 (1) The fair value of financial assets as fair value through Consolidated Statements of (Loss) is determined based on Level 1 fair value measurements and corresponds to the market value of the assets. (2) The fair value of “financial assets at amortized cost” as per IFRS 9 or “loans and receivables” as per IAS 39 corresponds to the value reported in the Consolidated Statements of Financial Position. (3) The book amount of “Non-derivative |
Operating Income
Operating Income | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Operating Income | Note 16: Operating Income The operating income is broken down in the following manner: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Revenues — — — Research tax credit 9,330 11,034 9,770 Subsidies 271 152 — Other operating income 2,308 3,351 3,369 Total 11,909 14,537 13,139 The Company recognized as other operating income a portion of the upfront fee and milestones agreed under the contract with Nestlé which are deferred over the performance obligation. As of December 31, 2019, the end of the service obligation period over which the revenue from Nestlé will be deferred is expected by 2024. |
Operating Expenses
Operating Expenses | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Operating Expenses | Note 17: Operating Expenses The research and development expenses are broken down as follows: December 31, Research and d 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 37,112 37,912 41,565 Sub-contracting, c c 54,397 52,927 47,750 Small equipment and other supplies 4,110 4,771 2,814 Rental (1) 2,018 2,703 1,170 Conferences and travel expenses 2,807 2,591 1,676 Depreciation and amortization 2,424 2,492 4,853 Others 2,364 3,776 1,669 Total r d 105,232 107,171 101,497 (1) As of December 31, 2019, rentals are composed of rents related to leases ending within less than 12 months and to leases of low value assets, excluded from the scope of application of IFRS 16 standard, and of rental expenses. By nature, the breakdown of sales and marketing expenses is as follows: December 31, Sales and marketing expenses 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 6,976 12,553 12,504 Fees 2,480 5,148 4,194 Marketing, tradeshows and travel expenses 5,984 14,021 1,340 Depreciation and amortization — 44 736 Others 384 402 168 Total s and m 15,824 32,169 18,941 The general and administrative expenses are broken down as follows: December 31, General and administrative expenses 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 19,742 19,101 25,751 Fees 10,347 12,718 10,883 Rental 1 584 911 43 Insurance policies 1,367 1,930 2,720 Corporate communication and travel expenses 1,599 1,576 972 Depreciation and amortization 422 1,720 516 Others 1,776 3,442 3,515 Total general and administrative expenses 35,837 41,399 44,401 (1) As of December 31, 2019, rentals are composed of rents related to leases ending within less than 12 months and to leases of low value assets, excluded from the scope of application of IFRS 16 standard, and of rental expenses. Personnel Expenses The Company had 319 average The personnel expenses are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Wages and salaries 22,451 31,684 48,261 Social security contributions 7,157 8,858 13,097 Expenses for pension commitments 1,583 2,095 2,383 Employer contribution to bonus shares 1,857 1,026 1,155 Share-based payments 30,781 25,904 14,923 Total 63,830 69,567 79,820 The increase in personnel charges is mainly due to the increase in the Company’s headcount. This increase was partially offset by the decrease of the share-based payments expense. |
Share-Based Payments
Share-Based Payments | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Share-Based Payments | Note 18: Share-Based Payments The Board of Directors has been authorized by the general meeting of the shareholders to grant employee warrants ( Bons de Souscription de Parts de Créateur d’Entreprise • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 2,296 BCEX (“BCEX”); • With the authorization of the General Meeting of Shareholders on June 14, 2007, December 16, 2010 and December 9, 2011, the board of Directors issued 194,552 BSA (“BSA”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 10,716 BSA (“BSA2”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 5,358 BCE (“BCE4”); • With the authorization of the General Meeting of Shareholders on December 16, 2010, the Board of Directors issued 19,377 BSA (“BSA2010”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 2,131 BSA (“BSAX”); • With the authorization of the General Meeting of Shareholders on December 16, 2010, the Board of Directors issued 34,039 BSPCE (“BSPCE2010”); • With the authorization of the General Meeting of Shareholders on December 9, 2011, the Board of Directors issued 518,000 options (“OPTIONS 2013”); • With the authorization of the General Meeting of Shareholders on December 9, 2011, the Board of Directors issued 1,340,737 Free shares (“Free shares”); • With the authorization of the General Meeting of Shareholders on June 4, 2013, the Board of Directors issued 73,000 BSA; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 20,000 BSA; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 918,960 options; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 186,000 free shares; • With the authorization of the General Meeting of Shareholders on June 23, 2015, the Board of Directors issued 88,500 BSA; • With the authorization of the General Meeting of Shareholders on September 21, 2015, the Board of Directors granted 1,107,350 Free shares which 241,844 have been issued as of December 31, 2017; • With the authorization of the General Meeting of Shareholders on June 21, 2016, the Board of Directors issued 54,008 BSA; • With the authorization of the General Meeting of Shareholders on June 15, 2017, the Board of Directors issued 9,000 BSA; • With the authorization of the General Meeting of Shareholders on June 15, 2017, the Board of Directors issued 900,700 options which 72,100 have been issued as of first half 2018; • With the authorization of the General Meeting of Shareholders on June 22, 2018, the Board of Directors issued 562,853 free shares; • With the authorization of the General Meeting of Shareholders on June 2, 2018, the Board of Directors issued 752,100 options; • With the authorization of the General Meeting of Shareholders on May 24, 2019, the Board of Directors issued 187,350 free shares; • With the authorization of the General Meeting of Shareholders on May 24, 2019, the Board of Directors issued 1,282,800 options. 18.1 BSA Date of Grant 09/25/2012 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 30,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 07/25/2013 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 73,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/03/2014 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 10,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 03/ 24/2015 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 10,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 11/ The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 15,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 12/ The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 73,500 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/21/2016 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 20,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 12/09/2016 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 34,008 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/15/2017 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 9,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 05/02/2018 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 44,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Details of BSA Date of grant (Board of Directors) 09/25/2012 09/25/2012 09/25/2012 09/25/2012 07/25/2013 06/03/2014 Vesting period (years) 1 2 3 4 — — Plan expiration date 09/25/2022 09/25/2022 09/25/2022 09/25/2022 07/25/2023 06/03/2024 Number of BSA granted 7,500 7,500 7,500 7,500 73,000 10,000 Share entitlement per BSA 1 1 1 1 1 1 Exercise price (in €) 8.59 8.59 8.59 8.59 8.1 18.79 Valuation method used Black-Scholes Grant date share fair value (in €) 8.4 8.4 8.4 8.4 8.15 19.01 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 5.0 5.0 Discount rate(1) 1.21 % 1.21 % 1.53 % 1.53 % 1.16 % 0.71 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per BSA (in €) 2.29 2.43 2.61 2.74 2.18 4.98 Date of grant (Board of Directors) 3/24/2015 11/19/2015 12/15/2015 6/21/2016 Vesting period (years) — — — — Plan expiration date 3/24/2025 11/19/2025 12/15/2025 6/21/2026 Number of BSA granted 10,000 15,000 90,000 (1) 20,000 Share entitlement per BSA 1 1 1 1 Exercise price (in €) 43 66.06 64.14 52.97 Valuation method used Black-Scholes Grant date share fair value (in €) 43 66.06 42.61 61.25 Expected volatility 36 % 51 % 51 % 47 % Average life of BSA 5 5 5 5 Discount rate (1) 0.68 % 0.81 % -0.09 % -0.41 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA (in €) 9.9 22.6 7.28 21.59 Date of grant (Board of Directors) 12/9/2016 6/15/2017 5/2/2018 Vesting period (years) — — — Plan expiration date 12/9/2026 6/15/2027 5/2/2028 Number of BSA granted 59,000 9,000 44,000 Share entitlement per BSA 1 1 1 Exercise price (in €) 69.75 59.05 37.24 Valuation method used Black-Scholes Grant date share fair value (in €) 63.18 73.32 32.74 Expected volatility 40 % 39 % 50 % Average life of BSA 5 5 5 Discount rate (1) -0.04 % -0.12 % -0.15 % Expected dividends 0 % 0 % 0 % Performance conditions NA NA NA Fair value per BSA (in €) 12.94 24.02 9.02 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Change in Number of BSA Outstanding December 31, 2017 2018 2019 Number of BSA Balance at beginning of period 147,359 181,008 217,508 Granted during the period 68,000 44,000 — Forfeited during the period 24,902 — — Exercised during the period 9,359 7,500 — Expired during the period — — — Balance at end of period 181,008 217,508 217,508 18.2 BSA2010 Date of Grant 06/24/2011 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSA on the 12/23/2011; • up to one fourth (1/4) of the BSA on the 12/23/2012; • up to one fourth (1/4) of the BSA on the 12/23/2013; • up to one fourth (1/4) of the BSA on the 12/23/2014; and • at the latest before the 11/22/2021. Details of BSA2010 Date of grant (Board of Directors) 6/24/2011 6/24/2011 6/24/2011 6/24/2011 Vesting period (years) 0.5 1.5 2.5 3.5 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 2,000 2,000 2,000 2,000 Share entitlement per BSA2010 15 15 15 15 Exercise price (in €) 77 77 77 77 Valuation method used Black - Grant date share fair value (in €) 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % Average life of BSA2010 5.5 6 6.5 7 Discount rate 2.55 % 2.68 % 2.68 % 2.87 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA2010 (in €) 31.15 32.7 34.02 35.57 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. Change in Number of BSA2010 Outstanding December 31 , 2017 2018 2019 Number of BSA2010 Balance at beginning of period 610 500 500 Granted during the period — — — Forfeited during the period — — — Exercised during the period 110 — — Expired during the period — — — Balance at end of period 500 500 500 18.3 BCE2010 Date of Grant 06/24/2011 The BCE may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BCE on the 12/23/2011; • up to one fourth (1/4) of the BCE on the 12/23/2012; • up to one fourth (1/4) of the BCE on the 12/23/2013; • up to one fourth (1/4) of the BCE on the 12/23/2014; and • at the latest within before the 11/22/2021. Date of Grant 11/22/2011 The BSPCE may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSPCE on the 11/22/2012; • up to one fourth (1/4) of the BSPCE on the 11/22/2013; • up to one fourth (1/4) of the BSPCE on the 11/22/2014; • up to one fourth (1/4) of the BSPCE on the 11/22/2015; and • at the latest within before the 11/22/2021. Details of BCE2010 Date of grant (Board of Directors) 6/24/2011 6/24/2011 6/24/2011 6/24/2011 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 0.5 1.5 2.5 3.5 1 2 3 4 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BCE2010 granted 6,000 6,000 6,000 6,000 2,510 2,510 2,510 2,509 Share entitlement per BCE2010 15 15 15 15 15 15 15 15 Exercise price (in €) 77 77 77 77 77 77 77 77 Valuation method used Black-Scholes Grant date share fair value (in €) 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BCE2010 5.5 6 6.5 7 5.4 5.9 6.4 6.9 Discount rate 2.55 % 2.68 % 2.68 % 2.87 % 2.05 % 2.42 % 2.42 % 2.66 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BCE2010 (in €) 31.16 32.71 34.03 35.58 30.42 32.29 33.58 35.2 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE2010. Change in Number of BCE2010 Outstanding December 31 , 2017 2018 2019 Number of BCE2010 Balance at beginning of period 12,339 11,005 7,166 Granted during the period — — — Forfeited during the period — — — Exercised during the period 1,334 3,839 — Expired during the period — — — Balance at end of period 11,005 7,166 7,166 18.4 SHARE OPTIONS Grant of 09/18/2013 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 518,000 SO (all the SO) on the fourth anniversary of the date of grant; and • at the latest within ten (10) years from the date of grant. Grant of 06/03/2014 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 75,000 SO (all the SO) on the 06/04/2016; and • at the latest before the 06/03/2024. Grant of 06/23/2015 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 30,000 SO on the 06/24/2016; • up to 30,000 additional SO on the 06/24/2017; • up to 30,000 additional SO on the 06/24/2018; • up to 30,000 additional SO on the 06/24/2019; • and at the latest before the 06/24/2025. Grant of 09/30/2015 The 195,000 share options may be exercised by the beneficiary subject to the fulfillment of a presence condition • up to 25% of the SO on the 09/30/2016; • up to additional 25% of the SO on the 09/30/2017; • up to additional 25% of the SO on the 09/30/2018; • up to additional 25% of the SO on the 09/30/2019; • and at the latest before the 09/30/2025. Grant of 12/15/2015 The 75,000 share options may be exercised by the beneficiary subject to the fulfillment of a presence condition • up to 25% of the SO on the 12/15/2016; • up to additional 25% of the SO on the 12/15/2017; • up to additional 25% of the SO on the 12/15/2018; • up to additional 25% of the SO on the 12/15/2019; • and at the latest before the 12/15/2025. Grant of 04/06/2016 The 55,000 share options may be exercised by the beneficiary subject to the fulfillment of a presence condition • up to 8,250 SO on the 04/21/2017; • up to additional 8,250 SO on the 04/21/2018; • up to additional 8,250 SO on the 04/21/2019; • up to additional 8,250 SO on the 04/21/2020; • up to 5,500 SO on the 05/02/2017; • up to additional 5,500 SO on the 05/02/201 8 • up to additional 5,500 SO on the 05/02/20 19 • up to additional 5,500 SO on the 05/02/20 20 • and at the latest before 10 years of the date of the Grant. Grant of 06/21/2016 The 154,100 share options may be exercised by the beneficiary subject to the fulfillment of a presence condition • up to 25% of the SO as of one year after the Grant date; • up to additional 12.5% of the SO as of 18 months after the Grant date; • up to additional 12.5% of the SO as of 24 months after the Grant date; • up to additional 12.5% of the SO as of 30 months after the Grant date; • up to additional 12.5% of the SO as of 36 months after the Grant date; • up to additional 12.5% of the SO as of 42 months after the Grant date; • up to additional 12.5% of the SO as of 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 12/09/2016 The 74,960 share options may be exercised by the beneficiary subject to the fulfillment of a presence condition • up to 18,740 SO as of one year after the Grant date; • up to additional 9,370 SO as of 18 months after the Grant date; • up to additional 9,370 SO as of 24 months after the Grant date; • up to additional 9,370 SO as of 30 months after the Grant date; • up to additional 9,370 SO as of 36 months after the Grant date; • up to additional 9,370 SO as of 42 months after the Grant date; • up to additional 9,370 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 1,100 options as of 12/15/2016, 19,100 options as of 01/16/2017, 7,200 options as of 03/15/2017, 16,500 options as of 04/18/2017, 237,600 options as of 06/15/2017, 30,900 options as of 07/17/2017, 52,600 options as of 09/15/2017, 625,200 options as of 12/05/2017 and 8,300 options as of 12/15/2017, 15,500 options as of 01/15/2018, 16,500 options as of 04/16/2018, 16,500 options as of 05/15/2018 and 23,600 options as of 06/15/2018. All options granted between 12/15/2016 and 06 8 • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 50,000 options as of 06/22/2018, 28,800 options as of 07/16/2018, 33,500 options as of 08/15/2018, 65,000 options as of 09/06/2018, 80,900 options as of 09/17/2018, 76,700 options as of 10/15/2018, 26,000 options as of 10/15/2018, 350,000 options as of 11/29/2018, 34,000 options as of 12/12/2018 and 7,200 options as of 12/17/2018. All the 2018 options From June 22, 2018 will be exercised by the beneficiary subject to the fulfillment of a presence condition and the following performance conditions: “authorization to market Viaskin ™ and Drug administration (FDA)” and on the basis of the following vesting schedule: • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. A turnover rate is applied per plan according to the characteristics and compositions of the plan. Details of SO Date of board of director meeting 9/18/2013 6/3/2014 6/23/2015 11/19/2015 12/15/2016 4/6/2016 4/6/2016 Date of grant 9/18/2013 6/3/2014 6/23/2015 11/19/2015 1/4/2016 4/21/2016 5/2/2016 Vesting period (years) 4 2 1-4 1-4 1-4 1-4 1-4 Plan expiration date 9/18/2023 6/3/2024 6/23/2025 11/19/2025 1/4/2026 4/21/2026 5/2/2026 Number of SO granted 518,000 75,000 120,000 195,000 75,000 33,000 22,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 7.57 19.01 48.9 66.06 65.68 62.82 59.04 Valuation method used Black-Scholes Grant date share fair value (in €) 7.9 19.01 48.9 66.06 65.68 62.82 58.62 Expected volatility 40 % 40 % 51 % 51 % 49.3%-49.8 % 49.4%-50.7 % 4.3%-50.6 % Average life of SO 7 6 7 7 5-7 5-7 5-7 Discount rate (1) 1.72 % 0.89 % 0.89 % 0.81 % 0.39 % 0.04 % 0.10 % Expected dividends 0% 0% 0% 0% 0% 0% 0% Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 3.57 7.46 25.28 34.05 29.5-32.6 28.3-30.9 26.4-28.8 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/21/2016 6/21/2016 6/21/2016 6/21/2016 6/21/2016 12/9/2016 6/21/2016 Date of grant 6/21/2016 8/1/2016 9/15/2016 10/17/2016 11/15/2016 12/9/2016 12/15/2016 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/21/2026 8/1/2026 9/15/2026 10/17/2026 11/15/2026 12/9/2026 12/15/2026 Number of SO granted 110,000 10,000 9,300 16,500 8,300 74,960 1,100 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 53.96 62.24 62.8 64.39 68.33 69.75 69.35 Valuation method used Black-Scholes Grant date share fair value (in €) 52.97 62.24 62.8 64.39 68.33 69.75 69.35 Expected volatility 49.1%-50.30 % 48.8%-49.80 % 48.6%-49.40 % 48.0%-48.90 % 47.8%-48.80 % 47.7%-48.50 % 40.44 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.01 % -0.25 % -0.18 % -0.32%-0.15 % -0.11%+0.16 % -0.2%+0.18 % -0.18%+0.17 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 23.4-25.5 27.3-29.9 27.4-30.1 27.6-30.6 29.4-32.7 29.7-33.4 25.23-28.67 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/21/2016 6/21/2016 6/21/2016 6/21/2016 6/15/2017 6/15/2017 6/15/2017 Date of grant 1/16/2017 3/15/2017 4/18/2017 6/15/2017 7/17/2017 9/15/2017 12/15/2017 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 1/16/2027 3/15/2027 4/18/2027 6/15/2027 7/17/2027 9/15/2027 12/15/2027 Number of SO granted 19,100 7,200 16,500 126,000 30,900 52,600 8,300 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 66.11 66.25 60.77 59.05 71.61 74.22 38.18 Valuation method used Black-Scholes Grant date share fair value (in €) 66.11 65.42 59.73 59.05 71.61 71.8 36.43 Expected volatility 40.21 % 39.82 % 39.63 % 39.23 % 38.84 % 38.57 % 43.13 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.17%+0.19 % +0.21%+0.61 % +0.02%+0.39 % -0.21%+0.07 % +0.01%+0.34 % -0.14%+0.19 % -0.23%+0.07 % Expected dividends 0% 0% 0% 0% 0% 0% 0% Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 23.9-27.2 23.6-27.1 21.2-24.2 20.8-23.6 25.3-28.2 24.3-27.8 13.5-15.4 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/15/2017 11/17/2017 6/15/2017 6/15/2017 6/15/2017 6/15/2017 Date of grant 6/15/2017 12/5/2017 1/15/2018 4/16/2018 5/15/2018 6/15/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/15/2027 12/5/2027 1/15/2028 4/16/2028 5/15/2028 6/15/2028 Number of SO granted 111,600 625,200 15,500 16,500 16,500 23,600 Share entitlement per SO 1 1 1 1 1 1 Exercise price (in €) 60.54 39 43.6 38.64 40.84 38.92 Valuation method used Black-Scholes Grant date share fair value (in €) 59.05 35.73 43.6 38.64 40.84 35.48 Expected volatility 39.23 % 43.23 % 45.57 % 46.37 % 46.15 % 45.95 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.21%+0.07 % - % 0.32 % 0.35 % 0.41 % 0.23 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per SO (in €) 20.4-23.22 12.9-14.7 18.09-20.16 16.29-18.16 17.19-19.16 13.81-15.58 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 Date of grant 6/22/2018 7/16/2018 8/15/2018 9/17/2018 10/15/2018 11/15/2018 12/17/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/22/2028 7/16/2028 8/15/2028 9/17/2028 10/15/2028 11/15/2028 12/17/2028 Number of SO granted 50,000 28,800 33,500 80,900 76,700 26,000 7,200 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 37.22 33.81 32.9 40.94 37.28 32.57 26.76 Valuation method used Black-Scholes Grant date share fair value (in €) 34.32 32.16 32.9 40.94 31.74 28.66 26.76 Expected volatility 45.85 % 46.51 % 46.67 % 46.92 % 47.12 % 47.44 % 47.90 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) 0.19 % 0.14 % 0.17 % 0.27 % 0.37 % 0.29 % 0.26 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 13.42-15.11 13.02-14.59 13.85-15.43 17.39-19.37 12.12-13.78 11.18-12.66 11.57-12.88 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ™ Date of board of director meeting 9/6/2018 11/29/2018 12/12/2018 6/22/2018 6/22/2018 6/22/2018 5/24/2019 Date of grant 9/6/2018 7/16/2018 12/12/2018 1/15/2019 3/20/2019 5/15/2019 5/24/2019 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 9/6/2028 11/29/2028 12/12/2028 1/15/2029 3/20/2029 5/15/2029 5/24/2029 Number of SO granted 65,000 350,000 34,000 9,500 547,100 7,200 150,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 36.96 30.02 27.96 14.10 14.25 16.82 16.37 Valuation method used Black - Grant date share fair value (in €) 36.96 27.44 27.96 14.10 14.25 16.82 16.37 Expected volatility 46.85 % 47.51 % 47.87 % 69.50 % 70.40 % 70.81 % 70.85 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) 0.21 % 0.27 % 0.27 % 0.19 % 0.02 % -0.08 % -0.08 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 15.65-17.43 11.08-12.47 12.09-13.46 8.19-8.89 8.52-9.23 10.1-10.99 9.7-10.59 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ™ Date of board of director meeting 5/24/2019 5/24/2019 5/24/2019 5/24/2019 5/24/2019 5/24/2019 Date of grant 6/17/2019 7/1/2019 7/22/2019 9/16/2019 10/16/2019 12/16/2019 Ve s 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/17/2029 7/1/2029 7/22/2029 9/16/2029 10/16/2029 12/16/2029 Number of SO granted 7,200 403,400 75,000 34,000 3,500 53,100 Share entitlement per SO 1 1 1 1 1 1 Exercise price (in €) 14.55 15.43 17.90 18.00 14.40 15.80 Valuation method used Black-Scholes Grant date share fair value (in €) 14.55 15.43 17.90 18.00 14.40 15.80 Expected volatility 70.96 % 71.03 % 71.51 % 71.93 % 72.41 % 71.98 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.22 % -0.31 % -0.36 % -0.41 % -0.38 % -0.26 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 8.35-9.2 8.97-11.02 10.71-11.72 10.79-11.83 8.51-9.37 9.51-10.42 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ™ Change in Number of SO Outstanding December 31 , 2017 2018 2019 Number of SO Balance at beginning of period 1,160,060 2,133,100 2,461,570 Granted during the period 998,500 824,200 1,290,000 Forfeited during the period 24,260 227,730 749,525 Exercised during the period 1,200 268,000 — Expired during the period — — — Balance at end of period 2,133,100 2,461,570 3,002,045 The exercise prices, anticipated lifetime, and fair value of the underlying shares based on the share price on the Euronext market on the grant date of the warrants were used for the valuation of each category of compensation in shares. 18.5 FREE SHARES Details of Free Shares Board of directors Grant date 3/14/2017 4/20/2017 6/22/2018 9/6/2018 11/1/2018 12/12/2018 12/17/2018 Vesting period (years) 2 2 1 1 1 1 1 Lockup period N/A (1) N/A 1) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) Number of free shares granted 22,500 24,000 486,153 450 57,000 16,250 3,000 Share entitlement per free share 1 1 1 1 1 1 1 Grant date share fair value (in €) 68.07 61.2 34.32 36.96 33.33 27.96 26.76 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (3) Yes (3) Yes (4) Yes (4) Yes (4) Yes (4) Yes (4) Expected turnover during the vesting period 0 % 0 % 0 % 0 % 5 % 5 % 5 % (1) Those free plans are not subject to a lock-up (2) Those free plans are subject to a lock-up two (3) The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria below: • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from grant date ™ • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from grant date ™ ( 4 The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement: • expiry of the current acquisition period as from their initial allocation; and • approval of Viaskin ™ . Board of directors Grant date 5/10/2019 7/31/2019 10/11/2019 12/20/2019 Vesting period (years) 1 (1) 2 2 2 Lockup period 2 N/A N/A N/A Number of free shares granted 100,000 23,750 40,000 23,600 Share entitlement per free share 1 1 1 1 Grant date share fair value (in €) 16.10 17.63 12.43 17.23 Expected dividends 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) No (3) No (3) Expected turnover during the vesting period 5 % 5 % 5 % 5 % (1) Those free plans are subject to a lock-up two (2) The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement: • expiry of the current acquisition period as from their initial allocation; and • approval of Viaskin ™ (3) The definitive allocation of the free shares will only occur at expiry of the current acquisition period as from their initial allocation, subject to the presence requirement. Performance conditions other than market conditions, which are taken into account by adjusting the number of equity instruments included in the measurement of the transaction amount but are not taken into account when estimating the fair value of the shares. In December 2018, following the decision to voluntarily withdraw its application for BLA for Viaskin ™ ™ ™ A turnover rate is applied for each instrument according to its respective characteristics and composition. Change in Number of Free Shares Outstanding December 31 , 2017 2018 2019 Number of free shares Balance at beginning of period 1,036,850 822,856 572,228 Granted during the period 46,500 562,853 187,350 Forfeited during the period 18,650 36,525 99,850 Exercised during the period 241,844 776,956 18,000 Expired during the period — — — Balance at end of period 822,856 572,228 641,728 |
Financial Revenue and Expenses
Financial Revenue and Expenses | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Financial Revenue and Expenses | Note 19: Financial Revenue and Expenses The financial income and expenses are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Financial revenues 616 493 67 Financial expenses (3,325 ) (351 ) (1,409 ) Total (2,709 ) 141 (1,341 ) The financial income was primarily composed of unrealized exchange effect of U.S.-dollar-denominated intercompany advances and capital gains on the disposal of investment securities. Financial expenses primarily included financial interest related to lease obligations recognized in the balance sheet as part of the implementation of IFRS 16, foreign exchange losses and expenses related to the accretion of repayable advances. |
Income Tax Expense
Income Tax Expense | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Income Tax Expense | Note 20: Income Tax Expense As mentioned in Note 3.13 — — Reconciliation between the Effective and Nominal Income Tax Expense The following table shows the reconciliation between the effective and nominal tax expense at the nominal standard French rate of 33.33% as of December 31, 2017 and 28.0% as of December 31, 2018 and 2019 (excluding additional contributions): December 31, 2017 2018 2019 (Amounts in thousands of Euros) (Loss) before taxes (147,692 ) (166,061 ) (153,042 ) Theor e 33,33 % 28,00 % 28,00 % Nominal tax expense 49,226 46,497 42,852 Increase/decrease in tax expense arising from: Permanent differences — — 4,080 * Research tax credit 3,110 3,089 2,736 Share-based compensation (10,260 ) (7,253 ) (4,179 ) Non - (41,453 ) (54,205 ) (45,260 ) Non - — (324 ) (294 ) Other differences (623 ) 12,196 (481 ) Effective tax expenses — (15 ) (545 ) Effective tax rate 0,00 % 0,01 % 0,36 % * For the years ended December 31, 2017 and 2018, the permanent differences were included in “Other differences.” Deferred Tax Assets and Liabilities As mentioned in Note 3.14, the Company has not recognized deferred tax assets in the Consolidated Statements of Financial Position. The amount of the losses carried forward at the end of December 2019 is €689 exclusively A.” |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Commitments | Note 21: Commitments Obligations Under the Terms of operating leases As noted in Note 3.2 lease contracts, the application of IFRS 16 on January 1, 2019 led the C off-balance Obligations Under the Terms of Other Agreements The Company signed with its bank CIC an acquisition contract of monetary market fund “SICAV CM-CIC” A letter of credit has also been signed by the Company in April 2016 for $143 thousand to ensure the lease of its premises of its Summit (NJ) subsidiary. This credit note has been extended in 2017, 2018 and 2019. A letter of credit w ec I , the Company took a term deposit for a sum of €227 thousand over 3 years. In addition, the Company has subscribed a €3,500 thousand term deposit with the CIC banking institution as collateral for a foreign exchange pledged security up to €50 million as at December 31, 2019 which remain ed As it has sub-contracted sub-contracting Within the context of launching its clinical studies for Viaskin ™ ™ The ongoing studies amount globally to €116.2 million. As of December 31, 2019, the amount remaining to pay as part of these contracts until year ended 2023 is €29.4 million. On January 7, 2009, the Company entered into an assignment, development and co-ownership AP-HP, co- AP-HP AP-HP TM AP-HP AP-HP AP-HP non-exclusive |
Relationships with Related Part
Relationships with Related Parties | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Relationships with Related Parties | Note 22: Relationships with Related Parties The compensation amounts for 2019 presented below, which were awarded to the Corporate Officers and the members of the Executive Committee of the Company total ed December 31, 2017 2018 2019 (Amounts in thousands of Euros) Short-term benefits 3,300 5,202 7,046 Post-employment benefits 36 87 57 Termination benefits — — 4,380 Share-based payment 12,018 12,189 4,520 Total 15,353 17,478 16,004 The methods for the valuation of the benefit related to share-based payments are presented in Note 18. The company has entered into agreements with some of its directors, particularly in the context of its commercial deployment in the United States. The expense recognized for these contracts amounted to €560 thousand at December 31, 2019 compared to €49 thousand at December 31, 2018 and €45 thousand at December 31, 2017. A schedule of amounts payable to related parties: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Compensation 1,121 535 2,964 Pension obligations 402 419 70 Total 1,523 954 3,034 As of December 31, 2019, the amount of compensation include d |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Earnings Per Share | Note 2 3 The basic earnings per share is calculated by dividing the net income going to the shareholders of the Company by the weighted average number of common shares outstanding during the course of the fiscal year. The instruments that entitle their holders to a portion of the share capital on a deferred basis (BSAs, BSPCEs, SOs and free shares) are considered to be anti-dilutive (3,309,539 instruments in 2017, 3,366,296 instruments in 2018 and 3,972,596 in 2019). These instruments are presented in detail in Note 18. Therefore, the diluted earnings per share are identical to the basic earnings per share. December 31, 2017 2018 2019 (Amounts in thousands of Euros) Net income of the reporting period (147,693 ) (166,076 ) (153,587 ) Adjusted weighted average number of outstanding shares 24,757,176 28,924,976 37,007,247 Basic / Diluted earnings per share (€/share) (5.97 ) (5.74 ) (4.15 ) The weighted average number of common shares outstanding was revalued at from the first quarter of 2020, which includes the common shares issued in connection with the partial exercise of the related overallotment option in March 2020. Basic and diluted earnings per share thus amount to €(3.94) per share. |
Management of Financial Risks
Management of Financial Risks | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Management of Financial Risks | Note 24: Management of Financial Risks The principal financial instruments of the Company are comprised of financial assets, cash, and investment securities. The purpose of managing these instruments is to allow the business activities of the Company to be financed. It is not the Company’s policy to subscribe to financial instruments for speculative purposes. The Company does not utilize derivatives. The principal risks to which the Company is exposed are liquidity risk, interest rate risk and credit risk. Liquidity Risk As of December 31, 2019, the Company had €172.0 million in cash and cash equivalents compared to €122.8 million of cash and cash equivalents as of December 31, 2018. The Company has incurred operating losses and negative cash flows from operations since inception. Net cash used in operating activities was €(128.5) million for the year ended December 31, 2019 and €(136.6) million for the year ended December 31, 2018. For the year ended December 31, 2019, the Company had a net loss of €153.6 million. The Company has primarily funded these losses through equity financings, and, to a lesser extent, by obtaining public assistance in support of innovation and reimbursements of research tax credit. To date, the Company has not generated any product revenue and the Company continues to prepare for the potential launch of its Viaskin Peanut product candidate in North America, which we expect in the second half of 2020, if approved. In October 2019, the Company announced the FDA’s acceptance for review of its Biologics License Application for Viaskin ™ ™ The Company expects operating losses to continue for the foreseeable future. Based on its current operations, plans and assumptions, current cash-on-hand The Company expects that it will need to raise additional capital in the future as it commercializes Viaskin Peanut, if approved, and continues to discover and develop other product candidates using its Viaskin Platform. The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive The financial statements have been prepared on a going concern basis, assuming that the Company will be successful in its financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. Long-term collaboration agreement Risk The Company may not generate the sales and financial results estimated at the time the commitments were made as reflected in the projected budget at completion. Given the number of factors that could affect the cost structure and profitability of a clinical study compared to initial estimates, and the difficulties in implementing appropriate management control procedures designed to identify and adjust for any budget change, significant additional costs could be incurred or certain collaboration agreements could underperform. An inability to anticipate these risks accurately and thus to contain costs could be significantly penalize the Company result. Foreign Exchange Risk The Company is exposed to foreign exchange risk inherent in some of its supplies obtained in the United States, which have been invoiced in U.S. dollars. As of the date of these financial statements, the Company does not have revenues in dollars nor in any other currency other than the euro. Due to the relatively low level of these expenditures, the Company believes its exposure to foreign exchange risk is unlikely to have a material adverse impact on its results of operations or financial position. The Company’s exposure to currencies other than the U.S. dollar is negligible. For 2019, approximately 25% of the Company’s purchases and other external expenses have been made in U.S. dollars compared with 34% in 2018 and less than 12% in 2017. Exchange rate effects have a non-significant |
Events After the Close of the F
Events After the Close of the Fiscal Year | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Events After the Close of the Fiscal Year | Note 25: Events after the Close of the Fiscal Year 1. CLINICAL PROGRAMS On January 8, 2020, the Company announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin ™ trial . On February 21, 2020, the Company announced an allergenic products advisory committee meeting from the FDA to be held on May 15, 2020 to discuss the BLA for Viaskin ™ submission, as part of the ongoing BLA review, of additional information on patch-site adhesion from the Company’s clinical program as well as on its long-term efficacy results from the three-year open-label extension trial, PEOPLE. At this time, the Company has received no additional information regarding the timeline of the BLA review and believes the target action date of August 5, 2020 remains unchanged. However, the submission of additional information to the FDA may constitute a major amendment to the BLA and could extend the target action date. 2. FINANCING On February 4, 2020, the Company announced the closing On March 2, 2020, the Company announced that the underwriters partially exercised their option to purchase 338,687 additional ordinary shares in the form of 677,374 ADSs at an offering price of $10.25 per ADS, before deducting commissions and estimated offering expenses (the “Option”). The Option closed on March 4, 2020. Consequently, following partial exercise of the Option, the total number of ordinary shares sold in the global offering was 7,838,687 ordinary shares, including 4,874,268 ordinary shares in the form of 9,748,536 ADSs, bringing the total gross proceeds from the global offering to approximately $160.7 million (approximately €146.1 million). 3. CHANGE IN THE GROUP’S EXECUTIVE COMMITTEE MEMBERSHIP AND BOARD MEMBERS On January 2, 2020, the Company announced the appointment of Ramzi Benamar as its Chief Financial Officer. He serves as a member of the Executive Committee and reports to Daniel Tassé, Chief Executive Officer of DBV Technologies. On January 9, 2020, Marie-Catherine Therene was appointed Deputy CEO as DBV’s responsible pharmacist ( Pharmacien Responsable On February 6, 2020, the Company announced the appointment of Pascal Wotling as its Chief Technical Operations Officer (CTOO), effective April 1, 2020. Pascal will be responsible for manufacturing, supply chain and new product process development, and will serve as a member of the Executive Committee, reporting to Daniel Tassé, Chief Executive Officer of DBV Technologies. 4. OTHER KEY EVENTS On January 23, 2020, the Company initiated a project of adjustment of its global organization, in order to focus on its key strategic priorities. In France, DBV Technologies has proposed to its staff representatives a Collective Performance Agreement to be negotiated, with the objective to meet the Company’s operational requirements while preserving and developing employment. The Company evaluated subsequent events that occurred after December 31, 2019 through the date of approval of the consolidated financial statements by the Board of Directors and determined that there are no other significant events that require adjustments or disclosure in such consolidated financial statements. |
Accounting Principles (Policies
Accounting Principles (Policies) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Methods of principles | Methods of consolidation The Financial Statements incorporate the standalone financial statements of DBV Technologies S.A and its subsidiaries which are controlled by the Company. Control is achieved when the Company: • has power over the subsidiary; • is exposed, or has rights, to variable returns from its involvement with the subsidiary; and • has the ability to use its power to affect its returns. The Company reassesses whether or not it controls a subsidiary if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of subsidiaries begins when the Company obtains control over the subsidiary and ceases when the Company loses control over the subsidiary. Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non- non-controlling non-controlling When necessary, adjustments are made to the financial statements of subsidiaries to align their accounting policies with the Group’s accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are neutralized in consolidation. Translation of financial statements in foreign currencies In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into euros using exchange rates prevailing at the end of each reporting period. Income and expense items are translated at the average exchange rates at the dates of the transactions. Exchange differences arising, if any, are recognized in other comprehensive income and accumulated in equity. |
Going concern | The Company has primarily funded these losses through equity financings, and, to a lesser extent, by obtaining public assistance in support of innovation and reimbursements of research tax credit. To date, the Company has not generated any product revenue and the Company continue s its The Company expects operating losses to continue for the foreseeable future. Current cash-on-hand and cash equivalents, including the €136.4 million net proceeds from the offering in first quarter of The Company expects that it will need to raise additional capital in the future as it commercializes Viaskin Peanut, if approved, and continues to discover and develop other product candidates using its Viaskin Platform The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings. However, no assurance can be given at this time as to whether the Company will be able to achieve these financing objectives. The financial statements have been prepared on a going concern basis assuming that the Company will be successful in its financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. Refer to the liquidity risk disclosed in Note 24 |
Intangible Assets | 3.1 Intangible Assets In application of the provisions in IAS 38 Intangible Assets Research and Development Expenses Research expenses are recorded in the Financial Statements as expenses. In accordance with IAS 38, development expenses are recorded in the Financial Statements as intangible assets only if all the following criteria are met: (a) technical feasibility necessary for the completion of the development project; (b) intention on the part of the Company to complete the project and to utilize it; (c) capacity to utilize the intangible asset; (d) proof of the probability of future economic benefits associated with the asset; (e) availability of the technical, financial, and other resources for completing the project; and (f) reliable evaluation of the development expenses. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 are only fulfilled once the Market Access Authorization has been obtained from the competent authorities. The application of this principle has resulted in all development costs being expensed as incurred. Software The costs related to the acquisition of licenses to software are posted to assets on the basis of the costs incurred to acquire and to implement the software in question. They are amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. |
Lease Contracts | 3.2 Lease contracts IFRS 16 became applicable on January 1, 2019, requiring the Company to update its accounting policies on leases. IFRS 16 aligns the balance sheet accounting treatment of operating leases on that of finance leases with the recognition of a liability for future lease payments, and of an asset for the associated rights-of-use. contract-by-contract The first-time application of IFRS 16 also lead to a change in presentation: • On the opening balance sheet: the recognition of an asset corresponding to the rights-of-use • On the income statement: the lease expense previously recognized as a component of operating income is, under IFRS 16, recognized partly as depreciation expense within operating income, and partly within Financial expenses; • On the statement of cash flows: the lease payments previously presented within net cash provided used in operating activities is, under IFRS 16, presented within net cash used in financing activities to the extent that those payments are allocated to repayment of the lease liability. For its transition method, the Group has elected to apply the simplified approach as of January 1, 2019. Prior-period comparative data will therefore not be restated at the transition date. The Group has decided to apply the exemptions to lease with a term of less than 12 months and to leases of low-value Measurement of the right- of use asset At the commencement date, the right-of-use • The amount of the initial measurement of the lease liability, adjusted by the amount of any prepaid or accrued lease payments recognized in the statement of financial position immediately before the date of initial application; • Where relevant, any initial direct costs incurred by the lessee for the conclusion of the contract. These are incremental costs which would not have been incurred if the contract had not been concluded; • Estimated costs for restoration and dismantling of the leased asset according to the terms of the contract. The majority of leases entered into by the Company are operating leases in which the Company is a lessee. The Group’s operating leases mainly relate to real estate assets and to a lesser extent to industrial equipment and company cars. Following the initial recognition, the right-of-use In accordance with IAS 36 “Impairment of Assets”, right-of-use Measurement of the lease liability At the commencement date, the lease liability is recognized for an amount equal to the present value of the lease payments over the lease term. Amounts involved in the measurement of the lease liability are the contractual rents. The lease liability is subsequently measured based on a process similar to the amortized cost method using the discount rate: • The liability is increased by the accrued interests resulting from the discounting of the lease liability, at the beginning of the lease period; • Less payments made. The discount rate applied to each contract takes into account the remaining terms of the contracts from the date of first application, i.e. January 1, 2019, and the currency of each contract. The discount rates applied at the transition date are based on the Company’s marginal borrowing rate, to which is added a spread of its own which takes into account the nature and the total duration of the contract. The discount rates and remaining term of the contracts determined by management are based on historical information and other factors considered reasonable in the circumstances. The interest cost for the period as well as variable payments, not taken into account in the initial measurement of the lease liability and incurred over the relevant period are recognized as costs. In addition, the lease liability may be remeasured in the following situations: • Change in the lease term; • Modification related to the assessment of the reasonably certain nature (or not) of the exercise of an option; • Adjustment to the rates and indices according to which the rents are calculated when rent adjustments occur. The following tables present the impacts of the first application of IFRS on the opening balance sheet: Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 ASSETS Intangible assets 29 — 29 Right-of-use — 23,792 23,792 Property, plant, and equipment 20,219 — 20,219 Other non-current 6,033 — 6,033 Total non-current 26,281 23,792 50,074 Total current assets 145,468 — 145,468 TOTAL ASSETS 171,749 23,792 195,542 Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 LIABILITIES Shareholders’ equity Total shareholders’ equity 121,286 — 121,286 Non-current Long-term financial debt 1,278 — 1,278 Long-term lease debt — 22,682 22,682 Non-current 1,536 — 1,536 Other non-current 4,105 (1,546 ) 2,559 Total non-current 6,919 21,136 28,055 Current liabilities Short-term financial debt 1,201 — 1,201 Short-term lease debt — 2,973 2,973 Current provisions 1,270 — 1,270 Supplier accounts payable 28,567 — 28,567 Other current liabilities 12,506 (317 ) 12,189 Total current liabilities 43,543 2,656 46,200 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 171,749 23,792 195,542 The following table present the reconciliation of lease liabilities on the date of transition with off-balance sheet (in thousands of euros) Commitments given under operating leases as of December 31, 2018 30,429 Effects of rental expenses not recognized into IFRS 16 (4,061 ) Other effects, including currency effects and rent-free periods 4,035 Lease debt before discounting 30,402 Effect of discounting (4,748 ) Lease debt after discounting 25,655 Existing finance leases as of December 31, 2018 — Lease debt as of January 1, 2019 after first-time application of IFRS 16 25,655 Commitments given at December 31, 2018 included €30,267 thousand under real estate leases and €163 thousand under industrial equipment and vehicles leases. |
Property, Plant, and Equipment | 3.3 Property, Plant, and Equipment Property, plant, and equipment are recorded at their acquisition cost or, if applicable, at their production cost. Property, plant, and equipment are depreciated on the basis of the straight-line method over the estimated use period of the property. The fixtures of property rented are depreciated over the term of their own lifetime or of the term of the rental agreement, whichever is shorter. The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years |
Financial Assets | 3.4 Financial Assets IFRS 9 defines the rules applicable to the classification and recognition of financial instruments, the impairment of financial assets (using a model of expected losses to replace the model of losses incurred) as well as hedge accounting. The Company did not hold any hedging instrument as of December 31, 2018 and as of December 31, 2019. As of December 31, 2019, financial assets can be classified into three categories: Financial assets at amortized cost Financial assets at amortized cost are mainly cash and cash equivalent, loans and receivables, measured at amortized cost using the effective interest rate method, adjusted for expected credit losses and at initial recognition at their fair value (acquisition cost and transaction costs). Interest recognized at the effective interest rate is recognized under “Other financial income and expenses” in the statement of profit and loss. Financial assets at fair value through profit or loss: Financial assets at fair value through profit or loss is comprised of: • instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are managed other than with a view to collecting cash flows and/or selling the asset; • instruments that management has designated as ‘fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items Financial income or Financial expenses. Financial assets at fair value through other comprehensive income mainly comprise: Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January 1, 2019 and as of December 31, 2019. Impairment of financial assets measured at amortized cost The Company considers that a financial asset is impaired according to the expected loss method in order to take into account any defaults during the asset holding period. The amount of the expected loss is recognized in the balance sheet. Impairment losses are recognized in profit or loss. |
Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment | 3.5 Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment The property, plant, and equipment and intangible assets that have an established lifetime are subjected to an impairment test when the recoverability of their book value is called into question by the existence of indications of impairment. An impairment is posted to the accounts up to the amount of the excess of the book value over the recoverable value of the asset. The recoverable value of an asset corresponds to its fair value minus the costs of sale or its use value, whichever is higher. |
Inventories and Work in Progress | 3.6 Inventories and Work in Progress Inventories are measured at production costs calculated using the first-in, first-out Depreciation may be recorded on finished goods and work in progress (i) if their production value is greater than their net realizable value, we estimate that the estimated costs for finalization and the estimated costs for the sale, or (ii) if certain products are no longer used by the company, otherwise they are perishable. At December 31, 2018 and at December 31, 2019, inventories were exclusively composed of work in progress relating to the production of the first batches that may be used for the commercialization and secondly to requalified batches that are not intended to be commercialized, which were fully depreciated. |
Share Capital | 3.7 Share Capital Common shares are classified under Shareholders’ Equity. The costs of share capital transactions that are directly attributable to the issue of new shares or options are recorded in the Financial Statements in Shareholders’ Equity as a deduction from the revenue from the issue, net of tax. |
Payments in Shares | 3.8 Payments in Shares Since its incorporation, the Company has established several plans for compensation paid in equity instruments in the form of employee warrants ( bons de souscription de parts de créateur d’entreprise “ bons de souscription d’actions non-employee Pursuant to IFRS 2 Share-based payment The Company has applied IFRS 2 to all equity instruments granted since 2002 to corporate officers, members of the Scientific Committee and employees of the Company, as well as to certain persons bound by a service or investment contract. consultant to the Company. The options are not subject to any market conditions. The characteristics of the options are presented in Note 18. |
Recognition and measurement of Financial Liabilities | 3.9 Recognition and measurement of Financial Liabilities Non-derivative Other non-derivative Borrowings and debt Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within Financial expenses in the income statement over the term of the debt using the effective interest method. |
Subsidies and Conditional Advances | 3.10 Subsidies and Conditional Advances The Company receives assistance in the form of subsidies, which are grants that are not repayable by the Company. Subsidies The subsidies are recognized when there is reasonable assurance that: • the Company will comply with the conditions attached to the subsidies, and • the subsidies will be received. Subsidies that are upfront non-refundable A public subsidy that is to be received (e.g. from OSEO, the French Agency for Innovation) either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without associated expenses or losses, is recognized as other income ratably over the duration of the funded project. Conditional advances The Company also receives from time to time assistance in the form of conditional advances, which are advances repayable in whole or in part based upon acknowledgment by the funder of a technical or commercial success of the related project by the funding entity. The details concerning the conditional advances are provided in Note 12. The amount resulting from the deemed benefit of the interest-free nature of the award is considered a subsidy for accounting purposes. This deemed benefit is determined by applying a discount rate equal to the rate of fungible treasury bonds over the time period that corresponds to the time period of the repayment of the advances. In the event of a change in payment schedule of the stipulated repayments of the conditional advances, the Company makes a new calculation of the net book value of the debt resulting from the discounting of the expected new future cash flows. The adjustment that results therefrom is recognized in the income statement for the fiscal year during which the modification is recognized. |
Provisions | 3.11 Provisions Provisions for Risks and Expenses The provisions for risks and lawsuits correspond to the commitments resulting from lawsuits and various risks whose due dates and amounts are uncertain. A provision is posted to the accounts when the Company has a legal or implicit obligation to a third party resulting from a past event, concerning which it is likely or certain that it will cause an outflow of resources to that third party, without consideration that is anticipated to be at least equivalent to the latter, and that the future outflows of liquid assets can be estimated reliably. The amount recorded in the accounts as a provision is the best estimation of the expenses necessary to extinguish the obligation. Pension Retirement Obligations The employees of the Company receive the retirement benefits stipulated by law in France: • obtaining a compensation paid by the Company to employees upon their retirement (defined-benefit plan); • payment of retirement pensions by the Social Security agencies, which are financed by the contributions made by companies and employees (defined-contribution plans). For the defined-benefit plans, the costs of the retirement benefits are estimated by using the projected credit unit method. According to this method, the cost of the retirement pensions is recognized in the Consolidated Statement of (Loss) so that it is distributed uniformly over the term of the services of the employees. The retirement benefit commitments are valued at the current value of the future payments estimated using, for the discounting, the market rate based on the long-term obligations of the first-category companies with a term that corresponds to that estimated for the payment of the services provided. The difference between the amount of the provision at the beginning of a fiscal year and at the close of that year is recognized through profit or loss for the portion representing the costs of services rendered and through other comprehensive income for the portion representing the actual gains and losses. The Company’s payments for the defined-contribution plans are recognized as expenses on the income statement of the period with which they are associated. |
Revenue | 3.12 Revenue The Company accounts for revenue when the amount can be reliably assessed, future economic benefits are likely to benefit the Company, and specific criteria are met for the Company’s business, which is in accordance with IFRS 15. |
Other Income | 3.13 Other Income Subsidies Since it was formed, because of its innovative character, the Company has received a certain number of sources of assistance or subsidies from the central government or from local public authorities such as OSEO or the Banque Publique d’Investissement (BPI), intended to finance its operations or the recruitment of specific personnel. When the obtention of the subsidy is reasonably certain, these subsidies are recognized as “Other income” during the calendar year over which the corresponding expenses or expenditures were recorded. Research Tax Credit The Research Tax Credit ( Crédit d’Impôt Recherche, The Company has received the Research Tax Credit annually since it was formed. The Company received the reimbursement of the 2018 Research Tax Credit for an amount of €10.8 million during the year 2019. Beginning in the fiscal year ending December 31, 2019, the Company will no longer benefit from the immediate reimbursement of the Research Tax Credit due to the loss of the Small and Medium-sized the event cannot The repayable portion of the Research Tax Credit in more than one year is recorded in other non-current Collaboration agreement with Nestlé Health Science On May 31, 2016, the Company announced its entry into an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use non-refundable Regarding the first application of IFRS 15 on January 1, 2018, an analysis has been completed on performance conditions, revenue recognition method for milestones payment and on the sale price allocation for the collaboration contract signed with Nestlé in 2016. It has been determined that the license and developments to be made by the Company are a unique performance obligation. As a result, the Company has concluded that under IFRS 15, revenue related to the contract will be recognized progressively, up to the costs incurred by the Company. No margin is recognized at this stage of the development. Deferred revenue is recognized and reversed over the period in which there is a contractual obligation. This this agreement is not considered an onerous contract for the year-ended December 31, |
Taxes | 3.14 Taxes Income Tax Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of the assets and liabilities that appear in the financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward. The tax rates that have been ratified by a legal text as of the closing date are utilized to determine the deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is likely that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforward in the Consolidated Statements of Financial Position. |
Segment Information | 3.15 Segment Information The Company operates in a single operating segment: the conducting of research and development of epicutaneous immunotherapy products in order to market them in the future. The assets, liabilities, and operating losses recognized are primarily located in France. |
Other Items in the Comprehensive (or Loss) | 3.16 Other Items in the Comprehensive (or Loss) The revenue and expense items for the period that are not posted in the Consolidated Statements of (Loss) as stipulated by the applicable standards are presented, as necessary, under the rubric “Other items in the comprehensive (or loss).” |
Use of Estimates | 3.17 Use of Estimates The preparation of the Company’s Financial Statements requires the management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. Estimates and assumptions are based on historical experience and other factors that management believes to be reasonable under the circumstances. Estimates and assumptions are measured on an ongoing basis. Actual results may differ from these estimates. These estimates and judgments mainly involve: • an estimate of time and costs required to complete the collaboration agreement with Nestlé Health Science; • a valuation of the fair value of the employee warrants (BSPCEs) granted to employees and/or executives and share warrants (BSAs) granted to non-employee • an estimate of the expected dates of achievement of the performance conditions for the duration of the spillover from the granting of stock options and free shares; • an estimate of the Research Tax Credit based on internal and external expenses incurred by the Company during the year. Only eligible research expenses are included in the calculation of the research tax credit; • an estimate of provisions. |
Presentation of Financial Assets and Financial Liabilities Measured at Fair Value | 3.18 Presentation of Financial Assets and Financial Liabilities Measured at Fair Value In accordance with the amendments to IFRS 13, Fair value measurement and IFRS 7, financial instruments are presented in three categories based on a hierarchical method used to determine their fair value: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. |
Subsequent events | 3.19 Subsequent events The Consolidated Statements of Financial Position and the Consolidated Statements of (Loss) of the Company are adjusted to reflect the subsequent events that alter the amounts related to the situations that exist as of the closing date. The adjustments are made until the date the financial statements are approved and authorized for issuance by the Board of Directors. |
Accounting Principles (Tables)
Accounting Principles (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Detailed information about current tax assets liabilities explanatory | The following tables present the impacts of the first application of IFRS on the opening balance sheet: Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 ASSETS Intangible assets 29 — 29 Right-of-use — 23,792 23,792 Property, plant, and equipment 20,219 — 20,219 Other non-current 6,033 — 6,033 Total non-current 26,281 23,792 50,074 Total current assets 145,468 — 145,468 TOTAL ASSETS 171,749 23,792 195,542 Information December 31, First-time application of IFRS 16 Information January 1, 2019 with IFRS 16 LIABILITIES Shareholders’ equity Total shareholders’ equity 121,286 — 121,286 Non-current Long-term financial debt 1,278 — 1,278 Long-term lease debt — 22,682 22,682 Non-current 1,536 — 1,536 Other non-current 4,105 (1,546 ) 2,559 Total non-current 6,919 21,136 28,055 Current liabilities Short-term financial debt 1,201 — 1,201 Short-term lease debt — 2,973 2,973 Current provisions 1,270 — 1,270 Supplier accounts payable 28,567 — 28,567 Other current liabilities 12,506 (317 ) 12,189 Total current liabilities 43,543 2,656 46,200 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 171,749 23,792 195,542 |
Summary of Depreciation Periods | The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years |
Schedule of Reconciliation between Finance Lease Obligations and Finance Lease Debts | The following table present the reconciliation of lease liabilities on the date of transition with off-balance sheet (in thousands of euros) Commitments given under operating leases as of December 31, 2018 30,429 Effects of rental expenses not recognized into IFRS 16 (4,061 ) Other effects, including currency effects and rent-free periods 4,035 Lease debt before discounting 30,402 Effect of discounting (4,748 ) Lease debt after discounting 25,655 Existing finance leases as of December 31, 2018 — Lease debt as of January 1, 2019 after first-time application of IFRS 16 25,655 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Intangible Assets | The intangible assets are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Patents, licenses, trademarks 414 201 201 Software 450 703 730 Total, gross 864 905 931 Accumulated depreciation of patents, licenses, and trademarks (340 ) (200 ) (201 ) Accumulated depreciation of software packages (401 ) (675 ) (688 ) Accumulated amortization and depreciation (741 ) (875 ) (889 ) Total, net 123 29 43 |
Lease Contracts (Tables)
Lease Contracts (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Analysis of Right-Of-Use Assets | Analysis of right-of-use Real Other Total At January 1, 2019 — — — First application of IFRS 16 23,462 330 23,792 Addition of assets — 130 130 D expense (3,257 ) (125 ) (3,382 ) Translation adjustments and other 48 — 48 At December 31, 2019 20,253 336 20,589 |
Summary of Analysis of Maturities of Lease Liabilities | Analysis of maturities of lease liabilities as of December 31, 2019. 12/31/2019 Less than One Y 3,281 One to Five Years 13,282 More than Five Years 6,296 Total 22,860 |
Property, Plant, and Equipment
Property, Plant, and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Property, Plant, and Equipment | 1/1/2017 Increase Decrease 12/31/2017 (Amounts in thousands of Euros) Laboratory equipment 3,097 2,806 (83 ) 5,820 Building fixtures 4,610 534 (46 ) 5,098 Office equipment 607 275 (116 ) 766 Computer equipment 986 116 (30 ) 1,073 Property, plant, and equipment in progress 6,385 3,384 (55 ) 9,714 Total, gross 15,685 7,114 (329 ) 22,470 Accumulated depreciation of laboratory equipment 1,505 802 (63 ) 2,244 Accumulated depreciation of the building fixtures 1,109 484 (14 ) 1,580 Accumulated depreciation of office equipment 212 213 (105 ) 320 Accumulated depreciation of computer equipment 377 172 (30 ) 520 Total accumulated amortization and depreciation 3,202 1,671 (211 ) 4,663 Total, net 12,482 5,443 (118 ) 17,807 1/1/2018 Increase Decrease 12/31/2018 (Amounts in thousands of Euros) Laboratory equipment 5,820 6,305 (12 ) 12,113 Building fixtures 5,098 133 — 5,231 Office equipment 766 25 — 790 Computer equipment 1,073 434 — 1,507 Property, plant, and equipment in progress 9,714 7,623 (9,750 ) 7,587 Total, gross 22,470 14,520 (9,762 ) 27,228 Accumulated depreciation of laboratory equipment 2,244 1,567 — 3,811 Accumulated depreciation of the building fixtures 1,580 352 (12 ) 1,919 Accumulated depreciation of office equipment 320 129 — 449 Accumulated depreciation of computer equipment 520 310 — 830 Total accumulated amortization and depreciation 4,663 2,358 (12 ) 7,009 Total, net 17,807 12,162 (9,750 ) 20,219 1/1/2019 Increase Decrease 12/31/2019 (Amounts in thousands of Euros) Laboratory equipment 12,113 383 (64 ) 12,432 Building fixtures 5,231 582 — 5,813 Office equipment 790 18 — 808 Computer equipment 1,507 187 — 1,694 Property, plant, and equipment in progress 7,587 3,842 (24 ) 11,405 Total, gross 27,228 5,012 (88 ) 32,152 Accumulated depreciation of laboratory equipment 3,811 1,786 (64 ) 5,533 Accumulated depreciation of the building fixtures 1,919 671 — 2,590 Accumulated depreciation of office equipment 449 129 — 578 Accumulated depreciation of computer equipment 830 351 — 1,181 Total accumulated amortization and depreciation 7,009 2,937 (64 ) 9,882 Total, net 20,219 2,075 (24 ) 22,270 |
Non-Current Financial Assets (T
Non-Current Financial Assets (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Non-Current Financial Assets | December 31, 2017 2018 2019 (Amounts in thousands of Euros) Research tax credit — — 9,764 Pledged securities and other non-current 1,102 4,226 4,314 Deposits 577 1,374 1,359 Liquidity contract 1,333 432 1,051 Total non-current 3,012 6,033 16,488 |
Summary of Research Tax Credit | The variance in Research Tax Credit during the three years presented is presented as follow: Amount in thousands Opening balance sheet receivable as of January 1, 2017 7,228 + Operating revenue 9,217 - Payment received (7,341 ) - Adjustement 113 Closing balance sheet receivable as of December 31, 2017 9,217 Amount in thousands Opening balance sheet receivable as of January 1, 2018 9,217 + Operating revenue 10,829 - Payment received (9,479 ) - Adjustement 262 Closing balance sheet receivable as of December 31, 2018 10,829 Amount in thousands Opening balance sheet receivable as of January 1, 2019 10,829 + Operating revenue 9,764 - Payment received (10,835 ) - Adjustement 6 Closing balance sheet receivable as of December 31, 2019 9,764 |
Inventories and Work in Progr_2
Inventories and Work in Progress (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Inventories | December 31, 2017 2018 2019 (Amounts in thousands of Euros) Inventories of raw materials — — 64 Work in progress — 2,338 3,150 Depreciation of inventories (charged to income statement) — (772 ) (1,177 ) Total net value of the inventories — 1,566 2,038 |
Customer Accounts Receivable _2
Customer Accounts Receivable and Other Current Assets (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Customer Accounts Receivable and Related Receivables | Customer Accounts Receivable and Related Receivables December 31, 2017 2018 2019 (Amounts in thousands of Euros) Accounts receivable 1,265 — — Valuation allowance (charged to income statement) — — — Total net value of accounts receivable 1,265 — — |
Summary of Other Current Assets | The other current assets are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Research tax credit 9,217 10,829 — Other tax claims 5,258 4,292 3,995 Other receivables 1,192 1,745 825 Prepaid expenses 2,054 4,265 3,201 Total 17,721 21,131 8,021 |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Cash and Cash Equivalents | The cash and cash equivalents item is broken down as follows (in thousands of Euros): 2017 2018 2019 (Amounts in thousands of Euros) Cash 32,054 77,236 51,524 Cash equivalent term deposits 105,826 45,534 120,503 Total cash and cash equivalent as reported in statement of financial position 137,880 122,770 172,027 Bank overdrafts — — — Total net cash and cash equivalents as reported in the statement of cash flow 137,880 122,770 172,027 |
Capital (Tables)
Capital (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Historical Changes in the Share Capital of the Company | The table below presents the historical changes in the share capital of the Company as of December 31, 2017, 2018 and 2019: Date Nature of the transactions Share Share Number of Nominal Balance as of January 1, 2017 2,464 . 405,882 . 24,648,828 0.10 € 2/3/2017 Capital increase by issuance of common shares 2.0 100.7 20,010 0.10 € 2/9/2017 Issue of share subscription warrants 237.4 5/16/2017 Capital increase by issuance of common shares 4.0 170.7 40,365 0.10 € 7/12/2017 Capital increase by issuance of common shares 0.2 8.3 1,650 0.10 € 8/4/2017 Capital increase by issuance of common shares 0.1 64.6 1,200 0.10 € 8/15/2017 Issue of share subscription warrants 53.1 9/14/2017 Capital increase by issuance of common shares 3.6 208.2 35,925 0.10 € 9/29/2017 Capital increase by issuance of common shares 0.1 4.0 500 0.10 € 9/30/2017 Capital increase by incorporation of reserve 23.1 -23.1 230,843 0.10 € 10/2/2017 Capital increase by issuance of common shares 0.1 4.0 500 0.10 € 12/15/2017 Capital increase by incorporation of reserve 1.1 -1.1 11,001 0.10 € Balance as of December 31, 2017 2,499 . 406,709 . 24,990,822 0.10 € Balance as of January 1, 2018 2,499 . 406,709 . 24,990,822 0.10 € 1/8/2018 Capital increase by issuance of common shares 0.7 52.3 7,000 0.10 € 1/9/2018 Capital increase by issuance of common shares 0.5 25.2 5,010 0.10 € 1/16/2018 Capital increase by issuance of common shares 2.0 100.4 19,950 0.10 € 1/18/2018 Capital increase by issuance of common shares 12.9 963.6 129,000 0.10 € 1/30/2018 Capital increase by issuance of common shares 1.3 97.1 13,000 0.10 € 1/31/2018 Capital increase by issuance of common shares 2.0 149.4 20,000 0.10 € 2/16/2018 Capital increase by incorporation of reserve 23.8 -23.8 238,337 0.10 € 3/13/2018 Capital increase by incorporation of reserve 23.8 -23.8 238,319 0.10 € 3/23/2018 Capital increase by issuance of common shares 352.8 122,095.5 3,527,752 0.10 € 3/26/2018 Capital increase by issuance of common shares 52.9 18,314.3 529,162 0.10 € 4/5/2018 Capital increase by issuance of common shares 1.2 91.9 12,302 0.10 € 4/6/2018 Capital increase by incorporation of reserve 5.8 -5.8 57,500 0.10 € 4/6/2018 Capital increase by issuance of common shares 1.4 105.6 14,138 0.10 € 4/9/2018 Capital increase by issuance of common shares 0.4 26.6 3,560 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 21.2 2,500 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 20.0 2,500 0.10 € 4/16/2018 Capital increase by issuance of common shares 0.3 46.7 2,500 0.10 € 6/21/2018 Capital increase by incorporation of reserve 19.3 -19.3 193,000 0.10 € 7/2/2018 Issue of share subscription warrants 163.7 7/5/2018 Capital increase by issuance of common shares 3.3 164.1 32,625 0.10 € 7/11/2018 Capital increase by issuance of common shares 6.4 478.1 64,000 0.10 € 8/16/2018 Capital increase by incorporation of reserve 1.0 -1.0 10,000 0.10 € 9/1/2018 Capital increase by incorporation of reserve 0.5 -0.5 5,000 0.10 € 9/21/2018 Capital increase by issuance of common shares 0.5 37.3 5,000 0.10 € 10/27/2018 Capital increase by incorporation of reserve 1.5 -1.5 15,000 0.10 € 12/9/2018 Capital increase by incorporation of reserve 2.0 -2.0 19,800 0.10 € 12/31/2018 Fees charged to share premium -10,292.6 Balance as of December 31, 2018 3,015 . 539,292 . 30,157,777 0.10 € Balance as of January 1, 2019 3,015 . 539,292 . 30,157,777 0.10 € 4/8/2019 Capital increase by issuance of common shares 600.0 71,520.0 6,000,000 0.10 € 9/30/2019 Fees charged to share premium -5,733.4 10/4/2019 Capital increase by incorporation of reserve 1.8 -1.8 18,000 0.10 € 10/11/2019 Capital increase by issuance of common shares 948.4 113,255.8 9,484,066 0.10 € 10/15/2019 Capital increase by issuance of common shares 136.9 16,344.7 1,368,667 0.10 € 12/31/2019 Fees charged to share premium -9,216.7 Balance as of December 31, 2019 4,702 . 725,460 . 47,028,510 0.10 € |
Summary of Share Warrants and Employee Warrants | The Company has issued share warrants (BSAs), employee warrants (BSPCEs), f r Grant date Type Number of Number of Number of Number of Number of Maximum of Number of Subscription 6/24/2011 BCE 7,166 — — — 7,166 107,490 107,490 5.13 6/24/2011 BSA2010 500 — — — 500 7,500 7,500 5.13 9/25/2012 BSA 5,000 — — — 5,000 5,000 5,000 8.59 7/25/2013 BSA 7,000 — — — 7,000 7,000 7,000 8.10 9/18/2013 SO 203,000 — — — 203,000 203,000 203,000 7.57 6/3/2014 SO 40,000 — — 40,000 — — — 19.01 3/24/2015 BSA 10,000 — — — 10,000 10,000 10,000 43.00 6/23/2015 SO 120,000 — — — 120,000 120,000 120,000 48.90 11/19/2015 BSA 15,000 — — — 15,000 15,000 15,000 66.06 11/19/2015 SO 170,000 — — 170,000 — — — 66.06 12/15/2015 BSA 73,500 — — — 73,500 73,500 73,500 64.14 1/4/2016 SO 75,000 — — — 75,000 75,000 56,250 65.68 4/21/2016 SO 22,000 — — — 22,000 22,000 16,500 62.82 6/21/2016 SO 87,500 — — 50,000 37,500 37,500 32,813 53.96 6/21/2016 BSA 20,000 — — — 20,000 20,000 20,000 52.97 8/1/2016 SO 10,000 — — — 10,000 10,000 7,500 62.24 9/15/2016 SO 9,300 — — — 9,300 9,300 6,975 62.80 10/17/2016 SO 9,300 — — — 9,300 9,300 6,975 64.39 11/15/2016 SO 8,300 — — — 8,300 8,300 6,225 68.33 12/9/2016 BSA 34,008 — — — 34,008 34,008 34,008 69.75 12/9/2016 SO 51,995 — — 9,050 42,945 42,945 32,209 69.75 12/15/2016 SO 1,100 — — — 1,100 1,100 825 69.35 1/16/2017 SO 19,100 — — 19,100 — — — 66.11 3/14/2017 AGA 17,000 — 6,000 5,000 6,000 6,000 — 3/15/2017 SO 7,200 — — 7,200 — — — 66.25 4/18/2017 SO 7,200 — — — 7,200 7,200 4,500 60.77 4/20/2017 AGA 24,000 — 12,000 4,000 8,000 8,000 — 6/15/2017 BSA 9,000 — — — 9,000 9,000 9,000 59.05 6/15/2017 SO 91,000 — — 30,000 61,000 61,000 38,125 60.54 6/15/2017 SO 111,600 — — 55,000 56,600 56,600 41,000 59.05 7/17/2017 SO 7,200 — — — 7,200 7,200 3,600 71.61 9/15/2017 SO 45,400 — — — 45,400 45,400 22,700 74.22 12/5/2017 SO 540,075 — — 204,050 336,025 336,025 183,013 39.00 12/15/2017 SO 8,300 — — — 8,300 8,300 4,150 38.18 1/15/2018 SO 8,300 — — — 8,300 8,300 3,113 43.60 4/16/2018 SO 16,500 — — — 16,500 16,500 6,188 38.64 7/2/2018 BSA 44,000 — — — 44,000 44,000 44,000 37.24 5/15/2018 SO 16,500 — — — 16,500 16,500 6,188 40.84 6/15/2018 SO 23,600 — — — 23,600 23,600 8,850 38.92 6/22/2018 AGA 465,028 — — 64,100 400,928 400,928 — 6/22/2018 SO 50,000 — — — 50,000 50,000 — 37.22 7/16/2018 SO 28,800 — — — 28,800 28,800 — 33.81 8/15/2018 SO 33,500 — — 7,200 26,300 26,300 — 32.90 9/6/2018 AGA 450 — — — 450 450 — 9/6/2018 SO 65,000 — — — 65,000 65,000 — 36.96 9/17/2018 SO 80,900 — — 36,425 44,475 44,475 — 40.94 10/15/2018 SO 76,700 — — 5,400 71,300 71,300 — 37.28 11/1/2018 AGA 46,500 — — 2,500 44,000 44,000 — 11/15/2018 SO 26,000 — — 7,200 18,800 18,800 — 32.57 11/29/2018 SO 350,000 — — — 350,000 350,000 — 30.02 12/12/2018 AGA 19,250 — — 4,250 15,000 15,000 — 12/12/2018 SO 34,000 — — — 34,000 34,000 — 27.96 12/17/2018 SO 7,200 — — — 7,200 7,200 — 26.76 1/15/2019 SO — 9,500 — 7,200 2,300 2,300 — 15.61 3/20/2019 SO — 547,100 — 52,300 494,800 494,800 — 14.58 5/10/2019 AGA — 100,000 — 20,000 80,000 80,000 — 5/15/2019 SO — 7,200 — — 7,200 7,200 — 16.82 5/24/2019 SO — 150,000 — — 150,000 150,000 — 16.99 6/17/2019 SO — 7,200 — — 7,200 7,200 — 16.38 7/1/2019 SO — 403,400 — 49,400 354,000 354,000 — 15.43 7/22/2019 SO — 75,000 — — 75,000 75,000 — 17.90 7/31/2019 AGA — 23,750 — — 23,750 23,750 — 9/16/2019 SO — 34,000 — — 34,000 34,000 — 18.00 10/11/2019 AGA — 40,000 — — 40,000 40,000 — 10/16/2019 SO — 3,500 — — 3,500 3,500 — 15.30 12/16/2019 SO — 53,100 — — 53,100 53,100 — 15.80 12/20/2019 AGA — 23,600 — — 23,600 23,600 — Total 3 258 972 1,477,350 18,000 849,375 3,868,947 3,976,271 1,143,194 |
Financial and Other Non-Curre_2
Financial and Other Non-Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Debt Recorded on Statement of Financial Position | The table below presents the details of the debts recorded on the statement of financial position by the type of conditional advance: 3rd OSEO 4th OSEO BPI contract contract advance Total Balance sheet debt at start of period 01/01/2017 192 1,684 2,751 4,627 Receipts — — — — Repayments (128 ) — (450 ) (578 ) Other transactions 1 16 84 101 Balance sheet debt as at 12/31/2017 64 1,700 2,386 4,150 Of which - Non-current 1,825 Of which - Current portion 2,325 Stated interest rate No 2,05 % No Discount rate 0.4%- 1.9% 1.5%- 1.8% 3.2 % Maturity (in years) 0-3 7-9 2-7 3rd OSEO 4th OSEO BPI contract contract advance Total Balance sheet debt at start of period 01/01/2018 64 1,700 2,386 4,150 Receipts — — — — Repayments (64 ) (1,136 ) (60 ) (1,80 ) Other transactions — 60 69 129 Balance sheet debt as at 12/31/2018 — 624 1,854 2,479 Of which - Non-current 1,278 Of which - Current portion 1,201 Stated interest rate No 2,05 % No Discount rate 0.4%- 1.9% 1.5%- 1.8% 3.2 % Maturity (in years) 0-3 7-9 2-7 4th OSEO BPI contract Balance sheet debt at start of period 01/01/2019 624 1,854 2,479 Receipts — — — Repayments (624 ) (600 ) (1,224 ) Other transactions — 44 44 Balance sheet debt as at 12/31/2019 — 1,298 1,298 Of which - Non-current 721 Of which - Current portion 577 Stated interest rate 2.05% No Discount rate 1.5%- 1.8% 3.2 % Maturity (in years) 7-9 2-7 |
Summary of Due Dates of the Financial Liabilities | Due dates of the financial liabilities recognized as of December 31, 2017: Gross Less than One One to Five More than (Amounts in thousands of Euros) Conditional advances 4,150 2,325 1,825 — Lease debt — — — — Other liabilities 24,620 15,751 8,421 448 Supplier accounts payable and related payables 16,941 16,941 — — Total financial, current and non-current 45,711 35,017 10,246 448 Due dates of the financial liabilities recognized as of December 31, 2018: Gross Less than One One to Five More than (Amounts in thousands of Euros) Conditional advances 2,479 1,201 1,278 — Lease debt — — — — Other liabilities 16,611 12,506 3,991 114 Supplier accounts payable and related payables 28,567 28,567 — — Total financial, current and non-current 47,656 42,273 5,269 114 Due dates of the financial liabilities recognized as of December 31, 2019: Gross Less than One to More than (Amounts in thousands of Euros) Conditional advances 1,298 577 721 — Lease debt 22,860 3,282 13,282 6,296 Other liabilities 22,268 22,197 71 — Supplier accounts payable and related payables 21,368 21,368 — — Total financial, current and non-current 67,794 47,423 14,074 6,296 |
Non-Current Provisions (Tables)
Non-Current Provisions (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Schedule of Non-Current Provisions | December 31, 2017 2018 2019 Pension retirement obligations 1,260 1,536 1,474 Total 1,260 1,536 1,474 |
Schedule of Commitments for Compensation Payable to Employees Upon Their Retirement | Commitments for Compensation Payable to Employees Upon Their Retirement Amounts in As of January 1, 2017 (853 ) Costs of services rendered (operating expense) (219 ) Interest expense (financial expense) (11 ) Benefit paid — Actuarial gains (177 ) As of December 31, 2017 (1,260 ) Costs of services rendered (operating expense) (412 ) Interest expense (financial expense) (24 ) Benefit paid 141 Actuarial gains 19 As of December 31, 2018 (1,536 ) Costs of services rendered (operating expense) (443 ) Interest expense (financial expense) (24 ) Benefit paid — Actuarial gains 529 As of December 31, 2019 (1,474 ) |
Schedule of Retirement Commitments | As part of the estimation of the retirement commitments, the following assumptions were used for all categories of employees: 2017 2018 2019 % social security contributions 50,0 % 50,0 % 50,0 % Salary increases 2,0 % 2,0 % 2,0 % Discount rate 1,30 % 1,57 % 0,77 % |
Supplier Accounts Receivable _2
Supplier Accounts Receivable and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Schedule of Other Current Liabilities | 14.2 Other Current Liabilities 2017 2018 2019 (Amounts in thousands of Euros) Social security 12,094 6,343 18,100 Tax liabilities 428 448 384 Other debts 440 1,354 510 Deferred revenues 2,789 4,360 3,204 Total 15,751 12,506 22,197 |
Financial Instruments Recogni_2
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Schedule of Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | 2017 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 3,012 1,333 1,679 — 3,012 Customer accounts receivables and related receivables 1,265 — 1,265 — 1,265 Other current financial assets 378 — 378 — 378 Cash and cash equivalents 137,880 137,880 — — 137,880 Total financial assets 142,534 139,213 3,321 — 142,534 Financial liabilities Long-term conditional advances 1,825 — — 1,825 1,825 Long term financial rent debt — — — — — Other long-term liabilities 8,869 — — 8,869 8,869 Short-term conditional advances 2,325 — — 2,325 2,325 Short - — — — — — Other short-term liabilities 15,751 — — 15,751 15,751 Account payable and other liabilities 16,941 — — 16,941 16,941 Total financial liabilities 45,711 — — 45,711 45,711 2018 Book value in the Fair value through Financial assets at Non- derivative Fair value (2) Financial assets Long-term financial assets 6,033 432 5,600 — 6,033 Customer accounts receivables and related receivables — — — — — Other current financial assets 912 — 912 — 912 Cash and cash equivalents 122,770 — 122,770 — 122,770 Total financial assets 129,715 432 129,283 — 129,715 Financial liabilities — — — — — Long-term conditional advances 1,278 — — 1,278 1,278 Long term financial rent debt — — — — — Other long-term liabilities 4,105 — — 4,105 4,105 Short-term conditional advances 1,201 — — 1,201 1,201 Short - — — — — — Other short-term liabilities 12,506 — — 12,506 12,506 Account payable and other liabilities 28,567 — — 28,567 28,567 Total financial liabilities 47,656 — — 47,656 47,656 2019 Book value in Fair value Financial assets Non- Fair value (2) Financial assets Pledged securities and other non-current 4,314 — 4,314 — 4,314 Deposits 1,359 — 1,359 — 1,359 Liquidity contract 1,051 1,051 — — 1,051 Other current financial assets 679 — 679 — 679 Cash and cash equivalents 172,027 — 172,027 — 172,027 Total financial assets 179,430 1,051 178,379 — 179,430 Financial liabilities Conditional advances 1,298 — — 1,298 1,298 Lease debt 22,860 — — 22,860 22,860 Other liabilities 22,268 — — 22,268 22,268 Supplier accounts payable 21,368 — — 21,368 21,368 Total financial liabilities 67,794 — — 67,794 67,794 (1) The fair value of financial assets as fair value through Consolidated Statements of (Loss) is determined based on Level 1 fair value measurements and corresponds to the market value of the assets. (2) The fair value of “financial assets at amortized cost” as per IFRS 9 or “loans and receivables” as per IAS 39 corresponds to the value reported in the Consolidated Statements of Financial Position. (3) The book amount of “Non-derivative |
Operating Income (Tables)
Operating Income (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Operating Income | The operating income is broken down in the following manner: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Revenues — — — Research tax credit 9,330 11,034 9,770 Subsidies 271 152 — Other operating income 2,308 3,351 3,369 Total 11,909 14,537 13,139 |
Operating Expenses (Tables)
Operating Expenses (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Research and Development Expense | The research and development expenses are broken down as follows: December 31, Research and d 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 37,112 37,912 41,565 Sub-contracting, c c 54,397 52,927 47,750 Small equipment and other supplies 4,110 4,771 2,814 Rental (1) 2,018 2,703 1,170 Conferences and travel expenses 2,807 2,591 1,676 Depreciation and amortization 2,424 2,492 4,853 Others 2,364 3,776 1,669 Total r d 105,232 107,171 101,497 (1) As of December 31, 2019, rentals are composed of rents related to leases ending within less than 12 months and to leases of low value assets, excluded from the scope of application of IFRS 16 standard, and of rental expenses. |
Summary of Sales And Marketing Expense | By nature, the breakdown of sales and marketing expenses is as follows: December 31, Sales and marketing expenses 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 6,976 12,553 12,504 Fees 2,480 5,148 4,194 Marketing, tradeshows and travel expenses 5,984 14,021 1,340 Depreciation and amortization — 44 736 Others 384 402 168 Total s and m 15,824 32,169 18,941 |
Summary of General and Administrative Expense | The general and administrative expenses are broken down as follows: December 31, General and administrative expenses 2017 2018 2019 (Amounts in thousands of Euros) Personnel expenses 19,742 19,101 25,751 Fees 10,347 12,718 10,883 Rental 1 584 911 43 Insurance policies 1,367 1,930 2,720 Corporate communication and travel expenses 1,599 1,576 972 Depreciation and amortization 422 1,720 516 Others 1,776 3,442 3,515 Total general and administrative expenses 35,837 41,399 44,401 |
Summary of Personnel Expense | The personnel expenses are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Wages and salaries 22,451 31,684 48,261 Social security contributions 7,157 8,858 13,097 Expenses for pension commitments 1,583 2,095 2,383 Employer contribution to bonus shares 1,857 1,026 1,155 Share-based payments 30,781 25,904 14,923 Total 63,830 69,567 79,820 |
Share-Based Payments (Tables)
Share-Based Payments (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
BCE2010 [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BCE2010 Date of grant (Board of Directors) 6/24/2011 6/24/2011 6/24/2011 6/24/2011 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 0.5 1.5 2.5 3.5 1 2 3 4 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BCE2010 granted 6,000 6,000 6,000 6,000 2,510 2,510 2,510 2,509 Share entitlement per BCE2010 15 15 15 15 15 15 15 15 Exercise price (in €) 77 77 77 77 77 77 77 77 Valuation method used Black-Scholes Grant date share fair value (in €) 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BCE2010 5.5 6 6.5 7 5.4 5.9 6.4 6.9 Discount rate 2.55 % 2.68 % 2.68 % 2.87 % 2.05 % 2.42 % 2.42 % 2.66 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BCE2010 (in €) 31.16 32.71 34.03 35.58 30.42 32.29 33.58 35.2 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE2010. |
Summary Of Change in Number of Outstanding shares | Change in Number of BCE2010 Outstanding December 31 2017 2018 2019 Number of BCE2010 Balance at beginning of period 12,339 11,005 7,166 Granted during the period — — — Forfeited during the period — — — Exercised during the period 1,334 3,839 — Expired during the period — — — Balance at end of period 11,005 7,166 7,166 |
BSA [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BSA Date of grant (Board of Directors) 09/25/2012 09/25/2012 09/25/2012 09/25/2012 07/25/2013 06/03/2014 Vesting period (years) 1 2 3 4 — — Plan expiration date 09/25/2022 09/25/2022 09/25/2022 09/25/2022 07/25/2023 06/03/2024 Number of BSA granted 7,500 7,500 7,500 7,500 73,000 10,000 Share entitlement per BSA 1 1 1 1 1 1 Exercise price (in €) 8.59 8.59 8.59 8.59 8.1 18.79 Valuation method used Black-Scholes Grant date share fair value (in €) 8.4 8.4 8.4 8.4 8.15 19.01 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 5.0 5.0 Discount rate(1) 1.21 % 1.21 % 1.53 % 1.53 % 1.16 % 0.71 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per BSA (in €) 2.29 2.43 2.61 2.74 2.18 4.98 Date of grant (Board of Directors) 3/24/2015 11/19/2015 12/15/2015 6/21/2016 Vesting period (years) — — — — Plan expiration date 3/24/2025 11/19/2025 12/15/2025 6/21/2026 Number of BSA granted 10,000 15,000 90,000 (1) 20,000 Share entitlement per BSA 1 1 1 1 Exercise price (in €) 43 66.06 64.14 52.97 Valuation method used Black-Scholes Grant date share fair value (in €) 43 66.06 42.61 61.25 Expected volatility 36 % 51 % 51 % 47 % Average life of BSA 5 5 5 5 Discount rate (1) 0.68 % 0.81 % -0.09 % -0.41 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA (in €) 9.9 22.6 7.28 21.59 Date of grant (Board of Directors) 12/9/2016 6/15/2017 5/2/2018 Vesting period (years) — — — Plan expiration date 12/9/2026 6/15/2027 5/2/2028 Number of BSA granted 59,000 9,000 44,000 Share entitlement per BSA 1 1 1 Exercise price (in €) 69.75 59.05 37.24 Valuation method used Black-Scholes Grant date share fair value (in €) 63.18 73.32 32.74 Expected volatility 40 % 39 % 50 % Average life of BSA 5 5 5 Discount rate (1) -0.04 % -0.12 % -0.15 % Expected dividends 0 % 0 % 0 % Performance conditions NA NA NA Fair value per BSA (in €) 12.94 24.02 9.02 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. |
Summary Of Change in Number of Outstanding shares | Change in Number of BSA Outstanding December 31, 2017 2018 2019 Number of BSA Balance at beginning of period 147,359 181,008 217,508 Granted during the period 68,000 44,000 — Forfeited during the period 24,902 — — Exercised during the period 9,359 7,500 — Expired during the period — — — Balance at end of period 181,008 217,508 217,508 |
Share Option [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of SO Date of board of director meeting 9/18/2013 6/3/2014 6/23/2015 11/19/2015 12/15/2016 4/6/2016 4/6/2016 Date of grant 9/18/2013 6/3/2014 6/23/2015 11/19/2015 1/4/2016 4/21/2016 5/2/2016 Vesting period (years) 4 2 1-4 1-4 1-4 1-4 1-4 Plan expiration date 9/18/2023 6/3/2024 6/23/2025 11/19/2025 1/4/2026 4/21/2026 5/2/2026 Number of SO granted 518,000 75,000 120,000 195,000 75,000 33,000 22,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 7.57 19.01 48.9 66.06 65.68 62.82 59.04 Valuation method used Black-Scholes Grant date share fair value (in €) 7.9 19.01 48.9 66.06 65.68 62.82 58.62 Expected volatility 40 % 40 % 51 % 51 % 49.3%-49.8 % 49.4%-50.7 % 4.3%-50.6 % Average life of SO 7 6 7 7 5-7 5-7 5-7 Discount rate (1) 1.72 % 0.89 % 0.89 % 0.81 % 0.39 % 0.04 % 0.10 % Expected dividends 0% 0% 0% 0% 0% 0% 0% Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 3.57 7.46 25.28 34.05 29.5-32.6 28.3-30.9 26.4-28.8 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/21/2016 6/21/2016 6/21/2016 6/21/2016 6/21/2016 12/9/2016 6/21/2016 Date of grant 6/21/2016 8/1/2016 9/15/2016 10/17/2016 11/15/2016 12/9/2016 12/15/2016 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/21/2026 8/1/2026 9/15/2026 10/17/2026 11/15/2026 12/9/2026 12/15/2026 Number of SO granted 110,000 10,000 9,300 16,500 8,300 74,960 1,100 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 53.96 62.24 62.8 64.39 68.33 69.75 69.35 Valuation method used Black-Scholes Grant date share fair value (in €) 52.97 62.24 62.8 64.39 68.33 69.75 69.35 Expected volatility 49.1%- 50.30 % 48.8%- 49.80 % 48.6%- 49.40 % 48.0%- 48.90 % 47.8%- 48.80 % 47.7%- 48.50 % 40.44 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.01 % -0.25 % -0.18 % -0.32%-0.15 % -0.11%+0.16 % -0.2%+0.18 % -0.18%+0.17 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 23.4-25.5 27.3-29.9 27.4-30.1 27.6-30.6 29.4-32.7 29.7-33.4 25.23-28.67 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/21/2016 6/21/2016 6/21/2016 6/21/2016 6/15/2017 6/15/2017 6/15/2017 Date of grant 1/16/2017 3/15/2017 4/18/2017 6/15/2017 7/17/2017 9/15/2017 12/15/2017 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 1/16/2027 3/15/2027 4/18/2027 6/15/2027 7/17/2027 9/15/2027 12/15/2027 Number of SO granted 19,100 7,200 16,500 126,000 30,900 52,600 8,300 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 66.11 66.25 60.77 59.05 71.61 74.22 38.18 Valuation method used Black-Scholes Grant date share fair value (in €) 66.11 65.42 59.73 59.05 71.61 71.8 36.43 Expected volatility 40.21 % 39.82 % 39.63 % 39.23 % 38.84 % 38.57 % 43.13 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.17%+0.19 % +0.21%+0.61 % +0.02%+0.39 % -0.21%+0.07 % +0.01%+0.34 % -0.14%+0.19 % -0.23%+0.07 % Expected dividends 0% 0% 0% 0% 0% 0% 0% Performance conditions NA NA NA NA NA NA NA Fair value per SO (in €) 23.9-27.2 23.6-27.1 21.2-24.2 20.8-23.6 25.3-28.2 24.3-27.8 13.5-15.4 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/15/2017 11/17/2017 6/15/2017 6/15/2017 6/15/2017 6/15/2017 Date of grant 6/15/2017 12/5/2017 1/15/2018 4/16/2018 5/15/2018 6/15/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/15/2027 12/5/2027 1/15/2028 4/16/2028 5/15/2028 6/15/2028 Number of SO granted 111,600 625,200 15,500 16,500 16,500 23,600 Share entitlement per SO 1 1 1 1 1 1 Exercise price (in €) 60.54 39 43.6 38.64 40.84 38.92 Valuation method used Black-Scholes Grant date share fair value (in €) 59.05 35.73 43.6 38.64 40.84 35.48 Expected volatility 39.23 % 43.23 % 45.57 % 46.37 % 46.15 % 45.95 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.21%+0.07 % - % 0.32 % 0.35 % 0.41 % 0.23 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per SO (in €) 20.4-23.22 12.9-14.7 18.09-20.16 16.29-18.16 17.19-19.16 13.81-15.58 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of board of director meeting 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 6/22/2018 Date of grant 6/22/2018 7/16/2018 8/15/2018 9/17/2018 10/15/2018 11/15/2018 12/17/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/22/2028 7/16/2028 8/15/2028 9/17/2028 10/15/2028 11/15/2028 12/17/2028 Number of SO granted 50,000 28,800 33,500 80,900 76,700 26,000 7,200 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 37.22 33.81 32.9 40.94 37.28 32.57 26.76 Valuation method used Black-Scholes Grant date share fair value (in €) 34.32 32.16 32.9 40.94 31.74 28.66 26.76 Expected volatility 45.85 % 46.51 % 46.67 % 46.92 % 47.12 % 47.44 % 47.90 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) 0.19 % 0.14 % 0.17 % 0.27 % 0.37 % 0.29 % 0.26 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 13.42-15.11 13.02-14.59 13.85-15.43 17.39-19.37 12.12-13.78 11.18-12.66 11.57-12.88 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin TM Date of board of director meeting 9/6/2018 11/29/2018 12/12/2018 6/22/2018 6/22/2018 6/22/2018 5/24/2019 Date of grant 9/6/2018 7/16/2018 12/12/2018 1/15/2019 3/20/2019 5/15/2019 5/24/2019 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 9/6/2028 11/29/2028 12/12/2028 1/15/2029 3/20/2029 5/15/2029 5/24/2029 Number of SO granted 65,000 350,000 34,000 9,500 547,100 7,200 150,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price (in €) 36.96 30.02 27.96 14.10 14.25 16.82 16.37 Valuation method used Black - Grant date share fair value (in €) 36.96 27.44 27.96 14.10 14.25 16.82 16.37 Expected volatility 46.85 % 47.51 % 47.87 % 69.50 % 70.40 % 70.81 % 70.85 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) 0.21 % 0.27 % 0.27 % 0.19 % 0.02 % -0.08 % -0.08 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 15.65-17.43 11.08-12.47 12.09-13.46 8.19-8.89 8.52-9.23 10.1-10.99 9.7-10.59 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin TM Date of board of director meeting 5/24/2019 5/24/2019 5/24/2019 5/24/2019 5/24/2019 5/24/2019 Date of grant 6/17/2019 7/1/2019 7/22/2019 9/16/2019 10/16/2019 12/16/2019 Ve s 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 6/17/2029 7/1/2029 7/22/2029 9/16/2029 10/16/2029 12/16/2029 Number of SO granted 7,200 403,400 75,000 34,000 3,500 53,100 Share entitlement per SO 1 1 1 1 1 1 Exercise price (in €) 14.55 15.43 17.90 18.00 14.40 15.80 Valuation method used Black-Scholes Grant date share fair value (in €) 14.55 15.43 17.90 18.00 14.40 15.80 Expected volatility 70.96 % 71.03 % 71.51 % 71.93 % 72.41 % 71.98 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.22 % -0.31 % -0.36 % -0.41 % -0.38 % -0.26 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO (in €) 8.35-9.2 8.97-11.02 10.71-11.72 10.79-11.83 8.51-9.37 9.51-10.42 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ™ |
Disclosure of Change in Number of Share Options Outstanding | Change in Number of SO Outstanding December 31 2017 2018 2019 Number of SO Balance at beginning of period 1,160,060 2,133,100 2,461,570 Granted during the period 998,500 824,200 1,290,000 Forfeited during the period 24,260 227,730 749,525 Exercised during the period 1,200 268,000 — Expired during the period — — — Balance at end of period 2,133,100 2,461,570 3,002,045 |
Free Share [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of Free Shares Board of directors Grant date 3/14/2017 4/20/2017 6/22/2018 9/6/2018 11/1/2018 12/12/2018 12/17/2018 Vesting period (years) 2 2 1 1 1 1 1 Lockup period N/A (1) N/A 1) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) Number of free shares granted 22,500 24,000 486,153 450 57,000 16,250 3,000 Share entitlement per free share 1 1 1 1 1 1 1 Grant date share fair value (in €) 68.07 61.2 34.32 36.96 33.33 27.96 26.76 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (3) Yes (3) Yes (4) Yes (4) Yes (4) Yes (4) Yes (4) Expected turnover during the vesting period 0 % 0 % 0 % 0 % 5 % 5 % 5 % (1) Those free plans are not subject to a lock-up (2) Those free plans are subject to a lock-up two (3) The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria below: • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from grant date TM • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from grant date TM ( 4 The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement: • expiry of the current acquisition period as from their initial allocation; and • approval of Viaskin TM . Board of directors Grant date 5/10/2019 7/31/2019 10/11/2019 12/20/2019 Vesting period (years) 1 (1) 2 2 2 Lockup period 2 N/A N/A N/A Number of free shares granted 100,000 23,750 40,000 23,600 Share entitlement per free share 1 1 1 1 Grant date share fair value (in €) 16.10 17.63 12.43 17.23 Expected dividends 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) No (3) No (3) Expected turnover during the vesting period 5 % 5 % 5 % 5 % (1) Those free plans are subject to a lock-up two (2) The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement: • expiry of the current acquisition period as from their initial allocation; and • approval of Viaskin ™ (3) The definitive allocation of the free shares will only occur at expiry of the current acquisition period as from their initial allocation, subject to the presence requirement. Performance conditions other than market conditions, which are taken into account by adjusting the number of equity instruments included in the measurement of the transaction amount but are not taken into account when estimating the fair value of the shares. In December 2018, following the decision to voluntarily withdraw its application for BLA for Viaskin TM TM TM A turnover rate is applied for each instrument according to its respective characteristics and composition. |
Summary of Change in Number of Outstanding shares | Change in Number of Free Shares Outstanding December 31 , 2017 2018 2019 Number of free shares Balance at beginning of period 1,036,850 822,856 572,228 Granted during the period 46,500 562,853 187,350 Forfeited during the period 18,650 36,525 99,850 Exercised during the period 241,844 776,956 18,000 Expired during the period — — — Balance at end of period 822,856 572,228 641,728 |
BSA2010 [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BSA2010 Date of grant (Board of Directors) 6/24/2011 6/24/2011 6/24/2011 6/24/2011 Vesting period (years) 0.5 1.5 2.5 3.5 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 2,000 2,000 2,000 2,000 Share entitlement per BSA2010 15 15 15 15 Exercise price (in €) 77 77 77 77 Valuation method used Black - Grant date share fair value (in €) 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % Average life of BSA2010 5.5 6 6.5 7 Discount rate 2.55 % 2.68 % 2.68 % 2.87 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA2010 (in €) 31.15 32.7 34.02 35.57 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. |
Summary Of Change in Number of Outstanding shares | Change in Number of BSA2010 Outstanding December 31 2017 2018 2019 Number of BSA2010 Balance at beginning of period 610 500 500 Granted during the period — — 0 Forfeited during the period — — 0 Exercised during the period 110 — 0 Expired during the period — — — Balance at end of period 500 500 500 |
Financial Revenue and Expenses
Financial Revenue and Expenses (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Financial Income and Expenses | The financial income and expenses are broken down as follows: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Financial revenues 616 493 67 Financial expenses (3,325 ) (351 ) (1,409 ) Total (2,709 ) 141 (1,341 ) |
Income Tax Expense (Tables)
Income Tax Expense (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Reconciliation of Effective and Nominal Tax Expense | The following table shows the reconciliation between the effective and nominal tax expense at the nominal standard French rate of 33.33% as of December 31, 2017 and 28.0% as of December 31, 2018 and 2019 (excluding additional contributions): December 31, 2017 2018 2019 (Amounts in thousands of Euros) (Loss) before taxes (147,692 ) (166,061 ) (153,042 ) Theor e 33,33 % 28,00 % 28,00 % Nominal tax expense 49,226 46,497 42,852 Increase/decrease in tax expense arising from: Permanent differences — — 4,080 * Research tax credit 3,110 3,089 2,736 Share-based compensation (10,260 ) (7,253 ) (4,179 ) Non - (41,453 ) (54,205 ) (45,260 ) Non - — (324 ) (294 ) Other differences (623 ) 12,196 (481 ) Effective tax expenses — (15 ) (545 ) Effective tax rate 0,00 % 0,01 % 0,36 % * For the years ended December 31, 2017 and 2018, the permanent differences were included in “Other differences.” |
Relationships with Related Pa_2
Relationships with Related Parties (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Summary of Relationships with Related Parties | December 31, 2017 2018 2019 (Amounts in thousands of Euros) Short-term benefits 3,300 5,202 7,046 Post-employment benefits 36 87 57 Termination benefits — — 4,380 Share-based payment 12,018 12,189 4,520 Total 15,353 17,478 16,004 |
Schedule of Amounts Payable to Related Parties | A schedule of amounts payable to related parties: December 31, 2017 2018 2019 (Amounts in thousands of Euros) Compensation 1,121 535 2,964 Pension obligations 402 419 70 Total 1,523 954 3,034 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Text block [abstract] | |
Earnings Per Share | December 31, 2017 2018 2019 (Amounts in thousands of Euros) Net income of the reporting period (147,693 ) (166,076 ) (153,587 ) Adjusted weighted average number of outstanding shares 24,757,176 28,924,976 37,007,247 Basic / Diluted earnings per share (€/share) (5.97 ) (5.74 ) (4.15 ) |
The Company - Additional Inform
The Company - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions | Feb. 04, 2020€ / sharesshares | Oct. 15, 2019EUR (€)shares | Oct. 15, 2019USD ($)$ / sharesshares | Oct. 11, 2019EUR (€)€ / sharesshares | Oct. 11, 2019USD ($)$ / sharesshares | Apr. 08, 2019EUR (€)€ / sharesshares | Apr. 08, 2019USD ($)$ / sharesshares | Sep. 30, 2016 | Feb. 29, 2020EUR (€) | Sep. 30, 2016Patient | Mar. 31, 2020EUR (€) | Dec. 31, 2019Directorshares |
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 3,976,271 | |||||||||||
Exchange rate | 1.0999 | |||||||||||
Proceeds from offering of shares | € 130.7 | $ 143 | € 130.7 | $ 143 | € 72.1 | $ 81 | ||||||
Number of directors after additions | Director | 9 | |||||||||||
Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Underwritten ordinary shares | 7,500,000 | 9,484,066 | 9,484,066 | 6,000,000 | 6,000,000 | |||||||
Shares issued | 1,368,667 | 1,368,667 | 7,914,622 | 7,914,622 | ||||||||
Share offering price | € / shares | € 18.63 | |||||||||||
Number of additional shares issued | 2,964,419 | 1,368,667 | 1,368,667 | 9,484,066 | 9,484,066 | |||||||
Proceeds from offering of shares | € | € 136.4 | € 136.4 | ||||||||||
American depositary receipts [member] | Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 2,737,334 | 2,737,334 | 15,829,244 | 15,829,244 | ||||||||
Share offering price | $ / shares | $ 6.59 | |||||||||||
Exchange rate | 1.0945 | 1.0945 | 1.0945 | 1.0945 | 1.1233 | 1.1233 | ||||||
Public offering [member] | Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 4,535,581 | 2,447,500 | 2,447,500 | |||||||||
Public offering [member] | American depositary receipts [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Share offering price | $ / shares | $ 6.59 | |||||||||||
Public offering [member] | American depositary receipts [member] | Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 4,895,000 | 4,895,000 | ||||||||||
Share offering price | $ / shares | $ 6.59 | $ 6.75 | ||||||||||
Concurrent private placement [member] | Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 1,569,444 | 1,569,444 | ||||||||||
Share offering price | € / shares | € 12.04 | |||||||||||
Private Placement [Member] | Common Shares [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Shares issued | 3,552,500 | 3,552,500 | ||||||||||
Share offering price | € / shares | € 12.02 | |||||||||||
Proceeds from offering of shares | € 72.1 | $ 81 | ||||||||||
Viaskin Peanut [member] | Bottom of range [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Age of patients evaluated | 4 years | |||||||||||
Viaskin Peanut [member] | Top of range [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Age of patients evaluated | 11 years | |||||||||||
Viaskin Milk [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Number of patients evaluated | Patient | 198 | |||||||||||
Viaskin Milk [member] | Bottom of range [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Age of patients evaluated | 2 years | |||||||||||
Viaskin Milk [member] | Top of range [member] | ||||||||||||
Disclosure Of Company [Line items] | ||||||||||||
Age of patients evaluated | 17 years |
General Information and State_2
General Information and Statement of Compliance - Additional Information (Detail) | Dec. 21, 2018 | Aug. 13, 2018 | Jul. 03, 2018 | Apr. 07, 2014 |
US subsidiary [member] | ||||
Disclosure of subsidiaries [line items] | ||||
Proportion of ownership interest in subsidiary | 100.00% | |||
Australian subsidiary [member] | ||||
Disclosure of subsidiaries [line items] | ||||
Proportion of ownership interest in subsidiary | 100.00% | |||
Canadian subsidiary [member] | ||||
Disclosure of subsidiaries [line items] | ||||
Proportion of ownership interest in subsidiary | 100.00% | |||
French subsidiary [member] | ||||
Disclosure of subsidiaries [line items] | ||||
Proportion of ownership interest in subsidiary | 100.00% |
Accounting Principles - Additio
Accounting Principles - Additional Information (Detail) $ in Millions | Oct. 15, 2019EUR (€) | Oct. 15, 2019USD ($) | Oct. 11, 2019EUR (€) | Oct. 11, 2019USD ($) | Apr. 08, 2019EUR (€) | Apr. 08, 2019USD ($) | Feb. 29, 2020EUR (€) | Jul. 31, 2016EUR (€) | Mar. 31, 2020EUR (€) | Dec. 31, 2019EUR (€)HedgingInstrument | Dec. 31, 2018EUR (€) |
Disclosure of summary of significant accounting policies [line Items] | |||||||||||
Proceeds from offering of shares | € 130,700,000 | $ 143 | € 130,700,000 | $ 143 | € 72,100,000 | $ 81 | |||||
Number of hedging instruments held | HedgingInstrument | 0 | ||||||||||
Research tax credit reimbursement | € 10,800,000 | ||||||||||
Potential development, clinical, commercial milestones payment receivable | € 100,000,000 | ||||||||||
Non-refundable upfront payment | € 10,000,000 | ||||||||||
Tax refund credit period | 3 years | ||||||||||
Ordinary shares [member] | |||||||||||
Disclosure of summary of significant accounting policies [line Items] | |||||||||||
Proceeds from offering of shares | € 136,400,000 | € 136,400,000 | |||||||||
Real Estate Finance Lease [member] | |||||||||||
Disclosure of summary of significant accounting policies [line Items] | |||||||||||
Commitments given under operating leases | € 30,267,000 | ||||||||||
Industrial Equipment And Vehicles [member] | |||||||||||
Disclosure of summary of significant accounting policies [line Items] | |||||||||||
Commitments given under operating leases | € 163,000 |
Accounting Principles - Summary
Accounting Principles - Summary of Depreciation Periods (Detail) | 12 Months Ended |
Dec. 31, 2019 | |
Fixtures and improvements in structures [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 9 years |
Research and development / production tools [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Research equipment and technical facilities [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Computer equipment [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 3 years |
Office equipment and furniture [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Accounting principles and metho
Accounting principles and methods used - Summary of impacts of first application of IFRS 16 on opening balance sheet (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | [1] | Dec. 31, 2017 | [1] | Dec. 31, 2016 |
ASSETS | |||||||
Intangible assets | € 43 | € 29 | € 123 | ||||
Right-of-use assets related to leases | 20,589 | ||||||
Property, plant, and equipment | 22,270 | 20,219 | 17,808 | € 12,482 | |||
Other non-current assets | 16,488 | 6,033 | 3,012 | ||||
Total non-current assets | 59,390 | 26,281 | 20,942 | ||||
Total current assets | 182,086 | 145,468 | 156,865 | ||||
TOTAL ASSETS | 241,476 | 171,749 | 177,807 | ||||
Shareholders' equity | |||||||
Total shareholders' equity | 171,563 | 121,286 | 129,923 | 242,849 | |||
Non-Current liabilities | |||||||
Long-term financial debt | 721 | 1,278 | 1,825 | ||||
Long-term lease debt | 19,579 | ||||||
Non-current provisions | 1,474 | 1,536 | 1,260 | € 853 | |||
Other non-current liabilities | 71 | 4,105 | 8,869 | ||||
Total non-current liabilities | 21,845 | 6,919 | 11,954 | ||||
Current liabilities | |||||||
Short-term financial debt | 577 | 1,201 | 2,325 | ||||
Short-term lease debt | 3,282 | 0 | |||||
Current provisions | 644 | 1,270 | 913 | ||||
Supplier accounts payable | 21,368 | 28,567 | 16,941 | ||||
Other current liabilities | 22,197 | 12,506 | 15,751 | ||||
Total current liabilities | 48,068 | 43,543 | 35,930 | ||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | € 241,476 | € 171,749 | € 177,807 | ||||
Increase (decrease) due to changes in accounting policy required by IFRSs [member] | IFRS16 [member] | |||||||
ASSETS | |||||||
Right-of-use assets related to leases | € 23,792 | ||||||
Total non-current assets | 23,792 | ||||||
TOTAL ASSETS | 23,792 | ||||||
Non-Current liabilities | |||||||
Long-term lease debt | 22,682 | ||||||
Other non-current liabilities | (1,546) | ||||||
Total non-current liabilities | 21,136 | ||||||
Current liabilities | |||||||
Short-term lease debt | 2,973 | ||||||
Other current liabilities | (317) | ||||||
Total current liabilities | 2,656 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 23,792 | ||||||
After IFRS16 adoption [member] | |||||||
ASSETS | |||||||
Intangible assets | 29 | ||||||
Right-of-use assets related to leases | 23,792 | ||||||
Property, plant, and equipment | 20,219 | ||||||
Other non-current assets | 6,033 | ||||||
Total non-current assets | 50,074 | ||||||
Total current assets | 145,468 | ||||||
TOTAL ASSETS | 195,542 | ||||||
Shareholders' equity | |||||||
Total shareholders' equity | 121,286 | ||||||
Non-Current liabilities | |||||||
Long-term financial debt | 1,278 | ||||||
Long-term lease debt | 22,682 | ||||||
Non-current provisions | 1,536 | ||||||
Other non-current liabilities | 2,559 | ||||||
Total non-current liabilities | 28,055 | ||||||
Current liabilities | |||||||
Short-term financial debt | 1,201 | ||||||
Short-term lease debt | 2,973 | ||||||
Current provisions | 1,270 | ||||||
Supplier accounts payable | 28,567 | ||||||
Other current liabilities | 12,189 | ||||||
Total current liabilities | 46,200 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | € 195,542 | ||||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Accounting principles and met_2
Accounting principles and methods - Summary Of present the reconciliation of lease liabilities on the date of transition with Off-Statement of Financial Position commitments (Detail) € in Thousands | Dec. 31, 2018EUR (€) |
Disclosure Of Reconciliation Of Carrying Amounts Of Financial Assets And Financial Liabilities On The Date Of Initial Application Of Ifrs [Line Items] | |
Commitments given under operating leases as of December 31, 2018 | € 30,429 |
Effects of rental expenses not recognized into IFRS 16 | (4,061) |
Other effects, including currency effects and rent-free periods | 4,035 |
Lease debt before discounting | 30,402 |
Effect of discounting | (4,748) |
Lease debt after discounting | 25,655 |
Existing finance leases as of December 31, 2018 | 0 |
Adoption Of IFRS 16 [Member] | |
Disclosure Of Reconciliation Of Carrying Amounts Of Financial Assets And Financial Liabilities On The Date Of Initial Application Of Ifrs [Line Items] | |
Lease debt after discounting | € 25,655 |
Intangible Assets - Summary of
Intangible Assets - Summary of Intangible Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | € 43 | € 29 | [1] | € 123 | [1] |
Total, gross [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | 931 | 905 | 864 | ||
Total accumulated depreciation [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | (889) | (875) | (741) | ||
Patents, licenses, trademarks [member] | Total, gross [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | 201 | 201 | 414 | ||
Patents, licenses, trademarks [member] | Total accumulated depreciation [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | (201) | (200) | (340) | ||
Software [member] | Total, gross [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | 730 | 703 | 450 | ||
Software [member] | Total accumulated depreciation [member] | |||||
Disclosure of detailed information about intangible assets [line items] | |||||
Intangible assets other than goodwill | € (688) | € (675) | € (401) | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2019EUR (€) | |
Disclosure of detailed information about intangible assets [abstract] | |
Impairment of assets | € 0 |
Lease Contracts - Additional In
Lease Contracts - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2019EUR (€) | |
Statement [line items] | |
Interest expense on lease liabilities | € 1,013,000 |
Recognition of impairment loss | 0 |
Right-of-use assets [member] | |
Statement [line items] | |
Recognition of impairment loss | € 0 |
Lease Contracts - Summary of an
Lease Contracts - Summary of analysis of maturities of lease liabilities (Detail) € in Thousands | Dec. 31, 2019EUR (€) |
Disclosure of maturity analysis of operating lease payments [line items] | |
Less than one year | € 22,860 |
Not later than one year [member] | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Less than one year | 3,282 |
Later than one year and not later than five years [member] | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Less than one year | 13,282 |
More than five years [member] | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Less than one year | € 6,296 |
Lease Contracts - Summary of _2
Lease Contracts - Summary of analysis of right-of-use assets (Detail) € in Thousands | 12 Months Ended | |
Dec. 31, 2019EUR (€) | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Beginning balance | [1] | |
First application of IFRS 16 | 23,792 | |
Addition of assets | 130 | |
Depreciation expense | (3,382) | |
Translation adjustments and other | 48 | |
Ending balance | 20,589 | |
Real estate [member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Beginning balance | ||
First application of IFRS 16 | 23,462 | |
Depreciation expense | (3,257) | |
Translation adjustments and other | 48 | |
Ending balance | 20,253 | |
Other assets [member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Beginning balance | ||
First application of IFRS 16 | 330 | |
Addition of assets | 130 | |
Depreciation expense | (125) | |
Ending balance | € 336 | |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Property, Plant, and Equipmen_2
Property, Plant, and Equipment - Summary of Property, Plant, and Equipment (Detail) - EUR (€) € in Thousands | 12 Months Ended | |||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | € 20,219 | [1] | € 17,808 | [1] | € 12,482 | |
Increase in property, plant, and equipment | 2,075 | 12,162 | 5,443 | |||
Decrease in property, plant, and equipment | (24) | (9,750) | (118) | |||
Property, plant, and equipment ending balance | 22,270 | 20,219 | [1] | 17,808 | [1] | |
Total, gross [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 27,228 | 22,470 | 15,685 | |||
Increase in property, plant, and equipment | 5,012 | 14,520 | 7,114 | |||
Decrease in property, plant, and equipment | (88) | (9,762) | (329) | |||
Property, plant, and equipment ending balance | 32,152 | 27,228 | 22,470 | |||
Total, gross [member] | Laboratory equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 12,113 | 5,820 | 3,097 | |||
Increase in property, plant, and equipment | 383 | 6,305 | 2,806 | |||
Decrease in property, plant, and equipment | (64) | (12) | (83) | |||
Property, plant, and equipment ending balance | 12,432 | 12,113 | 5,820 | |||
Total, gross [member] | Building fixtures [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 5,231 | 5,098 | 4,610 | |||
Increase in property, plant, and equipment | 582 | 133 | 534 | |||
Decrease in property, plant, and equipment | (46) | |||||
Property, plant, and equipment ending balance | 5,813 | 5,231 | 5,098 | |||
Total, gross [member] | Office equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 790 | 766 | 607 | |||
Increase in property, plant, and equipment | 18 | 25 | 275 | |||
Decrease in property, plant, and equipment | (116) | |||||
Property, plant, and equipment ending balance | 808 | 790 | 766 | |||
Total, gross [member] | Computer equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 1,507 | 1,073 | 986 | |||
Increase in property, plant, and equipment | 187 | 434 | 116 | |||
Decrease in property, plant, and equipment | (30) | |||||
Property, plant, and equipment ending balance | 1,694 | 1,507 | 1,073 | |||
Total, gross [member] | Property, plant, and equipment in progress [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 7,587 | 9,714 | 6,385 | |||
Increase in property, plant, and equipment | 3,842 | 7,623 | 3,384 | |||
Decrease in property, plant, and equipment | (24) | (9,750) | (55) | |||
Property, plant, and equipment ending balance | 11,405 | 7,587 | 9,714 | |||
Total accumulated amortization and depreciation [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 4,663 | 3,202 | ||||
Increase in property, plant, and equipment | 2,937 | 2,358 | 1,671 | |||
Decrease in property, plant, and equipment | (64) | (12) | (211) | |||
Property, plant, and equipment ending balance | 9,882 | 4,663 | ||||
Total accumulated amortization and depreciation [member] | Scenario, Previously Reported [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 7,009 | |||||
Property, plant, and equipment ending balance | 7,009 | |||||
Total accumulated amortization and depreciation [member] | Laboratory equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 3,811 | 2,244 | 1,505 | |||
Increase in property, plant, and equipment | 1,786 | 1,567 | 802 | |||
Decrease in property, plant, and equipment | (64) | (63) | ||||
Property, plant, and equipment ending balance | 5,533 | 3,811 | 2,244 | |||
Total accumulated amortization and depreciation [member] | Building fixtures [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 1,919 | 1,580 | 1,109 | |||
Increase in property, plant, and equipment | 671 | 352 | 484 | |||
Decrease in property, plant, and equipment | (12) | (14) | ||||
Property, plant, and equipment ending balance | 2,590 | 1,919 | 1,580 | |||
Total accumulated amortization and depreciation [member] | Office equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 449 | 320 | 212 | |||
Increase in property, plant, and equipment | 129 | 129 | 213 | |||
Decrease in property, plant, and equipment | (105) | |||||
Property, plant, and equipment ending balance | 578 | 449 | 320 | |||
Total accumulated amortization and depreciation [member] | Computer equipment [member] | ||||||
Disclosure of detailed information about property, plant and equipment [line items] | ||||||
Property, plant, and equipment beginning balance | 830 | 520 | 377 | |||
Increase in property, plant, and equipment | 351 | 310 | 172 | |||
Decrease in property, plant, and equipment | (30) | |||||
Property, plant, and equipment ending balance | € 1,181 | € 830 | € 520 | |||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Non-Current Financial Assets -
Non-Current Financial Assets - Summary of Non-Current Financial Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of non financial assets. | |||
Non-current financial assets | € 16,488 | € 6,033 | € 3,012 |
Deposits [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | 1,359 | 1,374 | 577 |
Pledged securities [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | 4,314 | 4,226 | 1,102 |
Liquidity contract [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | 1,051 | € 432 | € 1,333 |
Research tax credit [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | € 9,764 |
Non-Current Financial Assets _2
Non-Current Financial Assets - Reconciliation of Research Tax Credit (Detail) - EUR (€) € in Thousands | Jul. 04, 2016 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Trade and other receivables [abstract] | ||||
Opening balance sheet receivable | € 10,829 | € 9,217 | € 7,228 | |
Operating revenue | 9,764 | 10,829 | 9,217 | |
Payment received | (10,835) | (9,479) | (7,341) | |
Adjustment | € 900 | 6 | 262 | 113 |
Closing balance sheet receivable | € 9,764 | € 10,829 | € 9,217 |
Non-Current Financial Assets _3
Non-Current Financial Assets - Additional Information (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of non financial assets. | ||||
Research tax credit current | € 9,764 | € 10,829 | € 9,217 | € 7,228 |
Liquidity contract [member] | ||||
Disclosure of non financial assets. | ||||
Number of treasury shares | 9,000 |
Inventories and Work in Progr_3
Inventories and Work in Progress - Summary of Inventories (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | [1] | |
Disclosure of inventories [abstract] | |||||
Inventories of raw materials | € 64 | ||||
Work in progress | 3,150 | € 2,338 | |||
Allowance for inventory write-down (charged to income statement) | (1,177) | (772) | |||
Total net value of the inventories | € 2,038 | € 1,566 | [1] | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Inventories and Work in Progr_4
Inventories and Work in Progress - Additional Information (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of inventories [abstract] | ||
Inventories of work in progress | € 2,038 | € 1,566 |
Customer Accounts Receivable _3
Customer Accounts Receivable and Other Current Assets - Summary of Customer Accounts Receivable and Related Receivables (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||
Trade and other receivables [abstract] | |||||
Accounts receivable | € 1,265 | ||||
Valuation allowance (charged to income statement) | |||||
Total net value of accounts receivable | [1] | € 1,265 | [1] | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Customer Accounts Receivable _4
Customer Accounts Receivable and Other Current Assets - Additional Information (Detail) - EUR (€) € in Thousands | Jun. 25, 2018 | Jul. 04, 2016 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Trade and other receivables [abstract] | |||||
Trade receivables payment terms | less than one year | ||||
Research tax credit current adjustment | € 900 | € 6 | € 262 | € 113 | |
Research tax credit final reassessment received | € 58 | ||||
Research tax credit current adjustment reversed | € 900 |
Customer Accounts Receivable _5
Customer Accounts Receivable and Other Current Assets - Summary of Other Current Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||
Disclosure of accounts receivables [abstract] | ||||||
Research tax credit | € 9,764 | € 10,829 | € 9,217 | € 7,228 | ||
Other tax claims | 3,995 | 4,292 | 5,258 | |||
Other receivables | 825 | 1,745 | 1,192 | |||
Prepaid expenses | 3,201 | 4,265 | 2,054 | |||
Total | € 8,021 | € 21,131 | [1] | € 17,721 | [1] | |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Cash and Cash Equivalents - Sum
Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | [1] | ||
Cash and cash equivalents [abstract] | |||||||
Cash | € 51,524 | € 77,236 | € 32,054 | ||||
Cash equivalent term deposits | 120,503 | 45,534 | 105,826 | ||||
Total cash and cash equivalent as reported in statement of financial position | 172,027 | 122,770 | [1] | 137,880 | [1] | € 256,473 | |
Total net cash and cash equivalents as reported in the statement of cash flow | € 172,027 | € 122,770 | [1] | € 137,880 | [1] | € 256,473 | |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Capital - Additional Informatio
Capital - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions | Feb. 04, 2020€ / sharesshares | Oct. 15, 2019EUR (€)€ / sharesshares | Oct. 15, 2019USD ($)$ / sharesshares | Oct. 11, 2019EUR (€)shares | Oct. 11, 2019USD ($)shares | Apr. 08, 2019EUR (€)€ / sharesshares | Apr. 08, 2019USD ($)$ / sharesshares | Feb. 29, 2020EUR (€) | Mar. 31, 2020EUR (€) | Dec. 31, 2019€ / sharesshares | Dec. 31, 2018shares | Dec. 31, 2017shares | Dec. 31, 2016shares |
Disclosure of classes of share capital [line items] | |||||||||||||
Number of share authorised | 47,028,510 | ||||||||||||
Number of share issued | 47,028,510 | ||||||||||||
Par value per share | € / shares | € 0.10 | ||||||||||||
Number of shares issued during period shares | 3,976,271 | ||||||||||||
Exchange rate | 1.0999 | ||||||||||||
Proceeds from offering of shares | € 130.7 | $ 143 | € 130.7 | $ 143 | € 72.1 | $ 81 | |||||||
Common Shares [member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Number of share issued | 47,028.510 | 30,157.777 | 24,990.822 | 24,648.828 | |||||||||
Number of shares issued during period shares | 1,368,667 | 1,368,667 | 7,914,622 | 7,914,622 | |||||||||
Issuances relating to underwritten global offering | 7,500,000 | 9,484,066 | 9,484,066 | 6,000,000 | 6,000,000 | ||||||||
Shares issued | 2,964,419 | 1,368,667 | 1,368,667 | 9,484,066 | 9,484,066 | ||||||||
Share offering price | € / shares | € 18.63 | ||||||||||||
Proceeds from offering of shares | € | € 136.4 | € 136.4 | |||||||||||
American depositary receipts [member] | Common Shares [member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Number of shares issued during period shares | 2,737,334 | 2,737,334 | 15,829,244 | 15,829,244 | |||||||||
Share offering price | $ / shares | $ 6.59 | ||||||||||||
Exchange rate | 1.0945 | 1.0945 | 1.0945 | 1.0945 | 1.1233 | 1.1233 | |||||||
Public offering [member] | American Depositary Shares [Member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Number of shares issued during period shares | 15,829,244 | 15,829,244 | 4,895,000 | 4,895,000 | |||||||||
Public offering [member] | Common Shares [member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Number of shares issued during period shares | 7,914,622 | 7,914,622 | 2,447,500 | 2,447,500 | |||||||||
Public offering [member] | American depositary receipts [member] | Common Shares [member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Share offering price | $ / shares | $ 6.59 | $ 6.75 | |||||||||||
Concurrent private placement [member] | Common Shares [member] | |||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||
Number of shares issued during period shares | 1,569,444 | 1,569,444 | 3,552,500 | 3,552,500 | |||||||||
Share offering price | € / shares | € 12.04 | € 12.02 |
Capital - Summary of Historical
Capital - Summary of Historical Changes in the Share Capital of the Company (Detail) - EUR (€) | 12 Months Ended | |||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||||
Disclosure of classes of share capital [line items] | ||||||
Beginning balance | € 121,286,000 | [1] | € 129,923,000 | [1] | € 242,849,000 | |
Capital increase by issuance of common shares | 71,520 | |||||
Ending balance | € 171,563,000 | € 121,286,000 | [1] | € 129,923,000 | [1] | |
Capital increase by incorporation of reserve | 11.001 | |||||
Ending balance | 47,028,510 | |||||
Beginning balance, Nominal value | € 0.10 | € 0.10 | € 0.10 | |||
Ending balance, Nominal value | € 0.10 | € 0.10 | € 0.10 | |||
Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Beginning balance | € 3,016,000 | [1] | € 2,499,000 | [1] | € 2,465,000 | |
Ending balance | € 4,703,000 | € 3,016,000 | [1] | € 2,499,000 | [1] | |
Beginning balance | 30,157,777 | [1] | 24,990,822 | [1] | 24,648,828 | |
Ending balance | 47,028,510 | 30,157,777 | [1] | 24,990,822 | [1] | |
Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Beginning balance | € 539,292,000 | [1] | € 406,709,000 | [1] | € 405,882,000 | |
Ending balance | € 725,460,000 | € 539,292,000 | [1] | € 406,709,000 | [1] | |
02/03/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
02/03/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 20,000 | |||||
02/03/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 1,007,000 | |||||
02/09/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Issue of share subscription warrants | € 2,374,000 | |||||
05/16/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
05/16/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 4,000 | |||||
05/16/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 170,700 | |||||
07/12/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
07/12/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 200 | |||||
07/12/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 8,300 | |||||
08/04/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
08/04/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 100 | |||||
08/04/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 64,600 | |||||
08/15/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Issue of share subscription warrants | € 53,100 | |||||
09/14/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
09/14/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 3,600 | |||||
09/14/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 208,200 | |||||
09/29/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
09/29/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 100 | |||||
09/29/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 4,000 | |||||
09/30/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
09/30/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 23,100 | |||||
09/30/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (23,100) | |||||
10/02/2017 [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
10/02/2017 [Member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 100 | |||||
10/02/2017 [Member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 4,000 | |||||
12/15/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
12/15/2017 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 1,100 | |||||
12/15/2017 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (1,100) | |||||
Share Capital Issued On 1/8/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share Capital Issued On 1/8/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 700 | |||||
Share Capital Issued On 1/8/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 52,300 | |||||
Share capital issued on 1/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 1/9/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 5,000 | |||||
Share capital issued on 1/9/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 252,000 | |||||
Share capital issued on 1/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 1/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 20,000 | |||||
Share capital issued on 1/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 1,004,000 | |||||
Share capital issued on 1/18/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 1/18/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 129,000 | |||||
Share capital issued on 1/18/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 9,636,000 | |||||
Share capital issued on 1/30/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 1/30/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 13,000 | |||||
Share capital issued on 1/30/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 971,000 | |||||
Share capital issued on 1/31/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 1/31/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 20,000 | |||||
Share capital issued on 1/31/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 1,494,000 | |||||
Share capital issued on 2/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 2/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 23.8 | |||||
Share capital issued on 2/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (23,800) | |||||
Share capital issued on 3/13/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 3/13/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 23.8 | |||||
Share capital issued on 3/13/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (23,800) | |||||
Share capital issued on 3/23/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 3/23/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 352,800 | |||||
Share capital issued on 3/23/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 122,095,500 | |||||
Share capital issued on 3/26/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 3/26/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 52,900 | |||||
Share capital issued on 3/26/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 18,314,300 | |||||
Share capital issued on 4/5/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/5/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 1,200 | |||||
Share capital issued on 4/5/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 91,900 | |||||
Share capital issued on 4/6/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 4/6/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 5.8 | |||||
Share capital issued on 4/6/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (5,800) | |||||
Share capital issued on 4/6/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/6/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 1,400 | |||||
Share capital issued on 4/6/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 105,600 | |||||
Share capital issued on 4/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/9/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 400 | |||||
Share capital issued on 4/9/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 26,600 | |||||
Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 300 | |||||
Share capital issued on 4/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 21,200 | |||||
Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 300 | |||||
Share capital issued on 4/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 20,000 | |||||
Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 4/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 300 | |||||
Share capital issued on 4/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 46,700 | |||||
Share capital issued on 6/21/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 6/21/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 19.3 | |||||
Share capital issued on 6/21/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | (19,300) | |||||
Share capital issued on 7/2/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Issue of share subscription warrants | € 163,700 | |||||
Share capital issued on 7/5/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 7/5/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 3,300 | |||||
Share capital issued on 7/5/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 164,100 | |||||
Share capital issued on 7/11/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 7/11/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 6,400 | |||||
Share capital issued on 7/11/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 478,100 | |||||
Share capital issued on 8/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 8/16/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 1 | |||||
Share capital issued on 8/16/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (1,000) | |||||
Share capital issued on 9/1/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 9/1/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.5 | |||||
Share capital issued on 9/1/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (500) | |||||
Share capital issued on 12/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 12/9/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 2 | |||||
Share capital issued on 12/9/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (2,000) | |||||
Share capital issued on 9/21/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share capital issued on 9/21/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 500 | |||||
Share capital issued on 9/21/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 37,300 | |||||
Share capital issued on 12/31/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Fees charged to share premium | € (10,292,600) | |||||
Share capital issued on 10/27/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share capital issued on 10/27/2018 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 1.5 | |||||
Share capital issued on 10/27/2018 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (1,500) | |||||
Share Capital Issued On 4/8/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share Capital Issued On 4/8/2019 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 6,000,000 | |||||
Share Capital Issued On 4/8/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 71,520,000 | |||||
Share Capital Issued On 9/30/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Fees charged to share premium | € (5,733,400) | |||||
Share Capital Issued On 10/4/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 0.10 | |||||
Share Capital Issued On 10/4/2019 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € 1.8 | |||||
Share Capital Issued On 10/4/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | € (1.8) | |||||
Share Capital Issued On 10/11/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share Capital Issued On 10/11/2019 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 9,484,000 | |||||
Share Capital Issued On 10/11/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 113,255,800 | |||||
Share Capital Issued On 10/15/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | |||||
Share Capital Issued On 10/15/2019 [member] | Share capital [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | € 1,369,000 | |||||
Share Capital Issued On 10/15/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 16,344,700 | |||||
Share Capital Issued On 12/31/2019 [member] | Share premium [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Fees charged to share premium | € (9,216,700) | |||||
Common Shares [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Beginning balance | 30,157.777 | 24,990.822 | 24,648.828 | |||
Ending balance | 47,028.510 | 30,157.777 | 24,990.822 | |||
Common Shares [member] | 02/03/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 20.010 | |||||
Common Shares [member] | 05/16/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 40.365 | |||||
Common Shares [member] | 07/12/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 1.650 | |||||
Common Shares [member] | 08/04/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 1.200 | |||||
Common Shares [member] | 09/14/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 35.925 | |||||
Common Shares [member] | 09/29/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 500 | |||||
Common Shares [member] | 09/30/2017 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 230.843 | |||||
Common Shares [member] | 10/02/2017 [Member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 500 | |||||
Common Shares [member] | Share Capital Issued On 1/8/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 7 | |||||
Common Shares [member] | Share capital issued on 1/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 5.010 | |||||
Common Shares [member] | Share capital issued on 1/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 19.950 | |||||
Common Shares [member] | Share capital issued on 1/18/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 129 | |||||
Common Shares [member] | Share capital issued on 1/30/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 13 | |||||
Common Shares [member] | Share capital issued on 1/31/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 20 | |||||
Common Shares [member] | Share capital issued on 2/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 238.337 | |||||
Common Shares [member] | Share capital issued on 3/13/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 238.319 | |||||
Common Shares [member] | Share capital issued on 3/23/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 3,527.752 | |||||
Common Shares [member] | Share capital issued on 3/26/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 529.162 | |||||
Common Shares [member] | Share capital issued on 4/5/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 12.302 | |||||
Common Shares [member] | Share capital issued on 4/6/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 57.500 | |||||
Common Shares [member] | Share capital issued on 4/6/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 14.138 | |||||
Common Shares [member] | Share capital issued on 4/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 3.560 | |||||
Common Shares [member] | Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 2.500 | |||||
Common Shares [member] | Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 2.500 | |||||
Common Shares [member] | Share capital issued on 4/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 2.500 | |||||
Common Shares [member] | Share capital issued on 6/21/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 193 | |||||
Common Shares [member] | Share capital issued on 7/5/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 32.625 | |||||
Common Shares [member] | Share capital issued on 7/11/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 64 | |||||
Common Shares [member] | Share capital issued on 8/16/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 10 | |||||
Common Shares [member] | Share capital issued on 9/1/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 5 | |||||
Common Shares [member] | Share capital issued on 12/9/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 19.800 | |||||
Common Shares [member] | Share capital issued on 9/21/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 5 | |||||
Common Shares [member] | Share capital issued on 10/27/2018 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 15 | |||||
Common Shares [member] | Share Capital Issued On 4/8/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 6,000 | |||||
Common Shares [member] | Share Capital Issued On 10/4/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by incorporation of reserve | 18 | |||||
Common Shares [member] | Share Capital Issued On 10/11/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 9,484.066 | |||||
Common Shares [member] | Share Capital Issued On 10/15/2019 [member] | ||||||
Disclosure of classes of share capital [line items] | ||||||
Capital increase by issuance of common shares | 1,368.667 | |||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Capital - Summary of Share Warr
Capital - Summary of Share Warrants and Employee Warrants (Detail) | 12 Months Ended |
Dec. 31, 2019$ / sharesshares | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 3,258,972 |
Number of options/warrants/ shares granted | 1,477,350 |
Number of options/warrants/ shares vested/ exercised | 18,000 |
Number of options/warrants/ shares voided | 849,375 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 3,868.947 |
Maximum of shares to be issued | 3,976,271 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 1,143,194 |
6/24/2011 [member] | BCE [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,166 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,166 |
Maximum of shares to be issued | 107,490 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 107,490 |
Subscription price | $ / shares | $ 5.13 |
6/24/2011 [member] | BSA2010 [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 500 |
Maximum of shares to be issued | 7,500 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 7,500 |
Subscription price | $ / shares | $ 5.13 |
9/25/2012 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 5,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 5,000 |
Maximum of shares to be issued | 5,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 5,000 |
Subscription price | $ / shares | $ 8.59 |
7/25/2013 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,000 |
Maximum of shares to be issued | 7,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 7,000 |
Subscription price | $ / shares | $ 8.10 |
9/18/2013 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 203,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 203,000 |
Maximum of shares to be issued | 203,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 203,000 |
Subscription price | $ / shares | $ 7.57 |
6/3/2014 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 40,000 |
Number of options/warrants/ shares voided | 40,000 |
Subscription price | $ / shares | $ 19.01 |
3/24/2015 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 10,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 10,000 |
Maximum of shares to be issued | 10,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 10,000 |
Subscription price | $ / shares | $ 43 |
6/23/2015 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 120,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 120,000 |
Maximum of shares to be issued | 120,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 120,000 |
Subscription price | $ / shares | $ 48.90 |
11/19/2015 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 15,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 15,000 |
Maximum of shares to be issued | 15,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 15,000 |
Subscription price | $ / shares | $ 66.06 |
11/19/2015 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 170,000 |
Number of options/warrants/ shares voided | 170,000 |
Subscription price | $ / shares | $ 66.06 |
12/15/2015 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 73,500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 73,500 |
Maximum of shares to be issued | 73,500 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 73,500 |
Subscription price | $ / shares | $ 64.14 |
1/4/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 75,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 75,000 |
Maximum of shares to be issued | 75,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 56,250 |
Subscription price | $ / shares | $ 65.68 |
4/21/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 22,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 22,000 |
Maximum of shares to be issued | 22,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 16,500 |
Subscription price | $ / shares | $ 62.82 |
6/21/2016 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 20,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 20,000 |
Maximum of shares to be issued | 20,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 20,000 |
Subscription price | $ / shares | $ 52.97 |
6/21/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 87,500 |
Number of options/warrants/ shares voided | 50,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 37,500 |
Maximum of shares to be issued | 37,500 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 32,813 |
Subscription price | $ / shares | $ 53.96 |
8/1/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 10,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 10,000 |
Maximum of shares to be issued | 10,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 7,500 |
Subscription price | $ / shares | $ 62.24 |
9/15/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 9,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 9,300 |
Maximum of shares to be issued | 9,300 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 6,975 |
Subscription price | $ / shares | $ 62.80 |
10/17/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 9,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 9,300 |
Maximum of shares to be issued | 9,300 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 6,975 |
Subscription price | $ / shares | $ 64.39 |
11/15/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 8,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 8,300 |
Maximum of shares to be issued | 8,300 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 6,225 |
Subscription price | $ / shares | $ 68.33 |
12/9/2016 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 34,008 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 34,008 |
Maximum of shares to be issued | 34,008 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 34,008 |
Subscription price | $ / shares | $ 69.75 |
12/9/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 51,995 |
Number of options/warrants/ shares voided | 9,050 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 42,945 |
Maximum of shares to be issued | 42,945 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 32,209 |
Subscription price | $ / shares | $ 69.75 |
9/17/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 80,900 |
Number of options/warrants/ shares voided | 36,425 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 44,475 |
Maximum of shares to be issued | 44,475 |
Subscription price | $ / shares | $ 40.94 |
10/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 76,700 |
Number of options/warrants/ shares voided | 5,400 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 71,300 |
Maximum of shares to be issued | 71,300 |
Subscription price | $ / shares | $ 37.28 |
11/1/2018 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 46,500 |
Number of options/warrants/ shares voided | 2,500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 44,000 |
Maximum of shares to be issued | 44,000 |
11/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 26,000 |
Number of options/warrants/ shares voided | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 18,800 |
Maximum of shares to be issued | 18,800 |
Subscription price | $ / shares | $ 32.57 |
11/29/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 350,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 350,000 |
Maximum of shares to be issued | 350,000 |
Subscription price | $ / shares | $ 30.02 |
12/12/2018 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 19,250 |
Number of options/warrants/ shares voided | 4,250 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 15,000 |
Maximum of shares to be issued | 15,000 |
12/12/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 34,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 34,000 |
Maximum of shares to be issued | 34,000 |
Subscription price | $ / shares | $ 27.96 |
12/17/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,200 |
Maximum of shares to be issued | 7,200 |
Subscription price | $ / shares | $ 26.76 |
12/15/2016 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 1,100 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 1,100 |
Maximum of shares to be issued | 1,100 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 825 |
Subscription price | $ / shares | $ 69.35 |
1/16/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 19,100 |
Number of options/warrants/ shares voided | 19,100 |
Subscription price | $ / shares | $ 66.11 |
3/14/2017 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 17,000 |
Number of options/warrants/ shares vested/ exercised | 6,000 |
Number of options/warrants/ shares voided | 5,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 6,000 |
Maximum of shares to be issued | 6,000 |
3/15/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,200 |
Number of options/warrants/ shares voided | 7,200 |
Subscription price | $ / shares | $ 66.25 |
4/18/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,200 |
Maximum of shares to be issued | 7,200 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 4,500 |
Subscription price | $ / shares | $ 60.77 |
4/20/2017 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 24,000 |
Number of options/warrants/ shares vested/ exercised | 12,000 |
Number of options/warrants/ shares voided | 4,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 8,000 |
Maximum of shares to be issued | 8,000 |
6/15/2017 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 9,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 9,000 |
Maximum of shares to be issued | 9,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 9,000 |
Subscription price | $ / shares | $ 59.05 |
6/15/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 91,000 |
Number of options/warrants/ shares voided | 30,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 61,000 |
Maximum of shares to be issued | 61,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 38,125 |
Subscription price | $ / shares | $ 60.54 |
6/15/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 111,600 |
Number of options/warrants/ shares voided | 55,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 56,600 |
Maximum of shares to be issued | 56,600 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 41,000 |
Subscription price | $ / shares | $ 59.05 |
7/17/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,200 |
Maximum of shares to be issued | 7,200 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 3,600 |
Subscription price | $ / shares | $ 71.61 |
9/15/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 45,400 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 45,400 |
Maximum of shares to be issued | 45,400 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 22,700 |
Subscription price | $ / shares | $ 74.22 |
12/5/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 540,075 |
Number of options/warrants/ shares voided | 204,050 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 336,025 |
Maximum of shares to be issued | 336,025 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 183,013 |
Subscription price | $ / shares | $ 39 |
12/15/2017 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 8,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 8,300 |
Maximum of shares to be issued | 8,300 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 4,150 |
Subscription price | $ / shares | $ 38.18 |
1/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 8,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 8,300 |
Maximum of shares to be issued | 8,300 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 3,113 |
Subscription price | $ / shares | $ 43.60 |
4/16/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 16,500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 16,500 |
Maximum of shares to be issued | 16,500 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 6,188 |
Subscription price | $ / shares | $ 38.64 |
7/2/2018 [member] | BSA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 44,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 44,000 |
Maximum of shares to be issued | 44,000 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 44,000 |
Subscription price | $ / shares | $ 37.24 |
5/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 16,500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 16,500 |
Maximum of shares to be issued | 16,500 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 6,188 |
Subscription price | $ / shares | $ 40.84 |
6/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 23,600 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 23,600 |
Maximum of shares to be issued | 23,600 |
Number of options/warrants/ shares exercisable as of 12/31/2019 | 8,850 |
Subscription price | $ / shares | $ 38.92 |
6/22/2018 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 465,028 |
Number of options/warrants/ shares voided | 64,100 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 400,928 |
Maximum of shares to be issued | 400,928 |
6/22/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 50,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 50,000 |
Maximum of shares to be issued | 50,000 |
Subscription price | $ / shares | $ 37.22 |
7/16/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 28,800 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 28,800 |
Maximum of shares to be issued | 28,800 |
Subscription price | $ / shares | $ 33.81 |
8/15/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 33,500 |
Number of options/warrants/ shares voided | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 26,300 |
Maximum of shares to be issued | 26,300 |
Subscription price | $ / shares | $ 32.90 |
9/6/2018 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 450 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 450 |
Maximum of shares to be issued | 450 |
9/6/2018 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares outstanding as of 01/01/2019 | 65,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 65,000 |
Maximum of shares to be issued | 65,000 |
Subscription price | $ / shares | $ 36.96 |
1/15/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 9,500 |
Number of options/warrants/ shares voided | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 2,300 |
Maximum of shares to be issued | 2,300 |
Subscription price | $ / shares | $ 15.61 |
3/20/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 547,100 |
Number of options/warrants/ shares voided | 52,300 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 494,800 |
Maximum of shares to be issued | 494,800 |
Subscription price | $ / shares | $ 14.58 |
5/10/2019 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 100,000 |
Number of options/warrants/ shares voided | 20,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 80,000 |
Maximum of shares to be issued | 80,000 |
5/15/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,200 |
Maximum of shares to be issued | 7,200 |
Subscription price | $ / shares | $ 16.82 |
5/24/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 150,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 150,000 |
Maximum of shares to be issued | 150,000 |
Subscription price | $ / shares | $ 16.99 |
6/17/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 7,200 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 7,200 |
Maximum of shares to be issued | 7,200 |
Subscription price | $ / shares | $ 16.38 |
7/1/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 403,400 |
Number of options/warrants/ shares voided | 49,400 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 354,000 |
Maximum of shares to be issued | 354,000 |
Subscription price | $ / shares | $ 15.43 |
7/22/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 75,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 75,000 |
Maximum of shares to be issued | 75,000 |
Subscription price | $ / shares | $ 17.90 |
7/31/2019 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 23,750 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 23,750 |
Maximum of shares to be issued | 23,750 |
9/16/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 34,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 34,000 |
Maximum of shares to be issued | 34,000 |
Subscription price | $ / shares | $ 18 |
10/11/2019 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 40,000 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 40,000 |
Maximum of shares to be issued | 40,000 |
10/16/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 3,500 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 3,500 |
Maximum of shares to be issued | 3,500 |
Subscription price | $ / shares | $ 15.30 |
12/16/2019 [member] | SO [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 53,100 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 53,100 |
Maximum of shares to be issued | 53,100 |
Subscription price | $ / shares | $ 15.80 |
12/20/2019 [member] | AGA [member] | |
Disclosure of classes of share capital [line items] | |
Number of options/warrants/ shares granted | 23,600 |
Number of options/warrants/ shares outstanding as of 12/31/2019 | 23,600 |
Maximum of shares to be issued | 23,600 |
Financial and Other Non-Curre_3
Financial and Other Non-Current Liabilities - Additional Information (Detail) | Jun. 30, 2017EUR (€)Patient | Sep. 30, 2015EUR (€) | Jan. 22, 2015EUR (€) | Sep. 30, 2014EUR (€) | Apr. 30, 2018EUR (€) | Oct. 31, 2015EUR (€) | Oct. 31, 2014EUR (€) | Apr. 30, 2013EUR (€) | Dec. 31, 2019EUR (€)Contracts | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€)Installments | Dec. 31, 2014EUR (€) | Dec. 31, 2013EUR (€) | Dec. 31, 2011EUR (€) | ||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Advances repayable at nominal value | 100.00% | ||||||||||||||||
Number of advance contracts | Contracts | 2 | ||||||||||||||||
Income earned on termination of contract | € 0 | € 0 | € 0 | ||||||||||||||
Cash collected from conditional advance | [1] | [1] | |||||||||||||||
Repayment of conditional advance | 1,181,000 | 1,800,000 | [1] | 578,000 | [1] | ||||||||||||
Borrowings repaid | € 256,000 | ||||||||||||||||
Number of installment payments | Installments | 4 | ||||||||||||||||
Installment payment start date | Sep. 30, 2014 | ||||||||||||||||
Borrowings paid in installments | € 64,000 | ||||||||||||||||
3rd OSEO contract [member] | |||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Cash collected from conditional advance | 0 | 0 | € 128,000 | € 256,000 | € 256,000 | ||||||||||||
Repayment of conditional advance | 64,000 | 128,000 | |||||||||||||||
3rd OSEO contract [member] | Top of range [member] | |||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Cash collected from conditional advance | € 640,000 | ||||||||||||||||
Cash collected from conditional advance | 0 | 0 | 0 | ||||||||||||||
Repayment of conditional advance | € 32,000 | € 64,000 | |||||||||||||||
4th OSEO contract [member] | |||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Cash collected from conditional advance | € 864,989 | € 481,162 | € 918,000 | € 903,500 | € 903,500 | 0 | 0 | € 0 | |||||||||
Repayment of conditional advance | € 624,000 | € 1,136,000 | |||||||||||||||
Annual interest rate on advance | 2.05% | 2.05% | 2.05% | 2.05% | |||||||||||||
4th OSEO contract [member] | Collaborative research and clinical development [member] | |||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Cash collected from conditional advance | € 3,206,162 | ||||||||||||||||
BPI advance [member] | |||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||
Cash collected from conditional advance | € 3,000,000 | ||||||||||||||||
Cash collected from conditional advance | € 0 | € 0 | |||||||||||||||
Repayment of conditional advance | € 150,000 | € 600,000 | € 60,000 | € 450,000 | |||||||||||||
Number of quarterly repayments | Patient | 20 | ||||||||||||||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Financial and Other Non-Curre_4
Financial and Other Non-Current Liabilities - Summary of Debt Recorded on Statement of Financial Position (Detail) - EUR (€) | Jun. 30, 2017 | Sep. 30, 2015 | Jan. 22, 2015 | Sep. 30, 2014 | Apr. 30, 2018 | Oct. 31, 2015 | Oct. 31, 2014 | Apr. 30, 2013 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2016 | ||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Beginning balance | € 2,479,000 | € 4,150,000 | € 4,627,000 | ||||||||||||||
Receipts | [1] | [1] | |||||||||||||||
Repayments | (1,181,000) | (1,800,000) | [1] | (578,000) | [1] | ||||||||||||
Other transactions | 44,000 | 129,000 | 101,000 | ||||||||||||||
Ending balance | 1,298,000 | 2,479,000 | 4,150,000 | ||||||||||||||
Of which - Non-current portion | 721,000 | 1,278,000 | 1,825,000 | ||||||||||||||
Of which - Current portion | 577,000 | 1,201,000 | 2,325,000 | ||||||||||||||
3rd OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Beginning balance | 64,000 | 192,000 | |||||||||||||||
Receipts | 0 | 0 | € 128,000 | € 256,000 | € 256,000 | ||||||||||||
Repayments | (64,000) | (128,000) | |||||||||||||||
Other transactions | 1,000 | ||||||||||||||||
Ending balance | 64,000 | ||||||||||||||||
4th OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Beginning balance | 624,000 | 1,700,000 | 1,684,000 | ||||||||||||||
Receipts | € 864,989 | € 481,162 | € 918,000 | € 903,500 | € 903,500 | 0 | 0 | 0 | |||||||||
Repayments | € (624,000) | (1,136,000) | |||||||||||||||
Other transactions | 60,000 | 16,000 | |||||||||||||||
Ending balance | € 624,000 | € 1,700,000 | |||||||||||||||
Stated interest rate | 2.05% | 2.05% | 2.05% | 2.05% | |||||||||||||
BPI advance [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Beginning balance | € 1,854,000 | € 2,386,000 | € 2,751,000 | ||||||||||||||
Receipts | 0 | 0 | |||||||||||||||
Repayments | € (150,000) | (600,000) | (60,000) | (450,000) | |||||||||||||
Other transactions | 44,000 | 69,000 | 84,000 | ||||||||||||||
Ending balance | € 1,298,000 | € 1,854,000 | € 2,386,000 | ||||||||||||||
Discount rate | 3.20% | 3.20% | 3.20% | ||||||||||||||
Bottom of range [member] | 3rd OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Discount rate | 0.40% | 0.40% | |||||||||||||||
Maturity (in years) | 0 | 0 | |||||||||||||||
Bottom of range [member] | 4th OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Discount rate | 1.50% | 1.50% | 1.50% | ||||||||||||||
Maturity (in years) | 7 | 7 | 7 | ||||||||||||||
Bottom of range [member] | BPI advance [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Maturity (in years) | 2 | 2 | 2 | ||||||||||||||
Top of range [member] | 3rd OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||||
Repayments | € (32,000) | € (64,000) | |||||||||||||||
Discount rate | 1.90% | 1.90% | |||||||||||||||
Maturity (in years) | 3 | 3 | |||||||||||||||
Top of range [member] | 4th OSEO contract [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Discount rate | 1.80% | 1.80% | 1.80% | ||||||||||||||
Maturity (in years) | 9 | 9 | 9 | ||||||||||||||
Top of range [member] | BPI advance [member] | |||||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||||
Maturity (in years) | 7 | 7 | 7 | ||||||||||||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Financial and Other Non-Curre_5
Financial and Other Non-Current Liabilities - Summary of Due Dates of the Financial Liabilities (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||
Disclosure of financial liabilities [line items] | |||||
Lease debt | € 22,860 | ||||
Supplier accounts payable and related payables | 21,368 | € 28,567 | [1] | € 16,941 | [1] |
Not later than one year [member] | |||||
Disclosure of financial liabilities [line items] | |||||
Conditional advances | 577 | 1,201 | 2,325 | ||
Lease debt | 3,282 | ||||
Other liabilities | 22,197 | 12,506 | 15,751 | ||
Supplier accounts payable and related payables | 21,368 | 28,567 | 16,941 | ||
Total financial, current and non-current liabilities | 47,423 | 42,273 | 35,017 | ||
Later than one year and not later than five years [member] | |||||
Disclosure of financial liabilities [line items] | |||||
Conditional advances | 721 | 1,278 | 1,825 | ||
Lease debt | 13,282 | ||||
Other liabilities | 71 | 3,991 | 8,421 | ||
Total financial, current and non-current liabilities | 14,074 | 5,269 | 10,246 | ||
More than five years [member] | |||||
Disclosure of financial liabilities [line items] | |||||
Lease debt | 6,296 | ||||
Other liabilities | 114 | 448 | |||
Total financial, current and non-current liabilities | 6,296 | 114 | 448 | ||
Total, gross [member] | |||||
Disclosure of financial liabilities [line items] | |||||
Conditional advances | 1,298 | 2,479 | 4,150 | ||
Lease debt | 22,860 | ||||
Other liabilities | 22,268 | 16,611 | 24,620 | ||
Supplier accounts payable and related payables | 21,368 | 28,567 | 16,941 | ||
Total financial, current and non-current liabilities | € 67,794 | € 47,656 | € 45,711 | ||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Non-Current Provisions - Schedu
Non-Current Provisions - Schedule of Non-Current Provisions (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||
Disclosure of other provisions [abstract] | ||||||
Pension retirement obligations | € 1,474 | € 1,536 | € 1,260 | |||
Total | € 1,474 | € 1,536 | [1] | € 1,260 | [1] | € 853 |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Non-Current Provisions - Sche_2
Non-Current Provisions - Schedule of Commitments for Compensation Payable to Employees Upon Their Retirement (Detail) - EUR (€) € in Thousands | 12 Months Ended | |||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||||
Disclosure of Retirement Benefits [abstract] | ||||||
Beginning balance | € (1,536) | [1] | € (1,260) | [1] | € (853) | |
Costs of services rendered (operating expense) | (443) | (412) | (219) | |||
Interest expense (financial expense) | (24) | (24) | (11) | |||
Benefit paid | 141 | |||||
Actuarial gains | 529 | 19 | (177) | |||
Ending balance | € (1,474) | € (1,536) | [1] | € (1,260) | [1] | |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Non-Current Provisions - Sche_3
Non-Current Provisions - Schedule of Retirement Commitments (Detail) | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of sensitivity analysis for actuarial assumptions [abstract] | |||
% social security contributions | 50.00% | 50.00% | 50.00% |
Salary increases | 2.00% | 2.00% | 2.00% |
Discount rate | 0.77% | 1.57% | 1.30% |
Non-Current Provisions - Additi
Non-Current Provisions - Additional Information (Detail) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure Of Noncurrent Provisions [abstract] | |||
Retirement age of employee | 65 years | 65 years | 65 years |
Supplier Accounts Receivable _3
Supplier Accounts Receivable and Other Current Liabilities - Additional Information (Detail) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure Of Supplier Accounts And Other Current Liabilities [abstract] | |||
Supplier accounts payable and related payables | € 0 | ||
Supplier accounts and related payables term | 1 year | ||
Deferred income | € 3,204,000 | € 4,360,000 | € 2,789,000 |
Supplier Accounts Receivable _4
Supplier Accounts Receivable and Other Current Liabilities - Schedule of Other Current Liabilities (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||
Disclosure Of Supplier Accounts And Other Current Liabilities [abstract] | |||||
Social security | € 18,100 | € 6,343 | € 12,094 | ||
Tax liabilities | 384 | 448 | 428 | ||
Other debts | 510 | 1,354 | 440 | ||
Deferred revenues | 3,204 | 4,360 | 2,789 | ||
Total | € 22,197 | € 12,506 | [1] | € 15,751 | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Financial Instruments Recogni_3
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) - Schedule of Financial Instruments Recognized (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | € 179,430 | € 129,715 | € 142,534 |
Financial liabilities, fair value | 67,794 | 47,656 | 45,711 |
Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 1,278 | 1,825 | |
Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 4,105 | 8,869 | |
Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 1,201 | 2,325 | |
Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 12,506 | 15,751 | |
Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 28,567 | 16,941 | |
Conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 1,298 | ||
Lease debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 22,860 | ||
Other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 22,268 | ||
Supplier accounts payable [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities, fair value | 21,368 | ||
Financial liabilities at amortised cost, category [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 67,794 | 47,656 | 45,711 |
Financial liabilities at amortised cost, category [member] | Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,278 | 1,825 | |
Financial liabilities at amortised cost, category [member] | Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 4,105 | 8,869 | |
Financial liabilities at amortised cost, category [member] | Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,201 | 2,325 | |
Financial liabilities at amortised cost, category [member] | Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12,506 | 15,751 | |
Financial liabilities at amortised cost, category [member] | Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 28,567 | 16,941 | |
Financial liabilities at amortised cost, category [member] | Conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,298 | ||
Financial liabilities at amortised cost, category [member] | Lease debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 22,860 | ||
Financial liabilities at amortised cost, category [member] | Other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 22,268 | ||
Financial liabilities at amortised cost, category [member] | Supplier accounts payable [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 21,368 | ||
Non-derivative Financial Liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 67,794 | 47,656 | 45,711 |
Non-derivative Financial Liabilities [member] | Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,278 | 1,825 | |
Non-derivative Financial Liabilities [member] | Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 4,105 | 8,869 | |
Non-derivative Financial Liabilities [member] | Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,201 | 2,325 | |
Non-derivative Financial Liabilities [member] | Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12,506 | 15,751 | |
Non-derivative Financial Liabilities [member] | Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 28,567 | 16,941 | |
Non-derivative Financial Liabilities [member] | Conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,298 | ||
Non-derivative Financial Liabilities [member] | Lease debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 22,860 | ||
Non-derivative Financial Liabilities [member] | Other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 22,268 | ||
Non-derivative Financial Liabilities [member] | Supplier accounts payable [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 21,368 | ||
Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 6,033 | 3,012 | |
Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 1,265 | ||
Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 679 | 912 | 378 |
Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 172,027 | 122,770 | 137,880 |
Pledged Securities And Other NonCurrent Financial Assets [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 4,314 | ||
Deposits [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 1,359 | ||
Liquidity Contract [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 1,051 | ||
Carrying amount [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 179,430 | 129,715 | 142,534 |
Carrying amount [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 6,033 | 3,012 | |
Carrying amount [member] | Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,265 | ||
Carrying amount [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 679 | 912 | 378 |
Carrying amount [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 172,027 | 122,770 | 137,880 |
Carrying amount [member] | Pledged Securities And Other NonCurrent Financial Assets [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 4,314 | ||
Carrying amount [member] | Deposits [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,359 | ||
Carrying amount [member] | Liquidity Contract [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,051 | ||
Fair value through Consolidated Statements of (Loss) [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,051 | 432 | 139,213 |
Fair value through Consolidated Statements of (Loss) [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 432 | 1,333 | |
Fair value through Consolidated Statements of (Loss) [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 137,880 | ||
Fair value through Consolidated Statements of (Loss) [member] | Liquidity Contract [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,051 | ||
Loans and receivables, category [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 129,283 | 3,321 | |
Loans and receivables, category [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 5,600 | 1,679 | |
Loans and receivables, category [member] | Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,265 | ||
Loans and receivables, category [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 912 | € 378 | |
Loans and receivables, category [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | € 122,770 | ||
Financial assets at amortised cost, class [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 178,379 | ||
Financial assets at amortised cost, class [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 679 | ||
Financial assets at amortised cost, class [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 172,027 | ||
Financial assets at amortised cost, class [member] | Pledged Securities And Other NonCurrent Financial Assets [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 4,314 | ||
Financial assets at amortised cost, class [member] | Deposits [Member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | € 1,359 |
Operating Income - Summary of O
Operating Income - Summary of Operating Income (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Analysis of income and expense [abstract] | |||||
Research tax credit | € 9,770 | € 11,034 | € 9,330 | ||
Subsidies | 152 | 271 | |||
Other operating income | 3,369 | 3,351 | 2,308 | ||
Total income | € 13,139 | € 14,537 | [1] | € 11,909 | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Operating Expenses - Summary of
Operating Expenses - Summary of Research and Development (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Disclosure of Other Operating Expense [abstract] | |||||
Personnel expenses | € 41,565 | € 37,912 | € 37,112 | ||
Sub-contracting, Collaboration, and Consultants | 47,750 | 52,927 | 54,397 | ||
Small equipments and other supplies | 2,814 | 4,771 | 4,110 | ||
Rental | 1,170 | 2,703 | 2,018 | ||
Conferences, travel expenses | 1,676 | 2,591 | 2,807 | ||
Depreciation and amortization | 4,853 | 2,492 | 2,424 | ||
Others | 1,669 | 3,776 | 2,364 | ||
Total research and development expenses | € 101,497 | € 107,171 | [1] | € 105,232 | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Operating Expenses - Summary _2
Operating Expenses - Summary of Sales and Marketing Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Disclosure of sales and marketing expense [abstract] | |||||
Personnel expenses | € 12,504 | € 12,553 | € 6,976 | ||
Fees | 4,194 | 5,148 | 2,480 | ||
Marketing, tradeshows and travel expenses | 1,340 | 14,021 | 5,984 | ||
Depreciation and amortization | 736 | 44 | |||
Others | 168 | 402 | 384 | ||
Total sales and marketing expenses | € 18,941 | € 32,169 | [1] | € 15,824 | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Operating Expenses - Summary _3
Operating Expenses - Summary of General and Administrative Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Disclosure Of General And Administrative Expense [abstract] | |||||
Personnel expenses | € 25,751 | € 19,101 | € 19,742 | ||
Fees | 10,883 | 12,718 | 10,347 | ||
Rental | 43 | 911 | 584 | ||
Insurance policies | 2,720 | 1,930 | 1,367 | ||
Corporate communication and travel expenses | 972 | 1,576 | 1,599 | ||
Depreciation and amortization | 516 | 1,720 | 422 | ||
Others | 3,515 | 3,442 | 1,776 | ||
Total general and administrative expenses | € 44,401 | € 41,399 | [1] | € 35,837 | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Operating Expenses - Additional
Operating Expenses - Additional Information (Detail) - Employees | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of personnel expense [abstract] | |||
Number of employees | 319 | 268 | 242 |
Operating Expenses - Summary _4
Operating Expenses - Summary of Personnel Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of personnel expense [abstract] | |||
Wages and salaries | € 48,261 | € 31,684 | € 22,451 |
Social security contributions | 13,097 | 8,858 | 7,157 |
Expenses for pension commitments | 2,383 | 2,095 | 1,583 |
Employer contribution to bonus shares | 1,155 | 1,026 | 1,857 |
Share-based payments | 14,923 | 25,904 | 30,781 |
Total | € 79,820 | € 69,567 | € 63,830 |
Share-Based Payments - Addition
Share-Based Payments - Additional Information (Detail) | May 24, 2019shares | Sep. 06, 2018 | Jun. 22, 2018shares | Jun. 02, 2018shares | May 02, 2018shares | Dec. 31, 2017shares | Jun. 15, 2017shares | Dec. 15, 2016 | Dec. 09, 2016 | Sep. 12, 2016shares | Jun. 24, 2016 | Jun. 21, 2016shares | Apr. 06, 2016 | Dec. 15, 2015shares | Nov. 19, 2015shares | Sep. 30, 2015 | Sep. 21, 2015shares | Jun. 23, 2015shares | Mar. 24, 2015shares | Dec. 23, 2014 | Jun. 03, 2014shares | Mar. 06, 2014shares | Dec. 23, 2013 | Sep. 18, 2013 | Jul. 25, 2013shares | Jun. 04, 2013shares | Dec. 23, 2012 | Sep. 25, 2012shares | Dec. 23, 2011 | Dec. 09, 2011shares | Nov. 22, 2011 | Jun. 24, 2011 | Dec. 16, 2010shares | Jan. 21, 2009shares | Jun. 14, 2007shares | Dec. 15, 2016 | Sep. 30, 2016 | Jun. 30, 2018shares | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Number of options granted | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 0.00% | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 1 year | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | |||||||||||||||||||||||||||||||||||||||||
BCEX [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 2,296 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 9,000 | 54,008 | 88,500 | 20,000 | 73,000 | 194,552 | 194,552 | 194,552 | |||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 7,500 | 9,359 | |||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Sep. 25, 2012 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 4 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jul. 25, 2013 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | 10 years | |||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 73,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 6/3/2014 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 03, 2014 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 03/24/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Mar. 24, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 03/24/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 10,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 11/19/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Nov. 19, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 15,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 15, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 73,500 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 21, 2016 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 20,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 09, 2016 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 34,008 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 15, 2018 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 5/2/2018 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | May 02, 2018 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 5/2/2018 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 44,000 | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 03/06/2014 [Member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 03/06/2014 [Member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 10,000 | ||||||||||||||||||||||||||||||||||||||||
BSA 2 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 10,716 | ||||||||||||||||||||||||||||||||||||||||
Bons De Createurs D Entreprise Bce Four [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 5,358 | ||||||||||||||||||||||||||||||||||||||||
BSA 2010 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 19,377 | ||||||||||||||||||||||||||||||||||||||||
BSAX [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 2,131 | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 34,039 | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest within before the 11/22/2021. | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | Date of Grant 12/7/2007 [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | Date of Grant 12/7/2007 [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | Date of Grant 12/7/2007 [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | Date of Grant 12/7/2007 [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||
OPTIONS 2013 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 518,000 | ||||||||||||||||||||||||||||||||||||||||
Free shares [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 187,350 | 562,853 | 241,844 | 186,000 | 1,340,737 | ||||||||||||||||||||||||||||||||||||
Number of options granted | 1,107,350 | ||||||||||||||||||||||||||||||||||||||||
Options [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 1,282,800 | 752,100 | 900,700 | 918,960 | 72,100 | ||||||||||||||||||||||||||||||||||||
BSA2010 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | 25.00% | 25.00% | 25.00% | |||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 110 | ||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Date of Grant 12/9/2016 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | ||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Date of Grant 06/15/2017 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | ||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 3,839 | 1,334 | |||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 24, 2011 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest within before the 11/22/2021 | At the latest before the 09/30/2025 | At the latest within before the 11/22/2021 | ||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 12/15/2025 | ||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||
Share Option [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,290 | 824.200 | 998.500 | ||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 0 | 268 | 1.200 | ||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 03, 2014 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 06/03/2024 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 75,000 | 518,000 | |||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 23, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 06/24/2025 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 7/25/2013 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 195,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 6/3/2014 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 15, 2015 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 75,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 03/24/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before 10 years of the date of the Grant | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 55,000 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 21, 2016 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | 10 years | |||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 154,100 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | |||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 09, 2016 | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 74,960 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 18,740 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 06/21/2016 [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 15, 2016 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than Four Years and Not Later Than Five Years [member] | |||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 |
Share-Based Payments - Summary
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSA (Detail) | Sep. 06, 2018€ / shares | May 02, 2018EUR (€)sharesyr€ / shares | Jun. 15, 2017EUR (€)sharesyr€ / shares | Dec. 09, 2016EUR (€)sharesyr€ / shares | Jun. 21, 2016EUR (€)sharesyr€ / shares | Dec. 15, 2015EUR (€)sharesyr€ / shares | Nov. 19, 2015EUR (€)sharesyr€ / shares | Mar. 24, 2015EUR (€)sharesyr€ / shares | Jun. 03, 2014EUR (€)sharesyr€ / shares | Jul. 25, 2013EUR (€)sharesyr€ / shares | Sep. 25, 2012EUR (€)sharesyr€ / shares | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 1 year | |||||||||||||
Plan expiration date | 11/19/2025 | 3/24/2025 | ||||||||||||
Number of BSA granted | 450 | 15,000 | 10,000 | |||||||||||
Share entitlement per BSA | € 1 | € 1 | € 1 | |||||||||||
Exercise price (in euros) | € 66.06 | € 43 | ||||||||||||
Grant date share fair value (in euros) | € | € 66.06 | € 43 | ||||||||||||
Expected volatility | 51.00% | 36.00% | ||||||||||||
Average life of BSA (in years) | yr | 5 | 5 | ||||||||||||
Discount rate | 0.81% | 0.68% | ||||||||||||
Expected dividends | 0.00% | 0.00% | 0.00% | |||||||||||
Fair value per BSA (in euros) | € 22.6 | € 9.9 | ||||||||||||
BSA [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Number of BSA granted | 44,000 | 68,000 | ||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 10 years | |||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche One [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 1 year | |||||||||||||
Plan expiration date | 09/25/2022 | |||||||||||||
Number of BSA granted | shares | 7,500 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 8.59 | |||||||||||||
Grant date share fair value (in euros) | € | € 8.4 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 5.5 | |||||||||||||
Discount rate | 1.21% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 2.29 | |||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Two [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 2 years | |||||||||||||
Plan expiration date | 09/25/2022 | |||||||||||||
Number of BSA granted | shares | 7,500 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 8.59 | |||||||||||||
Grant date share fair value (in euros) | € | € 8.4 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 6 | |||||||||||||
Discount rate | 1.21% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 2.43 | |||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Three [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 3 years | |||||||||||||
Plan expiration date | 09/25/2022 | |||||||||||||
Number of BSA granted | shares | 7,500 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 8.59 | |||||||||||||
Grant date share fair value (in euros) | € | € 8.4 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 6.5 | |||||||||||||
Discount rate | 1.53% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 2.61 | |||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 4 years | |||||||||||||
Plan expiration date | 09/25/2022 | |||||||||||||
Number of BSA granted | shares | 7,500 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 8.59 | |||||||||||||
Grant date share fair value (in euros) | € | € 8.4 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 7 | |||||||||||||
Discount rate | 1.53% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 2.74 | |||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 0 years | 10 years | ||||||||||||
Plan expiration date | 07/25/2023 | |||||||||||||
Number of BSA granted | shares | 73,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 8.1 | |||||||||||||
Grant date share fair value (in euros) | € | € 8.15 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | 1.16% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 2.18 | |||||||||||||
BSA [member] | Date of Grant 6/3/2014 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 0 years | |||||||||||||
Plan expiration date | 06/03/2024 | |||||||||||||
Number of BSA granted | shares | 10 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 18.79 | |||||||||||||
Grant date share fair value (in euros) | € | € 19.01 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | 0.71% | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 4.98 | |||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 10 years | |||||||||||||
Plan expiration date | 12/15/2025 | |||||||||||||
Number of BSA granted | shares | 90,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 64.14 | |||||||||||||
Grant date share fair value (in euros) | € | € 42.61 | |||||||||||||
Expected volatility | 51.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | (0.09%) | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 7.28 | |||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 10 years | |||||||||||||
Plan expiration date | 6/21/2026 | |||||||||||||
Number of BSA granted | shares | 20,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 52.97 | |||||||||||||
Grant date share fair value (in euros) | € | € 61.25 | |||||||||||||
Expected volatility | 47.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | (0.41%) | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 21.59 | |||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 10 years | |||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 10 years | |||||||||||||
BSA2010 [member] | Date of Grant 12/9/2016 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 0 years | |||||||||||||
Plan expiration date | 12/9/2026 | |||||||||||||
Number of BSA granted | shares | 59,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 69.75 | |||||||||||||
Grant date share fair value (in euros) | € | € 63.18 | |||||||||||||
Expected volatility | 40.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | (0.04%) | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 12.94 | |||||||||||||
BSA2010 [member] | Date of Grant 06/15/2017 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 0 years | |||||||||||||
Plan expiration date | 6/15/2027 | |||||||||||||
Number of BSA granted | shares | 9,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 59.05 | |||||||||||||
Grant date share fair value (in euros) | € | € 73.32 | |||||||||||||
Expected volatility | 39.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | (0.12%) | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 24.02 | |||||||||||||
BSA2010 [member] | Grant Date 5/02/2018 [member] | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting period (years) | 0 years | |||||||||||||
Plan expiration date | 5/2/2028 | |||||||||||||
Number of BSA granted | shares | 44,000 | |||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||
Exercise price (in euros) | € 37.24 | |||||||||||||
Grant date share fair value (in euros) | € | € 32.74 | |||||||||||||
Expected volatility | 50.00% | |||||||||||||
Average life of BSA (in years) | yr | 5 | |||||||||||||
Discount rate | (0.15%) | |||||||||||||
Expected dividends | 0.00% | |||||||||||||
Fair value per BSA (in euros) | € 9.02 |
Share-Based Payments - Summar_2
Share-Based Payments - Summary of Change in BSA Outstanding Number (Detail) | Sep. 06, 2018 | Nov. 19, 2015shares | Mar. 24, 2015shares | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Granted during the period | 450 | 15,000 | 10,000 | |||
BSA [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 217,508 | 181,008 | 147,359 | |||
Granted during the period | 44,000 | 68,000 | ||||
Forfeited during the period | 24,902 | |||||
Exercised during the period | 7,500 | 9,359 | ||||
Balance at end of period | 217,508 | 217,508 | 181,008 |
Share-Based Payments - Summar_3
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSA 2010 (Detail) | Sep. 06, 2018 | Nov. 19, 2015yr | Mar. 24, 2015yr | Jun. 24, 2011EUR (€)shares$ / shares | Dec. 31, 2019 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Plan expiration date | 11/19/2025 | 3/24/2025 | |||
Number of options granted | |||||
Expected volatility | 51.00% | 36.00% | |||
Average life of BSA (in years) | yr | 5 | 5 | |||
Expected dividends | 0.00% | 0.00% | 0.00% | ||
0.5 Year [member] | BSA2010 [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of options granted | 2,000 | ||||
Share entitlement per BSA | 15 | ||||
Exercise price (in euros) | 77 | ||||
Grant date share fair value (in euros) | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BSA (in years) | 5.5 | ||||
Discount rate | 2.55% | ||||
Expected dividends | 0.00% | ||||
Fair value per BSA (in euros) | $ / shares | € 31.15 | ||||
1.5 Year [member] | BSA2010 [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of options granted | 2,000 | ||||
Share entitlement per BSA | 15 | ||||
Exercise price (in euros) | 77 | ||||
Grant date share fair value (in euros) | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BSA (in years) | 6 | ||||
Discount rate | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BSA (in euros) | $ / shares | € 32.7 | ||||
2.5 Year [member] | BSA2010 [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 2 years 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of options granted | 2,000 | ||||
Share entitlement per BSA | 15 | ||||
Exercise price (in euros) | 77 | ||||
Grant date share fair value (in euros) | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BSA (in years) | 6.5 | ||||
Discount rate | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BSA (in euros) | $ / shares | € 34.02 | ||||
3.5 Year [member] | BSA2010 [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 3 years 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of options granted | 2,000 | ||||
Share entitlement per BSA | 15 | ||||
Exercise price (in euros) | 77 | ||||
Grant date share fair value (in euros) | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BSA (in years) | 7 | ||||
Discount rate | 2.87% | ||||
Expected dividends | 0.00% | ||||
Fair value per BSA (in euros) | $ / shares | € 35.57 |
Share-Based Payments - Share-Ba
Share-Based Payments - Share-Based Payments - Summary Of Change in Number of BSA 2010 Outstanding (Detail) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Granted during the period | |||
Forfeited during the period | |||
Exercised during the period | |||
BSA2010 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 500 | 500 | 610 |
Exercised during the period | 110 | ||
Balance at end of period | 500 | 500 | 500 |
Share-Based Payments - Summar_4
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BCE 2010 (Detail) | Sep. 06, 2018€ / shares | Nov. 19, 2015EUR (€)sharesyr€ / shares | Mar. 24, 2015EUR (€)sharesyr€ / shares | Nov. 22, 2011EUR (€)€ / shares | Jun. 24, 2011EUR (€)shares€ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year | ||||
Plan expiration date | 11/19/2025 | 3/24/2025 | |||
Number of BCE2010 granted | 450 | 15,000 | 10,000 | ||
Share entitlement per BCE2010(1) | € 1 | € 1 | € 1 | ||
Exercise price | € 66.06 | € 43 | |||
Grant date share fair value | € | € 66.06 | € 43 | |||
Expected volatility | 51.00% | 36.00% | |||
Average life of BCE2010 | yr | 5 | 5 | |||
Discount rate(2) | 0.81% | 0.68% | |||
Expected dividends | 0.00% | 0.00% | 0.00% | ||
Fair value per BCE2010 | € 22.6 | € 9.9 | |||
BCE2010 [member] | Not later than one year [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 6 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Not later than one year [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.5 | ||||
Discount rate(2) | 2.55% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 31.16 | ||||
BCE2010 [member] | Not later than one year [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Not later than one year [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.4 | ||||
Discount rate(2) | 2.05% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 30.42 | ||||
BCE2010 [member] | Later Than One Year and Not Later Than Two Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than One Year and Not Later Than Two Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6 | ||||
Discount rate(2) | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 32.71 | ||||
BCE2010 [member] | Later Than One Year and Not Later Than Two Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 2 years | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than One Year and Not Later Than Two Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.9 | ||||
Discount rate(2) | 2.42% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 32.29 | ||||
BCE2010 [member] | Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 2 years 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | shares | 6.5 | ||||
Discount rate(2) | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 34.03 | ||||
BCE2010 [member] | Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 3 years | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6.4 | ||||
Discount rate(2) | 2.42% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 33.58 | ||||
BCE2010 [member] | Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 3 years 6 months | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 7 | ||||
Discount rate(2) | 2.87% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 35.58 | ||||
BCE2010 [member] | Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 4 years | ||||
Plan expiration date | 11/22/2021 | ||||
Number of BCE2010 granted | 2,509 | ||||
Share entitlement per BCE2010(1) | € 15 | ||||
Exercise price | € 77 | ||||
BCE2010 [member] | Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6.9 | ||||
Discount rate(2) | 2.66% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € 35.2 |
Share-Based Payments - Summar_5
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BCE 2010 (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2019 | |
BCE2010 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Description of payment entitlement | The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. |
Share-Based Payments - Summar_6
Share-Based Payments - Summary Of Change in Number of BCE 2010 Outstanding (Detail) - BCE2010 [member] | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 7,166 | 11,005 | 12,339 |
Exercised during the period | 3,839 | 1,334 | |
Balance at end of period | 7,166 | 7,166 | 11,005 |
Share-Based Payment - Additiona
Share-Based Payment - Additional information (Detail) | Sep. 06, 2018 | Dec. 15, 2016 | Dec. 09, 2016 | Jun. 21, 2016 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | |||||||
Share based payment arrangement, vesting percentage | 0.00% | ||||||
Vesting period (years) | 1 year | ||||||
Share Option [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 0 | 268 | 1.200 | ||||
Share Option [member] | Date of Grant 11/19/2015 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, date of grant | Jun. 21, 2016 | ||||||
Share based payment arrangement, shares exercised | 154,100 | ||||||
Vesting period (years) | 10 years | 10 years | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Not later than one year [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Later Than One Year and Not Later Than Two Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | 24 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Later Than Two Years and Not Later Than Three Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | 36 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Later Than Three Years and Not Later Than Four Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 11/19/2015 [member] | 48 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | |||||
Share Option [member] | Date of Grant 12/15/2015 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, date of grant | Dec. 09, 2016 | ||||||
Share based payment arrangement, shares exercised | 74,960 | ||||||
Vesting period (years) | 10 years | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Not later than one year [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 18,740 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Later Than One Year and Not Later Than Two Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | 24 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Later Than Two Years and Not Later Than Three Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | 36 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Later Than Three Years and Not Later Than Four Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | 48 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||
Share Option [member] | Date of Grant 06/21/2016 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, date of grant | Dec. 15, 2016 | ||||||
Share Option [member] | 2018 grant date nine [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting period (years) | 10 years | ||||||
Share Option [member] | 2018 grant date nine [member] | Not later than one year [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||
Share Option [member] | 2018 grant date nine [member] | Later Than One Year and Not Later Than Two Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | ||||||
Share Option [member] | 2018 grant date nine [member] | 24 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | ||||||
Share Option [member] | 2018 grant date nine [member] | Later Than Two Years and Not Later Than Three Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | ||||||
Share Option [member] | 2018 grant date nine [member] | 36 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | ||||||
Share Option [member] | 2018 grant date nine [member] | Later Than Three Years and Not Later Than Four Years [member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% | ||||||
Share Option [member] | 2018 grant date nine [member] | 48 months [Member] | Top of range [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Share based payment arrangement, vesting percentage | 12.50% |
Share-Based Payments - Summar_7
Share-Based Payments - Summary of Details of Share Based Payment Arrangement SO (Detail) | Dec. 16, 2019EUR (€)Contracts€ / shares | Oct. 16, 2019EUR (€)Contracts€ / shares | Oct. 15, 2019yr | Sep. 16, 2019EUR (€)Contracts€ / shares | Jul. 22, 2019EUR (€)Contracts€ / shares | Jul. 01, 2019EUR (€)Contracts€ / shares | Jun. 17, 2019EUR (€)Contracts€ / shares | Jun. 17, 2019EUR (€)Contracts$ / shares | May 24, 2019EUR (€)Contracts€ / shares | May 24, 2019EUR (€)Contracts$ / shares | May 15, 2019EUR (€)Contracts€ / shares | May 15, 2019EUR (€)Contracts$ / shares | Mar. 20, 2019EUR (€)Contracts€ / shares | Mar. 20, 2019EUR (€)Contracts$ / shares | Jan. 15, 2019EUR (€)Contracts€ / shares | Jan. 15, 2019EUR (€)Contracts$ / shares | Dec. 17, 2018EUR (€)yr€ / shares | Dec. 17, 2018EUR (€)yr$ / shares | Dec. 12, 2018EUR (€)€ / shares | Nov. 15, 2018EUR (€)yr€ / shares | Nov. 15, 2018EUR (€)yr$ / shares | Oct. 15, 2018EUR (€)yr€ / shares | Oct. 15, 2018EUR (€)yr$ / shares | Sep. 17, 2018EUR (€)€ / shares | Sep. 17, 2018EUR (€)$ / shares | Sep. 06, 2018EUR (€)€ / shares | Aug. 15, 2018EUR (€)yr€ / shares | Aug. 15, 2018EUR (€)yr$ / shares | Jul. 16, 2018EUR (€)yr€ / shares | Jul. 16, 2018EUR (€)yr$ / shares | Jul. 03, 2018 | Jun. 22, 2018EUR (€)yr€ / shares | Jun. 22, 2018EUR (€)yr$ / shares | Jun. 15, 2018EUR (€)yr€ / shares | Jun. 15, 2018EUR (€)yr$ / shares | Jun. 09, 2018 | May 15, 2018EUR (€)yr€ / shares | May 15, 2018EUR (€)yr$ / shares | Apr. 16, 2018EUR (€)yr€ / shares | Apr. 16, 2018EUR (€)yr$ / shares | Jan. 15, 2018EUR (€)yr€ / shares | Jan. 15, 2018EUR (€)yr$ / shares | Dec. 15, 2017EUR (€)yr€ / shares | Dec. 15, 2017EUR (€)yr$ / shares | Dec. 05, 2017EUR (€)yr€ / shares | Dec. 05, 2017EUR (€)yr$ / shares | Sep. 15, 2017EUR (€)yr€ / shares | Sep. 15, 2017EUR (€)yr$ / shares | Jul. 17, 2017EUR (€)yr€ / shares | Jul. 17, 2017EUR (€)yr$ / shares | Jun. 15, 2017EUR (€)yr€ / shares | Jun. 15, 2017EUR (€)yr$ / shares | Apr. 18, 2017EUR (€)yr€ / shares | Apr. 18, 2017EUR (€)yr$ / shares | Mar. 15, 2017EUR (€)yr€ / shares | Mar. 15, 2017EUR (€)yr$ / shares | Jan. 16, 2017EUR (€)yr€ / shares | Jan. 16, 2017EUR (€)yr$ / shares | Dec. 15, 2016EUR (€)€ / shares | Dec. 09, 2016EUR (€)€ / shares | Nov. 15, 2016EUR (€)€ / shares | Oct. 17, 2016EUR (€)€ / shares | Sep. 15, 2016EUR (€)€ / shares | Aug. 01, 2016EUR (€)€ / shares | Jun. 21, 2016EUR (€)€ / shares | May 02, 2016EUR (€)€ / shares | May 02, 2016EUR (€)$ / shares | Apr. 21, 2016EUR (€)€ / shares | Apr. 21, 2016EUR (€)$ / shares | Jan. 04, 2016EUR (€)€ / shares | Jan. 04, 2016EUR (€)$ / shares | Nov. 19, 2015EUR (€)yr€ / shares | Nov. 19, 2015EUR (€)yr$ / shares | Jun. 23, 2015EUR (€)€ / shares | Jun. 23, 2015EUR (€)$ / shares | Mar. 24, 2015EUR (€)yr€ / shares | Jun. 03, 2014EUR (€)€ / shares | Jun. 03, 2014EUR (€)$ / shares | Sep. 18, 2013EUR (€)€ / shares | Sep. 18, 2013EUR (€)$ / shares | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/19/2025 | 11/19/2025 | 3/24/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | € 1 | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 66.06 | € 66.06 | € 43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 51.00% | 51.00% | 36.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,290 | 824.200 | 998.500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 38.84% | 38.84% | 39.23% | 39.23% | 39.23% | 39.23% | 39.63% | 39.63% | 39.82% | 39.82% | 40.21% | 40.21% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.15% | 46.15% | 46.37% | 46.37% | 45.57% | 45.57% | 43.13% | 43.13% | 43.23% | 43.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.08%) | (0.08%) | 0.37% | 0.37% | 0.27% | 0.27% | 0.17% | 0.17% | 0.14% | 0.14% | 0.19% | 0.19% | 0.41% | 0.41% | 0.35% | 0.35% | 0.32% | 0.32% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 47.44 | $ 47.12 | $ 46.92 | $ 46.67 | $ 46.51 | $ 45.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/18/2013 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 9/18/2023 | 9/18/2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 518,000 | 518,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 7.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/18/2013 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 7.9 | $ 7.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.00% | 40.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 1.72% | 1.72% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 3.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 6/3/2014 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 2 years | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/3/2024 | 6/3/2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 75,000 | 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 19.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 6/3/2014 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 19.01 | $ 19.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.00% | 40.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 6 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.89% | 0.89% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 7.46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/23/2025 | 6/23/2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 120,000 | 120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 48.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/23/2015 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 48.9 | $ 48.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 51.00% | 51.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.89% | 0.89% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 25.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 10 years | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/19/2025 | 11/19/2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 195,000 | 195,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 66.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 66.06 | € 66.06 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 51.00% | 51.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.81% | 0.81% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 34.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 1/4/2026 | 1/4/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 75,000 | 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 65.68 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 65.68 | $ 65.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.39% | 0.39% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 4/21/2026 | 4/21/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 33,000 | 33,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 62.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.82 | $ 62.82 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.04% | 0.04% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 5/2/2026 | 5/2/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 22,000 | 22,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 59.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 58.62 | $ 58.62 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.10% | 0.10% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/21/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 53.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 52.97 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.01%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/15/2027 | 6/15/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 111,600 | 111,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 60.54 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.05 | € 59.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.25%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/5/2027 | 12/5/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 625,200 | 625,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 35.73 | € 35.73 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.18%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 1/15/2028 | 1/15/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 15,500 | 15,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 43.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 43.6 | € 43.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 4/16/2028 | 4/16/2028 | 11/15/2026 | 11/15/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | 16,500 | 30,900 | 30,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | € 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 38.64 | € 71.61 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 38.64 | € 38.64 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 5/15/2028 | 5/15/2028 | 12/09/2026 | 12/09/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | 16,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 40.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 40.84 | € 40.84 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/15/2028 | 6/15/2028 | 12/15/2026 | 12/15/2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 23,600 | 23,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 38.92 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 35.48 | € 35.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.44% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/22/2028 | 6/22/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 37.22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 34.32 | $ 34.32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.26% | 0.26% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 7/16/2028 | 7/16/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 28,800 | 28,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 33.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 32.16 | $ 32.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 8/15/2028 | 8/15/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 33,500 | 33,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 32.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 32.9 | $ 32.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 9/17/2028 | 9/17/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 80,900 | 80,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 40.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 40.94 | $ 40.94 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 10/15/2028 | 10/15/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 76,700 | 76,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 37.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 31.74 | $ 31.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/15/2028 | 11/15/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 26,000 | 26,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 32.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 28.66 | $ 28.66 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/17/2028 | 12/17/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 7,200 | 7,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 26.76 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 26.76 | € 26.76 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.90% | 47.90% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.08%) | (0.08%) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | Yes | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 47.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 71.61 | € 71.61 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 38.84% | 38.84% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.14% | 0.14% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.23% | 0.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 45.95% | 45.95% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.23% | 0.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/9/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 9/6/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 65,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 36.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 6/9/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 36.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/29/2028 | 11/29/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 350,000 | 350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 30.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 27.44 | $ 27.44 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/12/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/12/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 34,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 27.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/12/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 27.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 1/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 1/15/2029 | 1/15/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 9,500 | 9,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 14.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 1/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 14.10 | € 14.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 3/20/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 3/20/2029 | 3/20/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 547,100 | 547,100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 14.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 3/20/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 14.25 | € 14.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 5/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 5/15/2029 | 5/15/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 7,200 | 7,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 16.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 5/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 16.82 | € 16.82 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 5/24/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 5/24/2029 | 5/24/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 150,000 | 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 16.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 5/24/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 16.37 | € 16.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 6/17/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/17/2029 | 6/17/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 7.200 | 7.200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 14.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 6/17/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 14.55 | € 14.55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 70.96% | 70.96% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.22%) | (0.22%) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 7/1/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 7/1/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 403.400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 15.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 7/1/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 15.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 71.03% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.31%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 7/22/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 7/22/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 17.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 7/22/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 17.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 71.51% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.36%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 9/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 9/16/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 9/16/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 71.93% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.41%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 10/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 10/16/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 3.500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 14.40 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 10/16/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 14.40 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 72.41% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.38%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 12/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/16/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | Contracts | 53.100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 1,580 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date of Grant 12/16/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 15.80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 71.98% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.26%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance conditions | [1] | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 8/1/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 62.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 8/1/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 9/15/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 9,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 62.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 10/17/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 64.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 10/17/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 64.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/15/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 8,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 68.33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 68.33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/9/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 74,960 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 69.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/9/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 69.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/15/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 69.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 69.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 1/16/2027 | 1/16/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 19,100 | 19,100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 66.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 66.11 | € 66.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.21% | 40.21% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 3/15/2027 | 3/15/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 7,200 | 7,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 66.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 65.42 | € 65.42 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.82% | 39.82% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 4/18/2027 | 4/18/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | 16,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 60.77 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.73 | € 59.73 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.63% | 39.63% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 16/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plan expiration date | 6/15/2027 | 6/15/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 126,000 | 126,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 59.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 16/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.05 | € 59.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.23% | 39.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 52,600 | 52,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 74.22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 71.8 | € 71.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 38.57% | 38.57% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 8,300 | 8,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | € 38.18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 36.43 | € 36.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 43.13% | 43.13% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 13.85 | € 13.02 | € 13.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.30% | 49.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 29.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.40% | 49.40% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 4.30% | 4.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 26.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 23.9 | € 23.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 23.6 | € 27.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 21.2 | € 27.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.32%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 20.8 | € 27.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.11%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 25.3 | € 29.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.20%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 24.3 | € 29.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.18%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 13.5 | € 25.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 15.65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 11.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 12.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 8.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 8.52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 10.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 11.57 | € 9.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.21%) | (0.21%) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 20.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.17% | 0.17% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.23% | 0.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.21% | 0.21% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 18.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.02% | 0.02% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 16.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.21% | 0.21% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 17.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.01% | 0.01% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 17.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 12.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 11.18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/9/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/12/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 8.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 3/20/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 3/20/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 8.97 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 5/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 5/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 10.71 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 5/24/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 5/24/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 10.79 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 6/17/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 6/17/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 8.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/1/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/22/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 9/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 10/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 12/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 12/16/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 9.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 16/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 15.43 | € 14.59 | € 15.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.80% | 49.80% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 32.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.70% | 50.70% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 30.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.60% | 50.60% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 27.2 | € 25.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 27.1 | € 29.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.40% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.40% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 24.2 | € 30.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | (0.15%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 23.6 | € 30.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.16% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 28.2 | € 32.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.18% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 27.8 | € 33.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.17% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 15.4 | € 28.67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 17.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 12.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 13.46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 8.89 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 9.23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | $ 10.99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | (per share) | € 12.88 | € 10.59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.19% | 0.19% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 14.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.61% | 0.61% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.32% | 0.32% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 20.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.39% | 0.39% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.35% | 0.35% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 18.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.41% | 0.41% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 19.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.23% | 0.23% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.34% | 0.34% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.19% | 0.19% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | 0.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 19.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 13.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | yr | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 12.66 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/9/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/12/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 9.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 3/20/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 3/20/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 11.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 5/15/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 5/15/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 11.72 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 5/24/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 5/24/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 11.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 6/17/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | Contracts | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 6/17/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | $ / shares | € 9.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/1/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/22/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 9/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 10/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 12/16/2019 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 12/16/2019 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 10.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 16/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[1] | Performance conditions: Viaskin® Peanut’s marketing authorization by the US Food and Drug Administration (U.S. FD |
Share-Based Payments - Disclosu
Share-Based Payments - Disclosure of Change in Number of Share Options Outstanding (Detail) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Granted during the period | |||
Forfeited during the period | |||
Exercised during the period | |||
Share Option [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 2,461.570 | 2,133.100 | 1,160.060 |
Granted during the period | 1,290 | 824.200 | 998.500 |
Forfeited during the period | 749.525 | 227.730 | 24.260 |
Exercised during the period | 0 | 268 | 1.200 |
Balance at end of period | 3,002.045 | 2,461.570 | 2,133.100 |
Share-Based Payments - Summar_8
Share-Based Payments - Summary of Details of Share Based Payment Arrangement Free Shares (Detail) | Dec. 20, 2019€ / shares | Oct. 11, 2019€ / shares | Jul. 31, 2019€ / shares | May 10, 2019€ / shares | Dec. 17, 2018€ / shares | Dec. 12, 2018€ / shares | Nov. 01, 2018€ / shares | Sep. 06, 2018€ / shares | Jun. 22, 2018€ / shares | Apr. 20, 2017€ / shares | Mar. 14, 2017€ / shares | Nov. 19, 2015shares€ / shares | Mar. 24, 2015shares€ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 450 | 15,000 | 10,000 | ||||||||||
Share entitlement per free share | € 1 | € 1 | € 1 | ||||||||||
Grant date share fair value | € 36.96 | ||||||||||||
Expected dividends | 0.00% | 0.00% | 0.00% | ||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||
Grant Date 3/14/2017 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 2 years | ||||||||||||
Number of free shares granted | 22,500 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 68.07 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||
Grant Date 4/20/2017 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 2 years | ||||||||||||
Number of free shares granted | 24,000 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 61.2 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||
Grant Date 6/22/2018 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 486,153 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 34.32 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||
Grant Date 1/11/2018 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 57,000 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 33.33 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Grant Date 12/12/2018 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 16,250 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 27.96 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Grant Date 12/17/2018 and 12/12/2018 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 3,000 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 26.76 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Date of Grant 5/10/2019 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 1 year | ||||||||||||
Lockup period | 2 years | ||||||||||||
Number of free shares granted | 100,000 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 16.10 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Date of Grant 7/31/2019 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 2 years | ||||||||||||
Number of free shares granted | 23,750 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 17.63 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | Yes | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Date of Grant 10/11/2019 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 2 years | ||||||||||||
Number of free shares granted | 40,000 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 12.43 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | No | ||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||
Date of Grant 12/20/2019 [member] | Free Share [member] | Board of Director [member] | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Vesting period (years) | 2 years | ||||||||||||
Number of free shares granted | 23,600 | ||||||||||||
Share entitlement per free share | € 1 | ||||||||||||
Grant date share fair value | € 17.23 | ||||||||||||
Expected dividends | 0.00% | ||||||||||||
Performance conditions | No | ||||||||||||
Expected turnover during the vesting period | 5.00% |
Share-Based Payments - Summar_9
Share-Based Payments - Summary of Details of Free Shares (Parenthetical) (Detail) | Sep. 06, 2018 | Dec. 31, 2019 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting period (years) | 1 year | |
Viaskin Peanut [Member] | Top of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half of the Shares | |
Vesting period (years) | 2 years | |
Date of Grant 6/3/2014 [member] | Viaskin Peanut [Member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half of the Shares | |
Vesting period (years) | 2 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Viaskin Peanut [Member] | Bottom of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 4 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Viaskin Peanut [Member] | Top of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 11 years |
Share-Based Payments - Change i
Share-Based Payments - Change in Number of Free Shares Outstanding (Detail) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Changes In Number Of Shares Outstanding [line items] | |||
Granted during the period | |||
Forfeited during the period | |||
Exercised during the period | |||
Free Share [member] | |||
Changes In Number Of Shares Outstanding [line items] | |||
Balance at beginning of period | 572,228 | 822,856 | 1,036,850 |
Granted during the period | 187,350 | 562,853 | 46,500 |
Forfeited during the period | 99,850 | 36,525 | 18,650 |
Exercised during the period | 18,000 | 776,956 | 241,844 |
Balance at end of period | 641,728 | 572,228 | 822,856 |
Financial Revenue and Expense_2
Financial Revenue and Expenses - Summary of Financial Income and Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | [1] | Dec. 31, 2017 | ||
Disclosure Of Detail Information About Financial Income And Expenses [line items] | |||||
Financial revenues | € 67 | € 493 | € 616 | [1] | |
Financial expenses | (1,409) | (351) | (3,325) | [1] | |
Total | € (1,341) | € 141 | (2,709) | [1] | |
Scenario, Previously Reported [member] | |||||
Disclosure Of Detail Information About Financial Income And Expenses [line items] | |||||
Financial revenues | 616 | ||||
Financial expenses | € (3,325) | ||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Income Tax Expense - Additional
Income Tax Expense - Additional Information (Detail) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | |||
Deferred tax assets | € 0 | ||
Parent [member] | |||
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | |||
Amount of losses carried forward | € 689,000,000 | ||
French (Member) | |||
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | |||
Effective income tax rate | 28.00% | 28.00% | 33.33% |
Income Tax Expense - Summary of
Income Tax Expense - Summary of Reconciliation of Effective and Nominal Tax Expense (Detail) - EUR (€) € in Thousands | 12 Months Ended | |||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | ||||
Major components of tax expense (income) [abstract] | ||||||
(Loss) before taxes | € (153,042) | € (166,061) | € (147,692) | |||
Theoretical group tax rate | 28.00% | 28.00% | 33.33% | |||
Nominal tax expense | € 42,852 | € 46,497 | € 49,226 | |||
Permanent differences | [1] | 4,080 | ||||
Research tax credit | 2,736 | 3,089 | 3,110 | |||
Share-based compensation | (4,179) | (7,253) | (10,260) | |||
Non-recognition of deferred tax assets related to tax losses | (45,260) | (54,205) | (41,453) | |||
Non-recognition of deferred tax assets related to temporary differences | (294) | (324) | ||||
Other differences | (481) | 12,196 | (623) | |||
Effective tax expenses | € (545) | € (15) | [2] | € (1) | [2] | |
Effective tax rate | 36.00% | 1.00% | 0.00% | |||
[1] | For the years ended December 31, 2017 and 2018, the permanent differences were included in “Other differences.” | |||||
[2] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Commitments - Additional Inform
Commitments - Additional Information (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2019 | May 31, 2017 | Apr. 30, 2016 | |
Other agreements [member] | Contract Research Organizations [member] | Viaskin Peanuts And Viaskin Milk Products [member] | |||
Disclosure of commitments [line items] | |||
Launching value of clinical studies | € 116,200 | ||
Remaining value of clinical studies | 29,400 | ||
CIC banking institution [member] | |||
Disclosure of commitments [line items] | |||
Sum of term deposit | 3,500 | ||
Maximum collateral foreign exchange pledged security | 50,000 | ||
Monetary market fund [member] | Other agreements [member] | |||
Disclosure of commitments [line items] | |||
Sum of term deposit | € 227 | ||
Term deposit period | 3 years | ||
Property, plant and equipment subject to operating leases [member] | Letter of credit 1 [member] | Other agreements [member] | |||
Disclosure of commitments [line items] | |||
Future rental payments | € 300 | € 143 | |
Bagneux [member] | Monetary market fund [member] | Other agreements [member] | |||
Disclosure of commitments [line items] | |||
Guarantee for ordinary rental agreements of the premises | € 400 |
Relationships with Related Pa_3
Relationships with Related Parties - Additional Information (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of transactions between related parties [line items] | |||
Compensation awarded to corporate officers and executive committee | € 16,004 | € 17,478 | € 15,353 |
Commercial deployment expense | € 560 | € 49 | € 45 |
Relationships with Related Pa_4
Relationships with Related Parties - Summary of Relationships with Related Parties (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure of transactions between related parties [line items] | |||
Short-term benefits | € 7,046 | € 5,202 | € 3,300 |
Post-employment benefits | 57 | 87 | 36 |
Termination benefits | 4,380 | ||
Share-based payment | 4,520 | 12,189 | 12,018 |
Total | € 16,004 | € 17,478 | € 15,353 |
Relationships with Related Pa_5
Relationships with Related Parties - Schedule of Amounts Payable to Related Parties (Detail) - EUR (€) € in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | € 3,034 | € 954 | € 1,523 |
Compensation [member] | Directors Fees [member] | |||
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | 2,964 | 535 | 1,121 |
Pension obligation [member] | Directors Fees [member] | |||
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | € 70 | € 419 | € 402 |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Detail) - € / shares | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Earnings per share [line items] | |||||
Anti-dilutive instruments | 3,972,596 | 3,366,296 | 3,309,539 | ||
Basic / Diluted earnings per share (€/share) | € (4.15) | € (5.74) | [1] | € (5.97) | [1] |
Common Shares [member] | |||||
Earnings per share [line items] | |||||
Weighted average number of shares outstanding | 38,944,899 | ||||
Basic / Diluted earnings per share (€/share) | € 3.94 | ||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Earnings Per Share - Summary of
Earnings Per Share - Summary of Earnings Per Share (Detail) - EUR (€) € / shares in Units, € in Thousands, shares in Thousands | 12 Months Ended | ||||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |||
Earnings per share [abstract] | |||||
Net income of the reporting period | € (153,587) | € (166,076) | [1] | € (147,693) | [1] |
Adjusted weighted average number of outstanding shares | 37,007,247 | 28,924,976 | 24,757,176 | ||
Basic / Diluted earnings per share (€/share) | € (4.15) | € (5.74) | [1] | € (5.97) | [1] |
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Management of Financial Risks -
Management of Financial Risks - Additional Information (Detail) € in Thousands, $ in Millions | Oct. 15, 2019EUR (€) | Oct. 15, 2019USD ($) | Oct. 11, 2019EUR (€) | Oct. 11, 2019USD ($) | Apr. 08, 2019EUR (€) | Apr. 08, 2019USD ($) | Feb. 29, 2020EUR (€) | Mar. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | [1] | ||
Disclosure Of Financial Risk Management [line items] | |||||||||||||||
Cash and cash equivalents | € 172,027 | € 122,770 | [1] | € 137,880 | [1] | € 256,473 | |||||||||
Net cash used in operating activities | (128,519) | € (136,620) | [1] | (114,314) | [1] | ||||||||||
Percentage of purchases and other external expenses made in U.S. dollars | 34.00% | ||||||||||||||
Net (loss) | € (153,587) | € (166,076) | [1] | € (147,693) | [1] | ||||||||||
Proceeds from offering of shares | € 130,700 | $ 143 | € 130,700 | $ 143 | € 72,100 | $ 81 | |||||||||
Ordinary shares [member] | |||||||||||||||
Disclosure Of Financial Risk Management [line items] | |||||||||||||||
Proceeds from offering of shares | € 136,400 | € 136,400 | |||||||||||||
Top of range [member] | |||||||||||||||
Disclosure Of Financial Risk Management [line items] | |||||||||||||||
Percentage of purchases and other external expenses made in U.S. dollars | 25.00% | 12.00% | |||||||||||||
[1] | The financial statements as of December 31, 2019 were prepared using the modified retrospective method of IFRS 16 accounting standard, requiring no restatement of the comparative period. |
Events After the Close of the_2
Events After the Close of the Fiscal Year - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions | Mar. 02, 2020EUR (€)shares | Mar. 02, 2020USD ($)$ / sharesshares | Feb. 04, 2020€ / sharesshares | Feb. 04, 2020$ / sharesshares | Jan. 08, 2020 | Jan. 08, 2020 | Jan. 08, 2020Patient | Jan. 08, 2020mg | Oct. 15, 2019EUR (€)shares | Oct. 15, 2019USD ($)shares | Oct. 11, 2019EUR (€)shares | Oct. 11, 2019USD ($)shares | Apr. 08, 2019EUR (€)shares | Apr. 08, 2019USD ($)shares | Feb. 29, 2020EUR (€) | Mar. 31, 2020EUR (€) | Dec. 31, 2019shares |
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Foreign Exchange Rate | 1.0999 | 1.0999 | |||||||||||||||
Shares issued | 3,976,271 | ||||||||||||||||
Proceeds from offering of shares | € 130.7 | $ 143 | € 130.7 | $ 143 | € 72.1 | $ 81 | |||||||||||
Ordinary shares [member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued | 1,368,667 | 1,368,667 | 7,914,622 | 7,914,622 | |||||||||||||
Share offering price | € / shares | € 18.63 | ||||||||||||||||
Number of shares available to underwriters | 7,500,000 | 7,500,000 | 9,484,066 | 9,484,066 | 6,000,000 | 6,000,000 | |||||||||||
Additional number of shares issued | 2,964,419 | 2,964,419 | 1,368,667 | 1,368,667 | 9,484,066 | 9,484,066 | |||||||||||
Proceeds from offering of shares | € | € 136.4 | € 136.4 | |||||||||||||||
Ordinary shares [member] | Public Offering [member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued | 4,535,581 | 4,535,581 | 2,447,500 | 2,447,500 | |||||||||||||
Ordinary shares [member] | American depositary shares [member] | Public Offering [member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued | 9,071,162 | 9,071,162 | |||||||||||||||
Share offering price | $ / shares | $ 10.25 | ||||||||||||||||
PEPITES trial [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Number of patients evaluated | 1,000 | 1,000 | |||||||||||||||
PEPITES trial [Member] | Eliciting Dose Range One [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Eliciting dose percentage | 75.90% | ||||||||||||||||
PEPITES trial [Member] | Eliciting Dose Range Two [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Eliciting dose percentage | 51.80% | ||||||||||||||||
Events after reporting period [member] | Ordinary shares [member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued upon exercise of warrant | 338,687 | 338,687 | |||||||||||||||
Events after reporting period [member] | American Depository Shares [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Share offering price | $ / shares | $ 10.25 | ||||||||||||||||
Shares issued upon exercise of warrant | 677,374 | 677,374 | |||||||||||||||
Events after reporting period [member] | Global Offering [Member] | Ordinary shares [member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued | 4,874,268 | 4,874,268 | |||||||||||||||
Proceeds from offering of shares | $ | $ 160.7 | ||||||||||||||||
Shares issued upon exercise of warrant | 7,838,687 | 7,838,687 | |||||||||||||||
Events after reporting period [member] | Global Offering [Member] | American Depository Shares [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Shares issued | 9,748,536 | 9,748,536 | |||||||||||||||
Events after reporting period [member] | Ordinary shares [member] | Global Offering [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Proceeds from offering of shares | € | € 146.1 | ||||||||||||||||
Bottom of range [member] | PEPITES trial [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Age of patients evaluated | 4 years | ||||||||||||||||
Top of range [member] | PEPITES trial [Member] | |||||||||||||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||||||||||||
Age of patients evaluated | 11 years |